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Abstract
Background.
New drug regimens are needed for effective prophylaxis and treatment o f drug resistant 
Plasmodium falciparum and Plasmodium vivax malaria in northeastern Papua. 
Mefloquine and doxycycline, two standard prophylactic drugs, had high prophylactic 
efficacy in northeastern Papua but they have limited application for two vulnerable 
groups, young children and pregnant women. Azithromycin, an azalide antibiotic, had a 
prophylactic efficacy o f 83% against P. falciparum in malaria immune Kenyans. If 
successful in non immunes, it would be a significant addition to the current prophylactic 
drugs. Chloroquine, the current first line drug in northeastern Papua, is associated with 
high rates o f treatment failure for falciparum and vivax malaria. Cure rates might be 
improved by combining with chloroquine with doxycycline, two drugs that are 
inexpensive and widely available.
Methods.
Two clinical trials were conducted.
(1). The prophylactic efficacy of azithromycin against P. falciparum and P. vivax was 
determined in a double blind, placebo-controlled trial in Indonesian adults with limited 
immunity. After radical cure, three hundred randomised subjects received azithromycin 
(n=148, 750mg loading dose, 250mg/day), placebo (n=77), or doxycycline (n=75, 
lOOmg/day). The end point was slide proven parasitaemia.
(2). In an open trial chloroquine plus doxycycline (CQD) was compared to chloroquine or 
doxycycline alone for treating falciparum and vivax malaria. Eight nine falciparum 
patients were randomised to standard dose chloroquine (n=30), doxycycline [100 mg 12 
hourly (7 days), n=20], or chloroquine plus doxycycline (n=39); corresponding numbers 
for vivax patients were 23, 16, 24. Endpoints were parasite sensitivity (S) or resistance 
(RI, RII, and RIII) assessed by Day 28.
Findings.
(1). There were 58 P. falciparum  and 29 P. vivax prophylaxis failures over 20 weeks. 
Based on incidence rates, the prophylactic efficacy o f azithromycin relative to placebo 
was 71.6% (95% Cl 50.3-83.8) against P. falciparum, and 98.9% (93.1-99.9) against P. 
vivax. Corresponding figures for doxycycline were 96.3% (85.4-99.6) and 98% (88.0- 
99.9).
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(2). Of the 152 recruited patients, 133 reached a parasitological end point. P. falciparum  
cure rates (S) were 26/29 (89.65%) for chloroquine plus doxycycline patients [RIII (n=3)] 
vs. 5/23 (21.7%) for chloroquine (PO.OOl), and 12/18 [66.7% (41.0-86.6%)] for 
doxycycline (CQ vs. D, P=0.0037). The corresponding cure rates against P. vivax were 
15/22 (68.2%) vs. 6/21 (28.6%) vs. 6/14 (42.8%). Only the CQD vs. CQ cure rates were 
significantly different fP=0.01).
Interpretation.
Daily azithromycin prophylaxis was highly effective against P. vivax but modest against 
P. falciparum. It cannot be recommended as a first line prophylactic agent against P. 
falciparum. Chloroquine plus doxycycline was effective against drug-resistant P. 
falciparum but not chloroquine resistant P. vivax. It may offer an alternative to more 
expensive drugs e.g. mefloquine, atovaquone/proguanil for treating P. falciparum.
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Chapter 1 - Introduction
1.1 Malaria - biology and clinical classification
Human malaria is a parasitic disease caused by one or more of four Plasmodium 
species; Plasmodium falciparum, P. vivax, P. ovale, and P. malariae. P. malariae has a 
three-day blood stage life cycle and the other parasites have a two-day cycle. Plasmodium 
falciparum  is the most serious form of malaria because it may cause severe disease. Its 
virulence is attributed to its ability to produce heavy parasite burdens and to cytoadhere to 
the vascular endothelium leading to sequestration o f parasitised red cells in the 
micro vasculature o f vital organs. The other three species are often referred to as the 
benign malarias. They seldom parasitise more than 2% of the erythrocytes and do not 
cytoadhere. They cause acute febrile illnesses that rarely cause severe morbidity. P. vivax 
and P. ovale, the two relapsing malarias, have a dormant liver stage, called the 
hypnozoite, that gives rise to further bouts of infection after clearance o f the blood stage 
infection.
1.2 Overview of the current global status of malaria
Malaria is currently a serious global health problem that affects predominantly 
tropical countries (Appendix 1). Although accurate data are lacking, the WHO estimates
■i
the global annual incidence of clinical malaria to be 300-500 million cases. A more 
recent review estimates this to be 400 to 900 million African children less than five years 
of age.4 Plasmodium falciparum  and Plasmodium vivax account for the vast majority of 
the global malaria burden; P. vivax contributes an estimated 70-80 million cases per 
year.5 P. falciparum  predominates in sub-Saharan Africa; P. vivax predominates in the 
Middle East, Latin America, and parts of Asia. Within malaria endemic regions, there are 
many areas of mixed falciparum/vivax malaria where the relative proportions o f the 
species vary. Plasmodium falciparum  is responsible for virtually all o f the estimated 
700,000 to 2.7 million deaths per year that occur mostly (75%) in African children.3 4 
Sub-Saharan Africa bears most o f the global malaria burden, some 90%. Never the less, 
in absolute terms, malaria represents a significant public health problem in many endemic 
regions, including Indonesia.6
Compounding the seriousness of the malaria related morbidity and mortality is 
drug resistance. P. falciparum  is now resistant to several commonly used antimalarial
14
drugs. Chloroquine, the mainstay o f malaria treatment for the past fifty years, is now
n
ineffective in the vast majority o f malaria endemic countries. Chloroquine sensitive P. 
falciparum is confined to Central America, the Dominican Republic and Haiti. 
Sulfadoxine/pyrimethamine (S/P), an inexpensive second line drug in many countries, has 
been ineffective in SE Asia and the Amazon basin for several years, and is now losing
o
efficacy in other parts of Asia and Africa. Quinine, the principal drug for treating 
multidrug resistant malaria and severe malaria in many countries, is still effective despite 
reports o f reduced sensitivity.9 A recent development has been the emergence of 
chloroquine resistant P. vivax (CRPV) which has been reported in focal areas o f India, 
Burma, Indonesia, Papua New Guinea, Latin America, and the Solomon Islands (Schapira 
A, personal communication).10 11 12 13 14 15 16 17 18 In Papua, CRPV now constitutes a 
significant public health problem.19 CRPV has most often been reported as recurrent 
parasitaemia occurring by Day 28 but there are also reports o f failure to clear parasites, 
signifying high-grade resistance.15 20 Some of these reports have excluded inadequate CQ 
absorption as a cause o f treatment failure by measuring CQ drug levels.12 13 16 20
9 1The impact of drug resistant falciparum malaria is considerable. Increased
childhood morbidity and mortality in Africa due to chloroquine resistance is now well
22 93documented. Malaria related anaemia itself is also an important cause o f morbidity 
and mortality. It affects an estimated 1.5 to 6 million African children and is associated 
with a case fatality rate (CFR) o f 15%.24 Anaemia is also a significant problem in
9 <pregnant African women, affecting a median of 8.6%. The detrimental effects of CRPV 
have yet to be documented to the same extent as drug resistant falciparum malaria. 
Clinically, P. vivax may cause a debilitating febrile illness and anaemia in pregnant and 
non-pregnant patients.26 27 Rarely, vivax malaria may cause serious pathology in the form 
of pulmonary oedema and splenic rupture.28 29
For malaria control, recommending optimal treatment and prophylactic regimens 
is clearly more difficult in the face o f drug resistance.30 31 From a drug policy perspective, 
drug resistance is the most critical factor in reducing the useful life span o f a drug and 
undermining drug policy. How to detect and overcome drug resistance, and deploy 
effective measures to control malaria is the art and science of malaria control itself. From 
the research perspective, the development of new antimalarial drugs or drug combinations
15
of either new or currently available drugs that will be effective over the medium to long 
term is an important way forward.
1.3 Overview of malaria in Indonesia - published reports and 
unpublished data from the Indonesian Ministry of Health
1.3.1 Epidemiology
Indonesia is an archipelago consisting o f 13,767 islands.6 There are six main 
islands and 6,000 uninhabited islands (Appendix 2). There are two seasons, dry from June 
to September, and wet from December to March. The average humidity is 70-90%. The 
total population is estimated at 180 million; 70% of the population are rural inhabitants. 
Malaria transmission occurs in all parts o f Indonesia but endemicity varies (Figure 1.1). 
Approximately 50% of the total population live in areas o f little or no malaria 
transmission, chiefly Java and Bali (Appendix 3). The population at risk is located mostly 
in the outer eastern islands. Malaria surveillance is conducted chiefly through a system of 
passive case detection. This system covers completely Java and Bali but not all o f the 
outer islands. The number of reported malaria cases, diagnosed either clinically or 
microscopically, runs currently at about 2 million per year with 100 deaths (F. Laihad, 
Indonesian MoH, personal communication). The WHO estimate is 6 million and 700, 
respectively. In 1992, o f all the causes o f under five mortality, malaria ranked fifth,
9^accounting for 6.3% of the total.
Java, the largest island, has the least intense transmission. In 1997, the overall 
annual incidence of malaria was 0.12/1,000 population. (F. Laihad, personal 
communication). Malaria has been eradicated in large areas of eastern and western Java 
but there remain foci o f low transmission, especially in the central southern part. The 
annual parasite incidence (API) rates for east and west Java are very low, between 0 to 
0.1/1000 person-years; the figure for central Java (excluding Yogjakarta) averaged 0.5.6 
The focal nature o f malaria in central Java has been described by Baird.33 Malaria surveys 
conducted in the Yogjakarta area found that most of the malaria was confined to three 
areas o f the sub district of Kokap: their APIs were ~ 1 3 , - 9 4  and ~ 170. These areas 
were hilly with many potential mosquito breeding sites e.g. streams, open wells. Java 
owes its success in reducing the malaria burden because o f a campaign o f household DDT 
spraying that began in the 1950s. However, in 1997 Java saw a resurgence of malaria 
because of a breakdown in malaria control efforts due to the economic crisis o f that time.
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The results o f a retrospective investigation in Purworejo, a coastal district in central Java, 
have been reported by Barcus et a l}A
This area is geographically diverse with fish ponds and coconut groves in the tidal 
zone that give way to a coastal plain o f rice fields which then rise to form the forested 
Menoreh hills o f some 900 metres. Anopheles sundaicus predominates in the tidal zone, 
An. aconitus and barbirostris in the costal plan, and An. maculatus and balabacensis in 
the hills. Malaria transmission in this area is perennial and peaks in the dry season 
because suitable breeding sites are not washed away by the rains; dry rocky streambeds 
are the favoured breeding sites for An. maculatus and balabacensis, the two species 
responsible for Menoreh hills epidemic. A review of malaria data between 1986 and 2000 
showed that malaria was at a low level in 1995 (mean API < 5/1000) but this rose 
gradually in 1996 and 1997 with ever larger annual increases in malaria to reach a mean 
API o f 44.5 in 2000. Geographically, the epidemic was confined almost exclusively to the 
hills which have a higher a population density than the costal and tidal areas. Coincident 
with this epidemic was a reduction in economic resources for vector control, with reduced 
spraying activity, and a reduction in the number o f malaria control health workers.
This report illustrates well the potential for epidemic malaria to appear in areas 
where malaria control has been successful. Several factors were responsible. The 
economic crisis o f 1997 reduced drastically malaria control efforts. The epidemic was 
confined to the hills due to vectors that breed well in small pools of water. The population 
was poor, living in poorly constructed wooden buildings, and having limited access to 
health care.
The highest level o f malaria transmission occurs in the eastern outer islands and is 
related to the opening up o f new lands for industrial development and resettlement by 
mostly transmigrants (transmigrasi) from other parts o f Indonesia. The cutting down o f 
mangrove forest promotes the breeding of An. sundaicus and increased economic activity 
in the forests o f east Kalimantan, exposes workers to An. balabacensis, a mosquito that 
breeds easily in such an environment.35 Irian Jaya, renamed Papua in 1998, has the 
highest cumulative incidence rates o f malaria, ~ 15% and ~ 17% in 1992 and 1993, 
respectively; this compares with the overall figure for Java o f 0.98%.6 33
The two main species transmitted In Indonesia are P. falciparum  and P. vivax. 
Most studies have reported falciparum:vivax ratios of 2:1 (Figure 1.1). In central,
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southern Java, ratios have varied from 2:1 to 0.4:l.33 P. malariae and P. ovale account for 
very little of the malaria burden; the latter being reported mostly from the eastern 
islands.36 37 38 Several anopheline species transmit malaria in different parts of Indonesia 
(Table l . l ) 6.
C. J a va (94)
S. Lombok (95)
N. Sulawesi (95)
E. Flores (95)
W. Sumatra (95)
Gag island (97)
W. Papua (95)
C. Papua (94)
S. P apua(95)
NE. Papua (93)
~ 1  I
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Figure 1.1 Point prevalent surveys conducted from 1993 to 1997 by the US Navy and the
Indonesian Ministry of Health in several parts of Indonesia. The numbers in parentheses 
refer to the year of study conduct. Data from Lt. Cdr. D. Fryauff, US Navy.
P. falciparum  
P. vivax
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Table 1.1 Malaria vectors and their distribution on the main islands o f Indonesia.
Islands Vector species
Java and Bali An. aconitus, An. sundaicus, An. subpictus, An. balabacensis,
An. maculatus
Sumatra An. sundaicus, An. maculatus, An. hyrcanus group, An. letifer,
An. aconitus
Kalimantan An. balabacensis, An. Sundaicus, An. hyrcanus group, An. letifer,
An. umbrosus
Sulawesi An. barbirostris, An. sundaicus, An. subpictus, An. hyrcanus group,
An. flaviostris, An. minimus, An. nigerrimus
Nusa Tenggara An. barbirostris, An. sundaicus, An. subpictus, An. aconitus
Irian Jaya/Maluku An. punctulatus, An. koliensis, An.farauti, An. bancrofti,
An. karwari
1.3.2 Malaria control and resistance monitoring
Malaria control activities encompass active and passive case detection by 
microscopic confirmation, presumptive and radical drug treatment, indoor house 
spraying, and environmental management (e.g. land drainage). In the Outer islands, the 
focus is on spraying operations and malariometric surveys, passive case detection, 
treatment o f clinical malaria cases, and the control o f malaria outbreaks. Malaria drug 
resistance surveillance is conducted by the Ministry o f Health (called Litbangkes) using 
both the WHO 28 day in vivo test and the WHO in vitro microtest (Mark II); the latter has 
been used since 1984 for P. falciparum only. The focus has been P. falciparum  but in 
vivo tests o f P. vivax have also been conducted in collaboration with the US Navy.
1.3.3 Plasmodium falciparum
A comprehensive review o f drug resistant malaria has come from Tjitra.39 
Chloroquine resistant P. falciparum  was first documented in Kutai, in East Kalimantan in 
1973. Soon afterwards, two cases of RI CQ resistance were reported in two Japanese 
adults from East Kalimantan and Irian Jaya.40 All major provinces now have evidence of 
in vivo (RI/RII/RIII) or in vitro chloroquine resistant P. falciparum. Recent data from 
Java (Menoreh hills epidemic) and East Timor (post independence) have shown high rates 
(50 and 60%, respectively) o f chloroquine resistant P. falciparum?1 42
The recommended second line drug for chloroquine resistant P. falciparum  is 
sulfadoxine/pyrimethamine. Clinical resistance to S/P was first reported in 1979 43 44 Data 
on the distribution o f either in vitro or in vivo S/P resistance are limited. By 1995, in vivo 
or in vitro resistance to S/P was reported from 11 of 14 provinces. All three levels o f in
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vivo resistance have been reported. RI occurs most commonly but has generally been low, 
~ 2% of patients tested in South Sulawesi, and ~ 5% in Papua.39 45 However, the rate was 
12% (14/119) from central Java, 22% in the Menoreh hills epidemic, and 15% in NE 
Papua.39 41 46 High rates o f in vitro S/P resistance have been documented in Aceh (67%), 
central Java (71%), East Kalimantan (85-100%), East Timor (27%), Sulawesi (50%), and 
Irian Jaya (~ 80%).39 Foci of in vitro multidrug (chloroquine, S/P, amodiaquine, and 
mefloquine) resistant P. falciparum  have been reported from two provinces, East Timor 
and East Kalimantan.
Several other antimalarial drugs have undergone either in vivo or in vitro testing. 
In vitro mefloquine resistance has only been reported from East Kalimantan [1/37 (3%)] 
in 1991. In vivo resistance (2/36) to Fansimef (S/P and mefloquine) in Papua.45 RI 
resistance to halofantrine has been documented in East Kalimantan [1/63 (2%)], and 
North Sulawesi [7/59 (12%)] but resistance was not found in Papua (n=36). Evidence of 
in vitro quinine resistance has been reported from a number of provinces, including Aceh 
[14/21 (67%)], central Java [27/38 (71%)], and south Sulawesi [11/19 (58%)], north 
Sulawesi [12/20 (60%)], and east Kalimantan [74/82 (90%)]. Few studies of quinine 
efficacy have been conducted. Of those with a sample size >30, no resistance was found 
in Aceh (n=32) but resistance was found in central Java in 14 [RI (n=3), RII (n = ll)] of 
119 (12%) patients, south Sulawesi [1 (RII)/62 (2%)], and Irian Jaya [1(RII)/41 (2.4%)]. 
Although amodiaquine is not used in Indonesia, several small in vitro studies have 
documented a high proportion of P. falciparum isolates as resistant in east Kalimantan 
[27/27 (100%)], south Sulawesi [9/9 (100%)], and Irian Jaya [8/8 (100%)]; these areas 
also have high rates o f in vitro and in vivo chloroquine resistance.
1.3.4 Plasmodium vivax
Chloroquine resistant P. vivax (CRPV) was first documented in 1991 in an 
American visitor to Nias island off the west coast o f Sumatra.47 He developed 
symptomatic vivax malaria despite unfailing adherence to CQ prophylaxis. His illness 
recrudesced despite two therapeutic courses o f CQ, the second o f which included 
primaquine 15 mg/day for 14 days. He was eventually cured with a single dose of 
mefloquine (500mg). Surveys of in vivo resistance have found full sensitivity o f P. vivax 
to CQ in Lombok, Gag Island, and Java.48 49 50 However, there was evidence of reduced 
vivax sensitivity in the Lombok study because some patients had Day 0 chloroquine
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levels above the Berliner adapted reference o f 100 ng/ml (see 1.7.1.3). P. vivax resistant 
to prophylaxis was suspected in an Australian female traveller who had visited Bali and 
Lombok on the basis o f fever whilst on chloroquine and Malaprim® prophylaxis.51 
However, no malaria slide was done at the time. Seven weeks after stopping her 
prophylaxis, she developed acute vivax malaria that was cured with chloroquine and 
primaquine. Resistance o f P. vivax to chloroquine treatment has been documented in
12 19 52 53Papua, north Sulawesi, and West Kalimantan. Evidence o f vivax resistance has
been the failure to clear parasites or the recurrence o f vivax parasitaemia despite total, 
whole blood CQ concentrations > lOOng/ml. Papua has the most serious problem with 
CRPV where high-grade vivax resistance has been documented.
S/P resistant vivax has now been documented in Java and Irian Jaya. These studies 
have involved small numbers o f treated patients, so failure rates are broad e.g. 4/6 [66% 
(22-95)] in Java (S/P), and 2 o f 6 [33% (4-78)] in Irian Jaya (CQ & S/P). Treatment 
failures have been persistent parasitaemia during the first seven days o f follow up, or 
recurrence o f parasitaemia. Preliminary studies have identified mutations in the vivax 
dihydrofolate reductase gene at positions 57, 58, 61, and 117 that were associated with 
poor parasitological responses to vivax.41 54 55
1.3.5 Plasmodium malariae and ovale
There are no recent data on the drug sensitivity o f P. ovale. Indeed, as mentioned 
earlier, this species is now quite rare in Indonesia. Similarly, little is known about the 
epidemiology o f P. malariae in Indonesia but foci were described in Papua in the 1950s 
(see 1.4 and 1.5 below). Recently, chloroquine resistant P. malariae has been reported 
from Legundi island off the southern tip o f Sumatra.56 Using standard dose chloroquine 
and a 28 day follow up, two o f 28 patients failed to clear their parasites by Day 8. The 
total, whole blood concentrations of chloroquine were 205 and 680 pg/L on Day 2 and 
100 and 170 pg/L on Day 8. These levels confirm CQ absorption but the level o f 205 is 
somewhat low. Although the therapeutic range o f chloroquine against P. malariae is 
unknown (see 1.7.6), these data are consistent with CQ resistance.
1.4 Synopsis of the malaria situation in Papua
1.4.1 Malaria epidemiology
Papua is Indonesia's most eastern province and has diverse physical features that 
include central highlands, and areas o f forestation and swamps (Appendix 4). Gunawan
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has provided an excellent overview o f the malaria situation in Irian Jaya.57 Historical texts 
dating from the early 1800s describe a swamp fever that affected the young indigenous 
population as well as the Dutch colonial settlers. Fort de Bus, a Dutch military post, had 
to be abandoned eight years after it was established because o f the deleterious effects of 
swamp fever. Systematic data from the 1950's come from Dutch researchers. Using 
spleen rates as the epidemiological marker o f transmission, they found malaria ranged in 
endemicity from hypoendemic (spleen rate 10%) to holoendemic (> 75%; see Table 
2.1). The highest rates o f malaria were found on the south coast where transmission was 
hyperendemic with foci o f holoendemic malaria. Malaria transmission mirrored the 
rainfall pattern and decreased with increasing altitude. Unstable transmission with the risk 
of epidemics occurred at altitudes between 350 to 1,600 m.
In 1979, malaria was the diagnosis in 83,171 outpatient and clinic consultations 
throughout the province, representing 20% o f all diagnoses. From 1975-79, malaria was 
responsible for 16% of all hospital admissions and contributed 14% of all hospital deaths. 
The case fatality rate o f malaria at the Rumah Sakit Umum (public hospital) in Jayapura 
was 3.5%.57
1.4.1.1 Highland malaria
Two epidemics were described by Metselaar in 1959 in the Kemboe and Baliem 
valleys in the central highlands.58 In Kemboe, a dry weather spell, and visits of 
highlanders to a salt well were important factors in this epidemic which was first 
signalled by an increase in fever deaths. Malariometric surveys conducted at different 
altitudes o f the valley showed that villagers from high altitude villages had lower parasite 
prevalence rates (7-15%) than those living lower down (38%) with the exception of 
Boegelo (1,900 m) which had a prevalence rate o f 48%. Inhabitants from Boegelo would 
visit frequently a salt well, situated lower down at 1,400 m, and spend the night there; 
thus, increasing their risk o f malaria. In addition, dry climatic conditions favoured the 
preservation o f mosquito breeding sites which would normally be washed away by the 
rains. In the Baliem valley (1,600 m) near Wamena, evidence o f low levels o f local 
malaria transmission was found; spleen (0.2%) and parasite rates (1%) were low. An 
increase in malaria was thought to be due to contact with traders from outside the valley 
who had parasite rates o f 12%.
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Another survey o f malaria in the central highlands was conducted in the Oksibil 
valley (1,200-1,500 m), close to Papua New Guinea (Appendix 4).59 Five malariometric 
surveys were conducted in four villages in 1990-91. The overall malaria prevalence was 
25% (844 o f 3,380 slides examined); prevalence by age groups were: 10% (infants), 50% 
(children aged l-4y), 35% (5-9y), 28% (10-14y), and 16% for adults. The spleen rate was 
96% in children < 5 years o f age. Transmission of all four malaria species was 
documented. P. falciparum  accounted for 55%, P. vivax 31%, P. malariae 13%, and P. 
ovale 0.5%. In the village o f Kutdol (1,500 m), P. malariae accounted for 43%; rates for . 
falciparum and vivax malaria were 32 and 23%, respectively. Asymptomatic falciparum 
parasitaemia was common in children and adults. Increased transmission was associated 
with an increase in mosquito breeding sites brought about by replacing traditional huts 
with more modem housing. This required the constmction o f drainage ditches to drain off 
rainwater from the tin roofs. The mean mosquito biting rate was 10 bites/person/night 
(p/n) in the newly constructed houses compared to 1 bite/p/n in the traditional hut that 
served as a separate outbuilding. Anopheles punctulatus was the predominant vector, 
accounting for 97% o f mosquitoes examined; An. koliensis accounted for the remaining 
3%. Based on the high spleen rates, and rates of asymptomatic parasitaemia, it was 
concluded that this area had had stable malaria transmission for many years. The 
constmction of new housing favoured the breeding o f An. punctulatus with a 
consequential increase in transmission.
In 1997, a series o f localised malaria epidemics were reported from the 
Jayawijaya district, a large area o f the central highlands, at elevations o f 1,000 and 2,200 
metres (Appendix 4).60 These epidemics affected isolated and marginalised communities 
scattered over the highlands. Although data in the paper are based on clinical diagnoses, it 
is estimated that during a period o f 10 weeks, there were more than 550 deaths. Several 
factors played a role in this epidemic. There was a drought in the highlands that resulted 
in increased breeding o f vectors o f the An. punctulatus complex which in turn enhanced 
local transmission o f P. falciparum. Food shortages forced communities to search for 
food increasing their exposure to malaria, especially in the endemic lowlands. Poor health 
infrastructure and limited access to effective treatment also contributed to the high 
mortality.
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1.4.1.2 Lowland malaria
In 1995, malaria surveys were conducted in three villages 30 km south-east of 
Nabire, a coastal town 120 km west of Jayapura (Appendix 4). Irianese lived in two 
villages, Topo and Urusuma, and transmigrants, who had arrived five years earlier, lived 
in Margajaya.19 The spleen rates in children aged 2-9 were, respectively, 27%, 79%, and 
10%; the corresponding malaria prevalence rates were 9% (n=199), 18% (n=157), and 9% 
(n=573). The falciparum:vivax ratios were 2.5:1, 1.1:1, and 1.4:1, respectively. More 
recent work conducted on new transmigrasi villages in Armopa area on the north coast 
west of Jayapura have shown a higher prevalence of vivax over falciparum malaria: this 
was 2:1 in adults after 6 months of settlement; corresponding incidence rates were 1.8 and
1.5 infections per person-year.61
In the Timika area of southern Papua, Pribadi et al. conducted malariometric 
surveys in six villages.62 Four were long established, where local villagers had life long 
malaria exposure, and two were newly established. One housed Irianese from the 
highlands, and the other transmigrants from other parts of Indonesia. The spleen rates in 
children aged 2-9 years varied from 5-92% and correlated with the parasite rates that 
ranged from 14-60% (Figure 2). The lowest and highest rates were in Mapurujaya and 
Mwapi, respectively, and represent the spectrum of malaria endemicity in this area. 
Mapurujaya was hypo- and Mwapi holoendemic. The overall falciparum to vivax ratio 
was 2.5 to 1.
Spleen rate Parasite rate
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Figure 1.2 Spleen and malaria parasite rates conducted in the Timika area of southern 
Irian Jaya.
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1.4.2 Vector studies
Of the Anopheles vectors studied in Papua, the important species are Anopheles 
punctulatus, An. koliensis, An.farauti, An. longirostris, An. karwari, and An. bancrofti.
63 An. punctulatus needs little sunshine and breeds indiscriminately in all types o f water 
e.g. water near pig sties, ditches, drums o f stagnant water, irrigation ditches associated 
with the growing o f kangkung, a popular spinach like plant. An. punctulatus numbers vary 
with the season, peaking during November to April (rains) and declining significantly 
during May to October (dry season). Measured biting rates were 64 and 20 bites/person- 
night, respectively. The prevalence of An. punctulatus dropped during dry spells within 
the rainy season, indicating environmental vulnerability. An. punctulatus is endophilic
cn
(rests indoors) and endophagous (bites indoors).
1.5 Malaria control in Irian Jaya
In 1954, hut spraying with 5% DDT at six monthly intervals was started in 
northern and southern parts o f Irian Jaya. This was later supplemented by mass drug 
administration o f weekly chloroquine (e.g. 450 mg base for adults), or chloroquine 
combined with pyrimethamine (e.g. 50 mg for adults) administered at least at monthly 
intervals. Malaria transmission was reduced but not eradicated by these measures. In the 
Demta district along the north coast west o f Jayapura, DDT spraying reduced 
substantially the parasite rate o f all three species (11.2%) compared to baseline (41%). 
This reduction was augmented following the administration o f weekly CQ for eight 
weeks resulting in a parasite rate o f 0.1%.64 The effect was greatest for P. vivax and P. 
malariae. However, in two villages that were close to those where no malaria control 
measures were in place, the asexual and gametocyte parasite rates actually increased 
because o f a combination o f poor quality housing and frequent contact with the untreated 
villages. In the Sentani area, there was also a decline in the three main species 
(falciparum, vivax, and malariae) but this was subsequently followed by a relative 
increase in the proportion o f falciparum cases due to the high sensitivity o f P. vivax and 
P. malariae to the drugs used and the greater increase in gametocyte carriage by those 
infected with P. falciparum.65
In 1959, a medicated salt campaign was set up in villages along the north coast of 
Papua extending westwards towards Sarmi, the Tor river basin (some 230 km west of 
Jayapura), Arso, and Waris (south o f Arso). There were three phases. Pyrimethamine
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[PYR (= 25 mg/week)] was used initially, followed by a mixture o f PYR (= 25 mg/w) and 
CQ (= 140 mg/w), and finished with CQ (= 140 mg/w) only containing salt.66 Overall, the 
salt programme gave disappointing results even in areas o f DDT spraying and despite 
initial falls in parasite prevalence rates. The CQ only phase gave the best results in terms 
o f a reduction in the prevalence o f malaria. The main negative effects were an increase in 
P. falciparum  prevalence rates six months into the pyrimethamine only programme, 
relatively less effect on younger children for all salts used, and the failure to interrupt 
malaria transmission. Pyrimethamine and proguanil resistant P. falciparum was reported 
three and half months into the programme from Arso.67 The salt programme was 
discontinued in 1961. Other malaria control activities included the use o f larvicides in 
breeding sites in urban areas, parasite and entomological surveys, in vivo tests, staff 
training, and centralised drug purchase.
1.5.1 The effect of DDT spraying
DDT spraying has been conducted in different areas o f Irian Jaya. Acceptance by 
the population was generally high but there was a tendency for urban dwellers to refuse 
house spraying; consequently, coverage was only 10% in Jayapura, Biak, and Sorong. 
Parasite rates declined in areas where spraying was done but little effect was seen in 
Genyem (60 km south west o f Jayapura), Jayapura, and Abepura (part o f the Jayapura 
conurbation). This was due to a combination of poor quality spraying and the emergence 
of DDT and chloroquine resistance. In these areas P. falciparum  continued to be the 
predominant species with profound public health consequences.
1.5.2 Drug resistance studies in north-eastern Papua
Drug resistant P. falciparum  was first recorded to pyrimethamine and proguanil
f \  7by Meuwissen in Arso in 1959. He also documented the first clinical indication of 
reduced chloroquine sensitivity by recording prolonged parasite clearance times o f 144 
hours in 12 (41%) o f 29 local residents following the administration o f standard dose 
chloroquine.57 By the mid 1970s, chloroquine resistant falciparum malaria was confirmed 
clinically using the WHO in vivo test in residents from Jayapura and Hamadi (part o f the 
Jayapura conurbation). Seven o f 35 patients had recurrent parasitaemia, one on Day 11 
and six on Day 21; these cases were probably RI resistant infections.68 At about the same 
time, RI chloroquine resistant P. falciparum was reported in two Japanese males who had 
been working in Irian Jaya, one in the ‘bird's peak’ area o f western Irian (Manokwari
26
area), and the other in Kimi bay, west o f Jayapura. Both made uneventful recoveries with 
S/P.40 69 Clyde characterised a strain of P. falciparum from an English patient who had 
travelled to several areas o f Irian Jaya.70 By experimentally inducing malaria in non 
immune American volunteers, he found resistance to several antimalarials. This strain 
was RII resistant to chloroquine and amodiaquine, RIII resistant to pyrimethamine 
(50mg/d x 3d), and had reduced sensitivity to varying doses o f quinine but was hilly 
sensitive to mefloquine. Daily proguanil as prophylaxis was also unsuccessful with 
breakthrough parasitaemia occurring on days 19 and 2 0 .
In 1980, more in vivo and in vitro data of chloroquine resistant falciparum malaria 
were obtained in 21 patients from Nimboran district (-100  km west o f Jayapura), an area 
of hyperendemic malaria by spleen rate.71 Two (10%) had a RII response to standard dose 
chloroquine and six isolates were resistant using the WHO microtest. In Nabire, an in vivo 
test was conducted o f P. falciparum (n=26), P. vivax (n=22), and P. malariae (n=3), 
mixed falciparum/vivax (n= ll), and mixed vivax/malariae (n=l); falciparum cases were 
counted as 37 and vivax as 34. Patients were transmigrants o f five years residence and 
local Irianese. Chloroquine was well absorbed; Day 2 levels ranged from 691-3,119 
ng/ml. Cumulative treatment failure rates were high: 30%, 58%, and 89% in the 
falciparum arm, and 15%, 45%, and 64% in the vivax arm on Days 7, 14 and 28, 
respectively.19 In Timika, seven day in vivo tests conducted in 78 patients (ages not 
stated) found a high proportion (49%) o f RII (44%) and RIII (5%) resistance. In vitro 
testing (WHO microtest) also found evidence of chloroquine resistance but no resistance 
to S/P, quinine, or mefloquine.62 Clinical resistance (RI) to S/P was first reported in 1979 
in a resident o f Jayapura and a non immune visitor to Timika 43 44
In vivo tests combined with the molecular markers o f chloroquine and S/P 
resistance were conducted between 1996 and 1999 in Armopa. All grades o f chloroquine 
resistance were associated highly with the presence o f mutant codons at position 86 
(tyrosine-86) or 1042 (asparagine-1042) o f the pfm&rl gene. Similarly, gene mutations 
that encode for dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps) 
enzymes were associated with S/P resistance. The dhfr changes, Asn-108 and Arg-59, in 
combination with the dhps change o f Gly-437 were associated with RI and RII/RIII 
resistance. The presence o f the dhps mutation Gly-540, either alone, in combination with 
the dhfr mutations and/or the dhps Gly-437 mutation, was associated only with RII/RIII
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S/P resistance.72 In another study conducted in Arso, the pfmdrX genetic changes were 
consistent: the K1 (86-tyr) and 7G8 (Asp-1246) mutations were associated with in vivo 
chloroquine resistance.73 An assessment o f the T76 mutation o f the pfcrt gene has been 
carried out in Armopa in 107 transmigrasi adults and children.74 Using the 28 day in vivo 
test end points (S or any degree o f resistance), the T76 mutation had a sensitivity o f 96% 
(79/82) for detecting CQ resistant falciparum malaria with a specificity o f 52% (12/25). 
Using molecular techniques to reclassify recurrent parasitaemias (merozoite surface 
protein 2) as new or RI infections, and to detect subpatent parasitaemia (small subunit 
ribosomal RNA analysis) in microscopically diagnosed sensitive infections as sensitive or 
RI resistant infections, the sensitivity and specificity were 93% and 82%, respectively.
1.6 Towards an understanding of drug resistant malaria
Most o f our knowledge o f drug resistance has been gained by studying P. 
falciparum. Clinicians tend to assume drug resistance exists if sick malaria patients fail 
treatment despite taking properly prescribed, effective treatment or subjects develop 
malaria despite unfailing compliance with chemoprophylaxis. The clinical 
pharmacologist will observe a declining pharmacodynamic response o f an antimalarial 
drug over time, indicating reduced parasite sensitivity. The laboratory scientist will 
observe an increase in the concentration o f drug required to kill malaria parasites in 
culture, in vitro resistance, and the molecular biologist will detect changes in certain 
malaria parasite genes that are associated with in vivo and in vitro resistance. Deciding 
which indicator/s o f resistance is/are reliable is o f particular importance for malaria 
control programmes for the formulation o f drug policy.
The WHO definition o f resistance is a good working definition because it deals 
with the most important consequence o f drug resistance, namely, clinical resistance in the 
sick patient with malaria.75 Resistance is defined as the “ability o f a parasite strain to 
survive and/or multiply despite the administration and absorption o f a drug given in doses 
equal to or higher than those usually recommended but within tolerance o f the subject.” 
This definition was later modified to specify that the antimalarial drug “gain access to the 
parasite or the infected red blood cell for the duration o f the time necessary for its normal
7 f \action.” This definition does not apply to prophylaxis failure (the failure to prevent the 
emergence o f parasitaemia). Never the less, the latter is a useful indicator o f early drug
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resistance. A distinction should be made between drug resistance and treatment failure
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because the latter might be interpreted erroneously as resistance by clinicians. Drug 
resistance is only one cause o f treatment failure. Other causes o f treatment failure include 
incorrect dosing, fake drugs, poor patient compliance, poor drug absorption (e.g.
7fi 70  CA fi 1 fi7
kwashiorkor, certain beverages), and diarrhoea. Acute malaria may also affect
the absorption o f drugs because o f reduced food intake (empty stomach), vomiting, and 
reduced visceral perfusion.83 84 One important determinant o f treatment failure is the 
acquisition o f malaria immunity. A patient with naturally acquired immunity is more 
likely to clear resistant parasites than non-immune patients.85
1.6.1 The development and spread of drug resistance
Drug resistance develops as a natural phenomenon and arises primarily through an 
increase in the prevalence o f resistance-conferring gene mutations in an environment of 
selective drug pressure. Parasite replication results in random errors o f replication that 
produce genetic mutations.86 Most o f these mutations result in parasite death but others 
confer a survival advantage to the parasite when a given drug is present. There is inherent 
variation in the susceptibility of parasites to antimalarial drugs; highly susceptible 
parasites are killed by low drug concentrations and vice versa. The greater the biomass 
(parasitaemia), the more likely the diverse the parasite population regarding drug 
sensitivity. Failure to kill resistant asexual parasites will result in the passing on o f mutant 
gene/s to the next generation via gametocytes. These sexual forms are more likely to be
fi7produced by resistant infections. Other factors associated with resistance include the 
drug concentrations that the parasites are exposed to, the pharmacological characteristics 
of the antimalarial drugs used, the local malaria epidemiology, the genetic mechanisms 
underlying resistance, the level o f individual immunity, and the way drugs are used.
1.6.2 Drug pharmacokinetics and pharmacodynamics and resistance
The drug pharmacokinetic (PK), pharmacodynamic (PD) characteristics, and the 
molecular mechanism of drug resistance are key factors that define the intrinsic 
susceptibility o f drugs to resistance. Drugs more prone to resistance generally have the 
following properties: (i) intrinsically weak antimalarial activity manifest as a slow 
reduction o f the parasite biomass [a low parasite reduction ratio (PRR)], (ii) a long 
elimination half life, (iii) a 'flat1 dose response or concentration effect relationship, (iv) 
cross resistance between drugs o f a similar class, and (iv) a mechanism of action that can
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be overcome easily through single point mutations e.g. atovaquone, rather than through
oo on nn
several point mutations, so called polygenic resistance e.g. chloroquine.
Selection for resistance occurs in two ways. The first occurs when a primary 
infection is not cleared by drug treatment. If this infection contains sensitive and mutant 
parasites, then, as the parasites multiply, many asexual cycles will be exposed to 
progressively lower blood concentrations, exposing an increasing number o f parasites to 
the drug. This offers a greater opportunity for resistance conferring genetic mutations to 
occur and for these resistant parasites to survive the drug concentrations. This is more 
likely to occur if  the initial drug concentration is low e.g. because o f a sub therapeutic 
dose, and if  the drug has a longer half life, resulting in greater drug exposure. With short 
half-life drugs e.g. artesunate (Ti/2p ~ 1 hour), quinine (Ti/2p ~ 12 hours), dividing malaria 
parasites will encounter maximum therapeutic drug concentrations followed by sub 
therapeutic concentrations for only a short time. At the next dose, the parasites will again 
encounter maximum therapeutic drug concentrations. The probability o f selecting mutant 
parasites is, therefore, considerably reduced.
The second mechanism is when a newly acquired infection develops in the 
presence o f residual sub-maximal blood concentrations o f an antimalarial drug from an 
antecedent treatment. These drug concentrations may be sufficient to eradicate a sensitive 
infection but not a resistant one. In this way, the drug filters out (selects out) the sensitive 
parasites, leaving the resistant ones to emerge. This is important in enhancing the spread 
o f drug resistance. Again, the longer the terminal elimination half-life, the more likely 
these parasites will be exposed to low drug concentrations. An interesting example is the 
case o f the antifolate drugs sulfadoxine/pyrimethamine (S/P) and dapsone and 
chlorproguanil (LapDap). The half lives o f the S/P components (S=T0days, P=4days) are 
longer than those o f dapsone (20-30h) and cycloproguanil (12-20h). Use o f S/P was 
associated with the loss o f wild type parasites and an increase in the prevalence o f mutant 
parasites (mutant dhfr and dhps genes). By contrast, LapDap was not associated with a 
change in the proportions o f wild type dhfr and dhps alleles in the pretreatment and 
recurrent parasitaemias.91
Antimalarial drugs differ in their inhibitory effects on asexual malaria parasite 
development which and can be measured using the PRR. The PRR=1-parasite 
counts/parasite counto (48=48 hours). The PRR is related to the drug's stage specificity
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(stage/s in the life cycle). Antimalarial drugs reduce the parasite numbers with each 
asexual cycle by between 10-10,000 (Appendix 5).88 The artemisinin compounds have the 
highest PRR and the broadest stage specificity, killing young rings, trophozoites, and 
schizonts.92 The antimalarial antibiotics e.g. doxycycline, azithromycin, have the lowest 
PRR. In between are quinine, mefloquine, chloroquine, and amodiaquine whose greatest 
activity is against the mid-late trophozoite, and the antifolate drugs (e.g. sulfadoxine, 
pyrimethamine, dapsone, proguanil) which act against mature trophozoites and early 
schizonts. Very young rings and mature schizonts are relatively resistant to all 
antimalarial drugs. The clinical and parasitological responses are faster for drugs that act 
against earlier parasite stages.
Parasite killing as a function o f drug concentration has a sigmoid relationship 
(Appendix 6 ). The Emax represents the top o f the dose-response or concentration-effect 
relationship and differs widely between the different antimalarial drugs; the more active 
drugs with a higher PRR have a lower Emax. The lowest drug concentration that results in 
the Emax is the minimum parasiticidal concentration (MPC). Parasite reduction appears to 
be a first order (linear) process. Therefore, a fixed fraction o f the population is removed at 
each successive asexual cycle if  the MPC is exceeded. As resistance develops, parasite 
susceptibility and PRR decrease, and there is a shift to the right o f the sigmoid curve i.e. a 
higher drug concentration is required to achieve the same level o f parasite killing but the 
Emax is unchanged. The standard in vitro drug measurements (IC50, IC90, and IC99) will 
increase (see 1.7.4 for definitions). With further parasite resistance, the IC50 increases and 
the Emax falls. In vivo, parasite clearance still occurs, albeit more slowly, provided the free 
drug, plasma concentration exceeds the concentration required to maintain the parasite 
multiplication rate below one, the minimum inhibitory concentration (MIC).
The slope o f the sigmoid curve is also relevant to drug resistance. A steep slope 
indicates large parasite inhibition for a small change in drug concentration whereas a 
flatter slope indicates that a higher drug concentration is necessary to achieve the same 
antiparasitic effect. Selection o f resistance in bacteria is greatest at 'intermediate' levels of 
drug activity, generally between 20% to 80% of the maximum effect; this may also apply 
to malaria parasites.86 Drugs with long elimination half lives are more vulnerable because 
of the persistence o f sub therapeutic drug concentrations. In practice, the drug’s 
pharmacodynamic action may be improved by increasing its dose. In Thailand,
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mefloquine was increased from 15 mg/kg to 25 mg/kg with a resulting increase in 
efficacy but not to pre-resistant levels.93 However, over time the efficacy o f the higher 
dose also fell.94
1.6.3 Antimalarial drug cross resistance
Cross-resistance is the occurrence o f resistance in one drug as a result of 
resistance in another drug. These drugs usually have chemical similarities and share 
similar molecular mechanisms o f resistance. Several examples exist e.g. chloroquine and 
amodiaquine, halofantrine and mefloquine, quinine and mefloquine.95 96 97 There is one
Q O
report o f an inverse relationship between chloroquine and mefloquine resistance.
Cross resistance may have explained the high IC50 values for mefloquine in 
several west African countries that was interpreted as innate mefloquine resistance 
because o f the lack o f mefloquine drug pressure.99 Supporting evidence for this 
phenomenon also came from mefloquine prophylaxis failures in non immune 
travellers.100 101 102 However, as treatment, mefloquine has been highly efficacious (> 
90%) in west Africa.103 104 105 By contrast, in Cameroon an interesting geographical 
difference in mefloquine sensitivity has been documented.106 Using the radiolabelled 3H- 
hypoxanthine method and a cut off limit o f 30 nmol/L to define in vitro mefloquine 
resistance, 26 (20%) o f 133 isolates from northern Cameroon were mefloquine resistant 
compared to one o f 73 (1.4%) isolates from southern Cameroon. There was also a close 
correlation (r=0.67) between the in vitro response to quinine and mefloquine. Seven day 
in vivo tests were also performed using MQ 25 mg/kg in asymptomatic children aged 1 - 
10 years. RII-RIII responses were found in six of 46 (13%) northern children compared to 
no resistance in 40 southern children. Mefloquine was not in use at the time o f the study. 
Indeed, MQ has never been registered in Cameroon (P. Ringwald, personal 
communication, 2002). However, quinine was widely used in north Cameroon and may 
have led to secondary mefloquine resistance.
1.6.4 Epidemiological factors and resistance
Drug resistance will spread and increase if  the malaria life cycle is completed and 
resistant genes are transmitted to new hosts. The rate at which resistance spreads depends 
on the relative reproductive rates o f the drug sensitive versus the drug resistant parasites. 
Several factors are involved: (i) the probability o f drug resistant parasites transmitting 
viable gametocytes rather than sensitive parasites; this is a function o f the duration of
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patent gametocytaemia in man, and their infectivity to mosquitoes; (ii) the intensity of 
transmission, (iii) the immunity o f the human population that affects both asexual and 
sexual forms, (iv) the extent of antimalarial drug use, and (v) the ability o f the drug to 
reduce gametocyte carriage.107 108 109 110 The intensity o f transmission is also important 
but different factors favour the selection and spread of drug resistance in low and high 
transmission areas.
Chloroquine resistance was first documented in the low transmission areas of 
Venezuela and Colombia in the late 1950’s, and the early 1960's in Thailand.111 112 113 
Drug pressure was the main reason why resistance developed in these areas. In low 
transmission areas, high biomass infections are more likely, there is less naturally 
acquired immunity against asexual (less eradication) and sexual forms (effect on 
transmissibility), drug pressure is high because most patients are symptomatic and seek 
treatment, and male and female gametocytes are usually derived from the same 
infection.86 As transmission increases, the rate at which resistance spreads increases until 
premunition (anti parasitic immunity) is acquired and is a major factor in retarding the 
rate o f spread o f resistance. Thereafter, an increasing proportion o f transmission derives 
from older children and adults who harbour asymptomatic infections that are subject to 
less selective drug pressure. The combination o f less selective pressure and high 
background immunity are the main reasons for a slower rate o f transmission o f drug 
resistance.
1.6.5 Operational and behavioural factors and resistance
Drug use by communities is an important determinant o f drug resistance. Practices 
that lead to sub therapeutic drug levels promote drug resistance by failing to kill all 
parasites. In endemic areas, antimalarial drugs should, ideally, only be used to treat 
confirmed malaria cases and at therapeutic doses. However, limited access to the formal 
health sector often leads to the purchase o f drugs from local vendors or pharmacies. The 
high cost o f drugs may preclude the purchase o f a therapeutic course. Inappropriate 
antimalarial dosages and inappropriate drugs may also be dispensed. Fever is often 
regarded as malaria and leads to over use o f antimalarial drugs. 114 115 Compliance is 
another key issue. Mothers commonly give their children a partial dose, saving the rest of 
the drug for siblings or the next bout o f fever. 116 Many patients also stop taking drugs 
when they feel better before the full course has been taken; this is more likely after
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rapidly acting drugs like artesunate, or chloroquine and amodiaquine because o f their anti 
inflammatory properties. Long or complex drug regimens, and poor tolerability also 
compromise compliance.117 The formulation and proper implementation o f drug policy by 
malaria control programmes is crucial to ensure that all parts o f the health system are 
properly informed and understand the basics o f prescribing appropriate drug regimens.
1.7 Measuring and detecting drug resistance
In vivo and in vitro tests, and the detection of the genetic markers o f resistance are 
used for measuring and detecting resistance. For clinicians, the in vivo test is the most 
important. In vitro testing and the genetic markers o f resistance are more useful in 
epidemiological studies.118 The roles of these methods in malaria control programmes is a 
constantly changing field. Although the in vivo test provides the best data, it is costly and 
requires long follow up which can be difficult to achieve in the field outside o f the 
research setting. In vitro testing has its technical problems, several methodologies exist, 
and in vitro in vivo correlations vary.119 Molecular markers are potentially good public 
health tools for resistance surveillance because o f the ease o f obtaining filter paper blood 
spots. Correlation o f these markers with the in vivo tests varies and is the subject o f much 
research.
1.7.1 In vivo tests of resistance
1.7.1.1 WHO test of parasitological response of Plasmodium falciparum
This test was designed originally to assess the P. falciparum  parasitological 
response to chloroquine in asymptomatic individuals but has since become used for all
nc i
antimalarial drugs in symptomatic patients. This in vivo test was used for the clinical 
trials in this thesis for both vivax and falciparum malaria because at the time there were 
no published WHO recommendations for vivax or falciparum malaria testing in areas of 
low transmission.
The parasitological responses for P. falciparum  are divided into four categories: 
parasite sensitivity (S) or resistance at three levels: RI, RII, or RIII. The parasitological 
definitions are:
•  S or S/Rl. In the extended test, the parasites are sensitive if  no asexual parasites are 
found by Day 7 and parasites do not reappear by Day 28. In the 7-day field test, the
34
infection may be either S or resistant at RI (S/RI) level if  no asexual parasites are 
present on Day 7.
• RI. In the extended test, parasites are resistant at the RI level if  asexual parasites 
disappear by Day 7 but return within 28 days, if  reinfection has been excluded. In 
the 7-day field test, parasites are resistant at the RI level if  asexual parasites 
disappear for at least 2 consecutive days but return and are present on Day 7.
•  RII. The parasites are resistant at RII level if  asexual parasite does not clear by Day 
7 but is reduced to 25% or less o f the original pre-test level during the first 48 hours 
of treatment.
• RIII. The parasites are resistant at RIII level if  asexual parasitaemia is reduced by 
less than 75% during the first 48 hours, or if  it continues to rise or remain stable.
Clearly, the duration o f follow-up affects the interpretation of the test e.g. the 7- 
day in vivo test only detects high grade resistance. Ideally, the duration o f in vivo tests 
should be extended e.g. to 42 or 63 days for drugs with long half lives such as CQ, MQ, 
S/P because drug concentrations persist that may be pharmacologically active against sub 
patent parasites. The longer the follow up, the greater the probability o f detecting a late 
resistant infection but this also increases the chance o f a new infection. With a mean 
incubation period for P. falciparum  o f 12 days, a recurrent parasitaemia within 14 days is 
more likely to be a resistant (RI) infection.
1.7.1.2 The WHO assessment of therapeutic efficacy for P. falciparum
The WHO introduced a new in vivo test in 1996 (Appendix 7) that was designed 
primarily for use in high transmission areas as a public health tool for drug policy
I2i
makers. This protocol has since been revised and published following a consultation in
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2002. The 2003 edition uses both clinical and parasitological criteria and has four 
end points: (i) adequate clinical and parasitological response (ACPR), (ii) early treatment 
failure, and (iii) late clinical failure, and (iv) late parasitological failure (Appendix 8). 
Follow up extends to Day 14 or Day 28, if  adequate resources are available, including the 
use o f the polymerase chain reaction (PCR) to differentiate cases o f recurrent 
parasitaemia. This protocol removes asymptomatic recurrent parasitaemia from the 
definition o f ACR, a weakness o f the 1996 protocol. Another improvement is a minimum 
level of parasitaemia for entry into the test to reflect the pyrogenic density (the level of
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parasitaemia at which symptoms and fever occur) for different areas o f transmission. This 
allows for comparisons between studies.
1.7.1.3 An in vivo test of P. vivax
An in vivo test for P. vivax has only recently been developed by the WHO and is
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detailed in the 2003 document mentioned above. Hitherto, defining vivax resistance 
could be done by either applying the Berliner adapted system o f Baird or to use the WHO 
parasitological in vivo test for falciparum malaria, as was done for this thesis (see 
Materials & Methods). Certainly, failure to clear vivax parasitaemia after supervised, 
standard dose chloroquine is good evidence o f resistance, even allowing for the wide 
interindividual absorption. Differentiating a recurrent vivax parasitaemia cannot be done 
on clinical grounds. PCR and the timing o f the recurrence offer some help but neither can 
exclude definitively a recrudescence from a new infection or a relapse o f liver 
hypnozoites. A recurrence within 14 days o f therapy is more likely to be a resistant 
infection; after this time, it could be a resistant, or new, or relapse infection.153 A fully 
sensitive P. vivax infection does not usually reappear within 28 days o f follow up; indeed 
in the early work on chloroquine treatment of P. vivax, relapses began to occur after five 
weeks following standard dose CQ.124 Using the CQ cut off o f > 100 ng/ml at the time of 
recurrent parasitaemia, the cause o f the recurrent parasitaemia is less important (See 
1.7.6). Although this is evidence of resistance, this finding does not in itself predict 
success or failure if  standard dose CQ is given to treat this recurrent parasitaemia.
This protocol also sets a lower limit o f parasitaemia o f 250 parasites per pL. The 
end points / definitions of treatment failure are defined below:
• Clinical deterioration due to P. vivax illness requiring hospitalisation in presence of 
vivax parasitaemia.
• Presence o f parasitaemia and fever (axillary temperature > 37.5 °C) any time 
between Day 3 and Day 28.
• Presence o f parasitaemia on any day between Day 7 and Day 28, irrespective o f the 
clinical condition o f the patient.
If a patient has a recurrent parasitaemia due to P. falciparum  infection after 
clearance o f P. vivax parasites, this is not classified as a P. vivax treatment failure.
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1.7.1.4 Problems with in vivo drug assessments
The WHO parasitological in vivo test only measures the parasitological response. 
When first used, there was no distinction made between patients with symptomatic and 
asymptomatic malaria, and there was no lower limit o f parasitaemia. If a patient 
deteriorated clinically within the first 48 hours e.g. due to drug induced vomiting, 
progression to severe malaria, he/she was excluded from the analysis because o f the 
failure to meet the strict parasitological definition o f resistance. The 1996 therapeutic 
efficacy test for areas o f high transmission classified asymptomatic recurrent parasitaemia 
as ACR and, therefore, underestimated resistance. Slow acting drugs may overestimate 
the rate o f ETF especially in children with high parasitaemias who still have a high 
proportion of parasites present on Day 3. In a study in two areas o f Mali, Bandiagara 
(lower CQ resistance) and Mopti, the 1996 in vivo test over estimated ETF at both sites. 
This was more marked in Bandiagara where 10 [71% (95% Cl 42-91)] o f 14 ETFs were 
either cured (n=8) or had recurrent parasitaemia (n=2 ) .125
During follow up, recurrence of parasitaemia may occur that may be due to a new 
infection, a relapse (P. vivax or P. ovale), or a resistant infection. The longer the follow 
up, the more likely recurrent parasitaemia will occur. A recurrent parasitaemia cannot be 
distinguished on clinical grounds. A recurrent parasitaemia may also arise if  (i) an 
incubating infection is present at the time of the test, and (ii) there is early reinoculation 
with the same infecting mosquito. PCR is a useful technology to assist with the 
interpretation of the in vivo test by genetically characterising and comparing the recurrent 
parasitaemia with the Day 0 parasitaemia.
1.7.1.5 Polymerase chain reaction and in vivo assessments
PCR is a method o f examining the DNA (deoxyribonucleic acid) o f malaria 
parasites and exploits the fact that malaria parasites o f the same species have different 
genetic compositions (parasite diversity). PCR detects the different malaria species and 
genetic differences within a species. 126 For differentiating recrudescent falciparum 
infections from new infections, three genes that encode for three highly polymorphic (the 
occurrence together in the same population o f two or more genetically determined 
phenotypes) antigens are commonly used: glutamate rich protein (GLURP) and the 
merozoite surface proteins one and two (MSP-1, MSP-2). The principle o f differentiating 
recurrent parasitaemias depends on genetically identifying the Day 0 and recurrent
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parasitaemias. For P. vivax, the MSP1 and the circumsporozoite protein genes have been
197used to compare the paired isolates. A matching pair is consistent with a recradescent 
infection and a non-matching pair with a new infection. In addition, for P. vivax, a 
matching pair is also consistent with a relapse parasitaemia from liver hypnozoites o f the 
original infection, and a non matching pair with a relapse from an antecedent infection.
There are certain technical issues with PCR that effect its sensitivity and 
specificity. These include: (i) the sensitivity of detecting the Day 0 parasitaemia e.g. low 
density parasites may be missed, (ii) the resolution limits for detecting differences in 
alleles, (iii) the occurrence o f genetically different multiple infections on Day 0 and/or 
during follow up, (iv) the local transmission patterns that may result in repeat inoculations 
within a short time span or inoculation with a different malaria species. Therefore, a 
matching pattern cannot be interpreted with a 100% certainty as a recrudescent infection. 
However, using a more refined technique e.g. nested PCR with single-stranded 
conformational polymorphism techniques to analyse GLURP, MSP-1 and MSP-2, the
19Aprobability o f differentiating a recurrent falciparum parasitaemia is > 95%. There is less 
experience with the PCR genotyping of P. vivax but a matching genotype indicates a 
>80% probability o f a recrudescent or relapse (K. Kain, personal communication) .127
1.7.2 The clinical assessment of drug responses
Clinicians assess patients and their responses to treatment using clinical or 
laboratory measures that include: (i) the fever clearance time, (ii) the parasite clearance 
time, (iii) cure rates, (iv) haematological recovery, (v) coma recovery in cerebral malaria, 
and (vi) resolution o f organ dysfunction and metabolic acidosis in severe malaria.128 In 
vivo resistance generally manifests initially as a slowing o f the parasite and fever 
clearance time - patients take longer to get better. This is then followed by an increase in 
the rate o f recrudescence in non-immune patients with uncomplicated malaria; clinicians 
will notice patients returning to the clinic for retreatment o f their malaria. In endemic 
areas this manifests first in young children who have less immunity and greater parasite 
burdens. As resistance increases treatment failure rates increase, and the median time to 
recrudescence shortens. Eventually patients are encountered whose parasitaemia does not 
clear, although they may improve symptomatically e.g. because o f the anti inflammatory 
effects o f chloroquine. Finally, with high grade resistance there is no or little clinical or 
parasitological response to treatment and patients are at risk o f developing severe malaria.
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In high transmission areas, an increasing prevalence o f anaemia may be the first sign of 
worsening drug resistance with a concomitant increase in blood transfusion
21 129requirements.
1.7.3 Prophylaxis breakthrough
Although not a formal test o f resistance, prophylaxis breakthrough in the presence 
o f adequate, prophylactic drug levels is evidence o f reduced parasite sensitivity because 
parasites have emerged at drug concentrations above the MIC o f fully sensitive parasites. 
Confirmation o f the latter requires formal efficacy testing. As with treatment, appropriate 
dosing is a critical factor before ‘prophylactic resistance’ can be diagnosed. This is 
illustrated well by the case of mefloquine.
When first tested, mefloquine dosed every two weeks, was as effective as weekly 
mefloquine in semi immune Thai adults in 1980.130 However, by 1984, there were a large 
number o f  failures using biweekly MQ.131 Mefloquine prophylactic failures also occurred 
in West Africa when the recommended regimen was weekly mefloquine for four weeks 
then bi-weekly.132 133 Breakthrough parasitaemias o f 1 to 1.4/100 person-months were 
documented in long term users during the phase o f the biweekly dosing. These occurred 
at a mean of 12 days after the last MQ dose when whole blood MQ levels were low, 
ranging from 62 to 398 ng/ml. Weekly mefloquine was subsequently introduced with a 
marked drop in prophylaxis failures, 0.2/100p-m. More detailed PK work in a different 
cohort o f long term travellers documented clearly lower mean Day 14, plasma MQ trough 
levels compared to Day 7: 888  vs. 1188 ng/mL, supporting the use o f the weekly 
mefloquine.134
The importance o f measuring drug levels to diagnose prophylactic failures was 
also shown in a study of 16 French travellers to West Africa.101 Some took the 
recommended dose (250 mg weekly), others half this dose, as recommended by the travel 
clinic to reduce toxicity, whilst others were not fully compliant. Plasma MQ levels, taken 
between 3 and 26 days after the last MQ dose in nine P. falciparum  failures, ranged from 
345 to 3,000 ng/ml. At the time of the study, the plasma MQ level that was considered 
adequate to suppress P. falciparum  by the drug manufacturer was between 200-300 
ng/ml. These nine failures were considered to be due to mefloquine resistance. However, 
more detailed PK MQ data led to a revision o f these drug levels. Lobel et al established 
that the prophylactic effectiveness of MQ was critically dependent on MQ levels. They
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measured whole blood MQ concentrations (ratio o f whole blood: serum/plasma is 1:1.28) 
and estimated that 99% prophylactic efficacy (PEf) could be achieved with whole blood 
MQ levels >915  ng/ml, 95% with > 620 ng/ml, and 90% with > 462 ng/ml.132 These data 
show that simply attaining a level above a certain threshold is insufficient for diagnosing 
prophylactic failure due to resistance. Accordingly, some o f the French 'prophylactic 
failures' were clearly due to inadequate MQ levels. In another report o f MQ prophylaxis 
failures in four travellers to West Africa, two had plasma MQ levels measured at the time 
o f patent parasitaemia; these were 507 ng/ml and 105 ng/ml. Both travellers said they 
were compliant but the traveller with a level o f 105 ng/ml stopped his MQ after three 
weeks (one week early) on return to France. In vitro data (3H-hypoxanthine microtest 
method) from three cases showed reduced MQ sensitivity. The measured IC50 values 
were > 30 nmol/L (35, 38, 82 nmol/L). Three were treated successfully with therapeutic 
doses o f MQ; the fourth was treated with CQ. Prophylactic failure in these travellers was 
probably due to a combination o f reduced parasite sensitivity to MQ, poor compliance, 
and/or poor drug absorption.100 The successful use o f MQ therapy excludes strictly 
defined parasite resistance as the cause of these failures.
Current recommendations for MQ prophylaxis vary. Some authorities recommend 
starting MQ one week before entry into the endemic area whilst others three weeks; the 
rationale for the latter is to detect MQ toxicity. Both recommendations, however, are too 
short to achieve steady state MQ levels which are attained after 6 to 7 weeks o f weekly 
dosing. During this time, mean MQ levels are significantly lower than those obtained 
after a loading dose o f mefloquine (250 mg/d x 3 days) at the start o f prophylaxis.135 The 
loading dose has not gained favour with civilian travellers but has been used and been
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well tolerated by soldiers. An important PK finding is the wide interindividual
absorption o f MQ. After 18 weeks o f MQ prophylaxis, plasma MQ concentrations (taken
2 days post last dose) in 87 Dutch Marines ranged from 242-1,918 with a mean o f 979
ng/ml. Corresponding whole blood levels were 159-1,671 and 788 ng/ml.138 In a small
cohort o f 15 travellers, the post, first dose (250 mg), plasma, Cmax values ranged from
412-956 ng/ml; at steady state the trough MQ levels also varied ~ two fold: 888-2080
ng/ml.134 For some MQ users, therefore, prophylaxis failures will occur despite full
compliance. A reasonable PK marker o f which is a CMQ:MQ ratio >2:1  (CMQ is the
118
non active carboxyacid metabolite of mefloquine).
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1.7.4 In vitro resistance - description and principles
In vitro laboratory methods assess the ability o f differing concentrations of
antimalarial drugs to inhibit the growth o f malaria parasites in culture and is a measure of
the intrinsic drug susceptibility o f a given malaria isolate. Most in vitro work has centred
on P. falciparum. P. vivax is very difficult to culture (C Ohrt, personal communication).
Parasite growth inhibition is assessed either biochemically or morphologically (rings to
schizonts). The WHO Mark III in vitro test assesses the inhibition o f P. falciparum from
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ring forms to schizonts. Patient's blood is inoculated into plates that are pre-dosed with 
different concentrations o f antimalarial drug; the control well contains no drug. Giemsa- 
stained slides are prepared and read after 24 to 48 hours o f culture. The degree o f parasite 
maturation (number o f schizonts) is compared with that of the control well. Although, this 
test has the advantage o f requiring minimal equipment, it is cumbersome and lacks 
precision. Incubating to 48 hours improved results in Indonesia. 140 Other in vitro tests rely 
on the use o f radiolabelled H-hypoxanthine, malaria parasite lactate dehydrogenase 
(pLDH), and the detection of the histidine rich protein-II (HRP-II). Hypoxanthine, a 
purine, is essential for the synthesis o f DNA. Measuring the uptake o f radiolabelled 3H- 
hypoxanthine as a marker of parasite growth is the basis o f this in vitro test.141 It is not 
widely used because o f the use of radio-labelled material (raising disposal problems) and 
the need for expensive equipment (a beta-counter). The basis o f the pLDH microtest is 
the production o f pLDH by asexual falciparum parasites. It is adapted for field use and 
requires minimal equipment e.g. spectrophotometer. It yields quantitative results, is 
unaffected by the immune status o f the host, and correlates well with the 3H-hypoxanthine 
in vitro method.142 The HRP-II in vitro relies on the detection by enzyme-linked 
immunosorbent assay (ELISA) o f the HRP-II protein that is produced by P. falciparum. It 
is reliable, easy to perform, and correlates well with the isotopic (3H-hypoxanthine) assay, 
and the WHO schizont maturation tests (R = 0.959; P < 0.0001) .143
The inhibition o f parasite growth as a function o f drug concentration is sigmoid in 
shape (Appendix 6). Drug activity is usually expressed as follows:
• Maximum drug effect (Emax) = maximal inhibitory effect o f drug (the top o f the 
sigmoid curve); greater drug concentrations do not produce more parasite inhibition.
•  MPC = minimum parasiticidal concentration; the lowest drug concentration that 
produces the maximum effect (Emax)
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•  IC50, IC90, IC99 = drug concentration at which 50%, 90%, and 99% of growth 
inhibition occurs relative to that o f the control.
• Minimum inhibitory concentration (MIC) = lowest drug concentration that prevents 
the growth o f asexual parasites.
One of the major problems with in vitro tests is the determination o f the threshold 
IC50 values that distinguish sensitive from resistant parasites. There are currently no fully 
validated cut-off points for assessing in vitro resistance. Therefore, the positive predictive 
value o f a given IC50 for predicting in vivo resistance is unknown.119 Certain drug levels 
have been proposed by the WHO (Mark III in vitro test) and the Walter Reed Army 
Institute o f Medical Research (WRAIR) to distinguish sensitive from resistant parasites 
(Table 1.2).
Table 1.2 In vitro drug concentrations used to determine drug resistance (Source: WHO 
and WRAIR).
Drug Drug concentrations
Resistant* Sensitive! Resistance!
Chloroquine > 8* 2 - 1 0 3 0 - 1 0 0
Sulfadoxine > 1,000 10-80 30,000
Pyrimethamine > 12.5 <0.1 1 5 -4 0
Quinine > 256 10-30 50 - 300
Mefloquine > 64 1 -7 1 0 -8 0
Amodiaquine > 4 - -
Halofantrine - 0 .1 -3 5 - 1 0
* values from the WHO in pmol/well
t  values from WRAIR in ng/ml
The WHO values for sensitive infections have been validated but not those for 
resistant infections. (P. Ringwald, personal communication). To circumvent the difficulty 
o f using cut off values, evidence o f emerging or increasing drug resistance over time is 
present if  the median IC50 increases over time using the same methodology. As resistance 
develops, the curve shifts to the right and eventually the E^x will fall. Large shifts o f the 
curve are associated with point mutations that cause a marked reduction in parasite 
susceptibility e.g. cytochrome be 1 gene (involved in the electron transport chain) and
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atovaquone resistance, dhfr and dhps genes and sulfadoxine/pyrimethamine resistance.
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In vitro tests have been used primarily to conduct surveillance o f drug resistance 
and to support the findings o f clinical trials. Monitoring trends is their most useful
i 10
application.
1.7.5 Drug pharmacokinetics and the measurement of resistance
The in vivo assessment of drug resistance should, where possible, include 
measuring drug concentrations to determine whether adequate drug absorption has taken 
place - a prerequisite for meeting the WHO definition o f resistance.75 Interpretation of 
these measurements requires an appreciation o f drug pharmacokinetics. Drug disposition 
in the humans, namely, absorption, distribution, metabolism, and elimination define the 
PK properties o f a given drug. The following PK parameters are routinely measured and 
reported:
• Tmax = the time taken to reach maximum concentration
• Cmax = the maximum drug concentration at Tmax
• Distribution half life (Ti/2a) = the time taken for half the drug to disappear from
blood because o f distribution
• Elimination or terminal half life (T i/2p) = the time taken for half the drug to 
disappear from the blood due to its metabolism and excretion
• Residence time = total time a drug is present in man and ~ 3 x T 1/2(3
• Volume o f distribution (Vd) = a measure o f drug distribution in body compartments
• Area under the curve (AUC) o f a plot o f drug concentration over time
• Therapeutic range = the concentration of drug that confers antimalarial activity 
within a safety margin
• Free plasma concentration = unbound drug concentration in plasma
• Protein binding = the degree to which drugs bind to plasma proteins e.g. albumin, a- 
1 acid glycoprotein
• Total drug concentration = the sum the free and protein bound drug concentrations
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In malaria, it is the asexual parasites that cause clinical disease. Although 
intraerythrocytic, they are exposed to drug concentrations that correspond closest to the 
free (unbound) plasma concentration rather than the red cell concentration (derived from 
measurements mainly in uninfected erythrocytes). It is unbound drug that enters 
parasitised red cells to exert its pharmacological action.83 Effective antimalarial therapy 
requires continual drug activity over at least four life cycles i.e. > 6 days.85 Extravascular 
drug distribution and tissue penetration are not important for parasite killing. Drugs with 
long half lives are dosed once e.g. mefloquine (Ti/2p 2-3 weeks), sulphadoxine (10 days) / 
pyrimethamine (4 days) or once daily e.g. chloroquine (1-2 months). Shorter half life 
drugs e.g. halofantrine (3-5 days), lumefantrine (3-6 days), and atovaquone (1-3 days) 
need to be given over several days. Drugs with the shortest half lives need dosing over 
seven days e.g. quinine (16 hours in patients) and artemisinin derivatives (1 hour).
Malaria itself may affect drug kinetics. Vomiting results in reduced drug 
absorption. There is contraction o f the volume o f distribution, especially for drugs that are 
highly bound to a-1 acid glycoprotein like quinine. The acute inflammatory response 
results in an increase in a-1 acid glycoprotein and an increase in the total quinine 
concentration. Reduced drug clearance due to impaired hepatic and renal function results 
in the prolongation o f the half life e.g. the T 1/2(3 o f quinine is l lh  (volunteers), 16h 
(uncomplicated malaria), and 18h (severe malaria) .145
1.7.6 The problem of defining a therapeutic range for chloroquine
Effective antimalarial treatment depends upon drug concentrations within the 
therapeutic range acting for a sufficient length o f time to kill all malaria parasites without 
undue toxicity to the host. Determining the therapeutic range, particularly its lower limit, 
is problematic because parasite sensitivity varies, interindividual CQ absorption varies 
widely, and immunity synergises with drug action. Currently the therapeutic range for 
chloroquine remains undefined for any malaria species (most work has focussed on P. 
falciparum  and P. vivax). In addition, the precise PK PD parameters determining parasite 
killing remain uncertain.85 Three PK PD parameters are considered important: (i) the 
MIC, (ii) the MPC, and (iii) the AUC. For chloroquine, and other long half life drugs, the 
AUC which lies above the MIC is important and is closely related to the time chloroquine 
concentrations exceed the MIC and the MPC. Therefore, the extent o f chloroquine 
absorption and its duration o f action are important. The Cmax appears less important
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because concentration dependent killing o f parasites by chloroquine is not a significant 
PK-PD factor for producing parasitological cure. In Gambian children with severe 
malaria, higher peak parenteral (sc, im, iv) CQ concentrations did not result in more rapid 
fever or parasite clearance times compared to chloroquine delivered by nasogastric 
tube.146 Measuring the drug concentration at the time o f recurrent parasitaemia is 
informative in terms o f giving an idea of the MIC for that particular infection.
In one study o f 39 semi immune Tanzanian children, Hellgren et al examined the 
PK-PD relationship o f CQ and uncomplicated falciparum malaria, using resistance 
(RI/II/III) as the PD endpoint.147 They estimated the in vivo MICs from the mean, plasma 
CQ concentrations on the day before and after either RII parasites increased in number or 
RI parasites reappeared. The median (range) MICs were 147 (44-673) nmol/L [= 44 (13- 
226) ng/ml] for a RI response, and 790 (444-869) nmol/L [= 237 (133-261) ng/ml] for a 
RII response, providing supporting pharmacological evidence for increased parasite 
resistance. This small study found a non significant CP=0.058) lower AUC in the RII 
cases (n=7) compared to the RI cases (n=19) but a significantly lower Cmax, suggesting 
PK factors (in this case absorption) might have been influenced by the disease itself. For 
field trials, to obviate the need for multiple sampling, the Cmax can be used as the PK 
surrogate marker for the AUC. This was done in the chloroquine doxycycline treatment 
trial presented in this thesis and in many in vivo tests conducted in Indonesia by the US 
Navy. The Cmax o f orally administered CQ (25 mg/kg) occurs at 51 hours.148
Determining the therapeutic range for P. vivax malaria is also problematic because 
of the changing sensitivity o f P. vivax over time. A rough estimate o f the lower end of the 
therapeutic range could be the minimum, Day 2 Cmax that cures patients, assessed by Day 
28. In a small study o f Swedish patients (n=15) with non-falciparum malaria, the 
minimum Day 2, total whole blood CQ level after standard dose CQ was 1.76 pmol/L (=
528.5 ng/ml). On Days 4 and 7, the respective levels were 1.48 pmol/L (= 444.4 ng/ml) 
and 1.09 pmol/L (= 327.3 ng/ml) .148 A similar result was obtained in 23 Vietnamese with 
CQ sensitive P. vivax (517 ng/ml) and in 25 Indonesians with CQ sensitive vivax and 
falciparum infections (472 ng/ml); the latter study did not distinguish between vivax and 
falciparum patients.149150
Research conducted in 1948 provides key data on the PK characteristics o f CQ in 
vivax malaria. Berliner and colleagues studied the dose response o f experimentally
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induced, McCoy strain (from Tallahassee, Florida, USA) P. vivax malaria in 25 American 
volunteers.151 They classified the therapeutic effects in three ways: (i) Class I - no certain 
effect, (ii) Class II - temporary suppression o f parasitaemia and/or fever, and (iii) Class III 
- 'permanent effect', the absence o f parasitaemia for 14 days for P. vivax, followed by a 
positive reinoculation to indicate continued host susceptibility to infection. The total 
doses o f CQ administered orally ranged from 130 to 600 mg. Mean plasma CQ 
concentrations, measured in 21 subjects, ranged from < 1 to 69 pg/L (median 12 pg/L). 
Of the 25 volunteers, there were two Class I, seven Class II, and 16 Class III responses. 
The critical mean plasma concentration that distinguished a Class III from a Class II 
effect was 10 pg/L over four days. Taking this seminal work and the PK data in monkey 
models, the minimum plasma concentration o f chloroquine required to cure vivax malaria
1 59is considered to be 15 pg/L. This is approximately equivalent to a whole blood, TCQ 
concentration of 120 ng/ml.153 Following standard dose CQ in 15 Swedish travellers, the 
mean, Day 28 TCQ concentration was 99 ng/ml, a level that suppressed P. vivax. For the 
purpose o f  defining the MIC for P. vivax, a level o f 100 ng/ml has been proposed by
1 53Baird. Field studies conducted in Indonesia have used this total CQ concentration as a 
marker o f P. vivax resistance. A recurrent vivax parasitaemia that occurs after supervised, 
standard dose CQ when the TCQ concentration is > 100 ng/ml, is considered evidence of 
resistance whether it is a new infection, relapse, or recrudescence.
1.8 Antimalarial drug resistance and drug combinations
Drug resistance may be inevitable but the rate o f its development can be altered. 
The importance o f treating an infection adequately and minimising selective pressures are 
crucial. The idea that resistance could be overcome, delayed or prevented by combining 
drugs with independent modes o f action is not new. This approach has been used to treat 
other infections such as subacute bacterial endocarditis, leprosy, and tuberculosis. The use 
o f drug combinations in malaria therapeutics has long been advocated by Peters.154
The main reason for using drugs with different modes o f action is to reduce the 
probability o f treatment failure due to resistance. On the assumption that resistance results 
from spontaneous genetic mutations, then the probability that a parasite is simultaneously 
resistant to two drugs with independent modes o f action is the product o f the individual 
parasite mutation frequencies. If 1 in 106 parasites is resistant to drug A, and 1 in 106 is 
resistant to drug B, then 1 in 1012 will be simultaneously resistant to A and B. If all these
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mutants result in a resistant parasite, then the chance of selecting a drug resistant mutant 
is reduced a million fold by using both drugs together. The sequential deployment o f the 
two drugs is much less effective because it fails to exploit the multiplicative reduction in 
selection risk. Combinations could theoretically delay the selection o f drug resistance and 
interrupt the spread o f established resistance. If a patient acquires an infection already 
resistant to drug A, then drug B should still be effective on its own and vice versa. If both 
drugs have matching PK profiles, then the mutual protection provided is high because the 
parasite will ’see' both drugs. It would, therefore, be more effective to deploy the two 
drugs together from the outset rather than waiting for resistance to develop to either 
drug.155
Data on resistance evolution and the use o f malaria combinations are few. 
Evidence from Vanuatu, an island o f mixed vivax/falciparum transmission, suggests that 
the deployment o f chloroquine and S/P in combination has resulted in low rates of 
resistance to either drug. (A. Schapira, personal communication). By contrast, there are 
ample data demonstrating increased treatment efficacy with antimalarial drug 
combinations that have different modes o f action e.g. antimalarial and antibiotic 
combinations, and artemisinin based combinations.
Mefloquine/artesunate cured > 95% of patients with highly resistant falciparum 
malaria acquired on the Thai-Burmese border at a time when mefloquine had a failure 
rate o f -  25%.156 In Gabon, clindamycin improved the efficacy o f a 3 days course of  
quinine from 32% to 88%, and that o f standard dose chloroquine from 9% to 70%.157 
Combining doxycycline or tetracycline with quinine, amodiaquine, or mefloquine, 
resulted in treatment efficacies exceeding 94% against falciparum malaria in Thailand.158 
159 160 i6i 162 j j y - g g  d a y S  0 f  doxycycline plus standard dose chloroquine in Gabonese 
adults resulted in a cure rate o f 75% in an area where the background, adult CQ resistance 
rate was 36%; all CQ-D failures were RI.163 164 This CQ-D cure rate was, however, 
significantly lower than those of halofantrine (100%) and CQ-clindamycin (97%) in the 
same study.
Despite promising results from controlled trials, deploying combinations is not 
without its challenges. In 1984 the triple combination o f mefloquine plus S/P was 
introduced for the treatment of multidrug resistance falciparum malaria in Thailand with 
the aim of delaying the onset of resistance to mefloquine. However, this strategy failed
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because P. falciparum was already highly resistant to S/P.7 Recent data on the 
deployment o f artesunate/mefloquine in the refugee camps along the Thai-Burmese 
border, where prescribing is well controlled, has resulted in sustained high cure rates, 
reduced infection rates o f falciparum malaria, and seen a fall in the median IC50 for 
mefloquine.94 This encouraging scenario needs to be tested in other areas where the 
patterns o f malaria transmission are different.
Developing countries, like Indonesia, have a pressing need to tackle the 
substantial burden o f drug resistant malaria. Using currently available drugs that are 
inexpensive with user friendly regimens is one way forward while waiting for newer 
drugs to be developed or efficacious combinations to be affordable. Although S/P is a 
useful inexpensive drug for chloroquine resistant P. falciparum , it lasted only five years 
in the low transmission areas o f Thailand following its deployment.7 S/P resistance is 
present in Africa and has been documented in Indonesia.39 165 Furthermore, S/P is a poor 
choice for treating P. vivax because it is intrinsically slow to clear vivax parasitaemia, and 
resistance by P. vivax is emerging in Thailand and Indonesia.54 166
In Papua combining S/P with CQ as an interim malaria control measure against P. 
falciparum  and P. vivax would be sub optimal because o f  the high degree o f CQ 
resistance already present to both species, and the emergence o f S/P resistance.39 46 
Inexpensive, alternative treatments to chloroquine are certainly needed for chloroquine- 
resistant falciparum and vivax malaria in north-eastern Papua. Doxycycline, produced 
locally, at a cost o f some US$3 per 100 capsules (52 cents for 7 days) might be a potential 
partner to chloroquine which costs about seven US cents for an adult treatment.
1.9 The treatment of CQ resistant P. vivax
Little attention has been given to the alternative treatment o f  chloroquine resistant 
or sensitive P. vivax. In Papua, CRPV has been treated with halofantrine alone (8 mg/kg x 
3 doses), and chloroquine combined with two dosing regimens o f primaquine (10 
mg/kg/d x 28d or 2.5 mg/kg/d x 3d).20 The Day 28 cure rates with halofantrine, either 
primaquine regimen, and chloroquine alone were, respectively, 94%, 85%, and 22%. In 
Thailand, CQ sensitive P. vivax was treated with several drugs: S/P, mefloquine, quinine, 
artesunate, and artemether. Cumulative cure rates were assessed after 30 days. For 
chloroquine and mefloquine, the cumulative cure rates were 100% due to their long 
duration o f action. The S/P cure rate was low (22%) and due to resistance. For the short
48
acting drugs, relapse occurring within a few weeks confounded the cure rates which 
appear modest at ~  45%, despite rapid parasite clearance.166
1.10 Malaria prophylaxis
1.10.1 Review of the current recommendations for malaria prophylaxis
Antimalarial prophylactic recommendations for travellers from non endemic areas 
are published by national and international authorities.31 167 The current British guidelines 
are based on several essential elements: (i) the country to be visited, (ii) the type o f travel 
e.g. ecotourism, business, (iii) local resistance patterns, (iv) the risk o f contracting 
malaria, (v) the prophylactic efficacy o f current drugs, (vi) drug tolerability, (vii) 
contraindications to the use o f prophylactic drugs, and (viii) their ease o f use. 
Recommended prophylactic regimens are weekly chloroquine alone or combined with 
daily proguanil, weekly mefloquine, daily doxycycline, and daily atovaquone/proguanil 
(Malarone®). Tafenoquine and primaquine are under development as prophylactic 
agents.168
1.10.2 Assessing the quality of the research data
Studies conducted in certain populations such as residents from malaria endemic 
countries and soldiers may not be directly applicable to travellers because malaria 
acquired immunity enhances drug action, and young, healthy soldiers tend to report fewer
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side effects than travellers. The best quality research data come from randomised,
placebo controlled trials but are costly, and difficult to conduct.171 Retrospective studies 
e.g. using post travel questionnaires are easier to conduct, and are able to collect data on 
very large numbers o f travellers. Although subject to bias because responders may be 
different to non responders and recall may be imprecise, they still provide useful data. 
Case reports o f drug toxicity are difficult to evaluate in terms o f drug relationship because 
the evidence is circumstantial. Never the less, they alert clinicians to the possibility of 
rare and, possibly, serious adverse effects. Assessing the risk o f drug related toxicity is 
crucial for formulating prophylactic policy because toxicity is associated with poor 
adherence, disrupted holidays, and malaria. Very large clinical trials are required to assess 
prospectively the risk o f rare side effects and to detect the relative risks o f low frequency 
events between different prophylactic regimens. This is not achievable during trials for 
drug registration. A system of pharmacovigilance operates once a drug has been 
registered and widely used. In the UK, pharmacovigilance operates through the Yellow
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Card System. However, it does not capture all the pertinent data because o f under 
reporting due to failure o f both physician and traveller to suspect, appreciate, and report 
toxicity. In addition, because background rates o f adverse events are generally unknown, 
a cause and effect relationship with the antimalarial drug cannot be established firmly. 
The latter is a particular problem for users o f long term prophylaxis because symptoms 
and complaints will occur naturally that are not drug related.172
1.10.3 Assessing the risk of acquiring malaria
Malaria transmission varies widely in different regions, countries, and within 
countries. Assessing the risk requires the continued collection and interpretation o f sound 
epidemiological data. Maps are available that stratify countries based on the risk of 
acquiring malaria; one such map is published by the WHO (Appendix 9). The risk of 
acquiring malaria depends on various factors, including length o f stay, urban vs. rural 
travel, awareness of the benefits o f preventative measures, use o f personal protective 
measures, and drug compliance. Quantifying the risks o f acquiring malaria has come from 
several studies o f travellers and Peace Corps volunteers.
Data o f British travellers from the mid 1980s, showed Oceania, principally Papua 
New Guinea, to be have the highest malaria risk, affecting 41/1,000 travellers per year; 
most o f these cases (37/1,000) were due to vivax malaria.173 Risk estimates were 
1.72/1,000 for East Africa, 3.75/1,000 for West Africa, 2.26/1,000 for India, 1.77/1,000 
for Pakistan, 0.12/1,000 for Latin America, 0.02/1,000 for SE Asia, and 0.01 for the 
Middle East. Figures within West Africa varied markedly and were 5.55/1,000 for 
Nigeria, 7.79/1,000 for Ghana, and 0.028/1,000 for the Gambia. For travellers to East 
Africa, the risk was high in the first week, falling over the next 3 weeks but rising 
thereafter. Business travellers had the highest risk. Poor drug compliance compromised 
the prophylactic efficacy o f all regimens and was greatest in adult men. Poor compliance 
with chloroquine/proguanil was associated with a 2.5 and 5 fold increase in the risk of 
acquiring P. falciparum  malaria for travellers to West and East Africa, respectively. In 
East Africa, poor compliance offered very little protection. Another report on risk trends 
of travellers to West Africa between 1986 and 1988 showed that immigrants from West 
Africa living in Britain who visited their families had the highest risk with attack rates 
rising from 0.4% ('86) to 0.8% ('87) to 1.4% ('88) for Ghana, and 0.4%, 0.6%, and 0.8% 
for Nigeria, respectively.174 These figures were higher than those for East Africa which
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remained stable at a rate 0.2%. A parallel situation was also seen in a study o f imported 
malaria into the USA from 1985 to 1988; there was a stable risk in East Africa and a 
rising risk for West Africa.175 The reasons for this rise were related to increasing CQ 
resistance, increased transmission in West Africa, and poor use o f chemoprophylaxis. 
Risk data from tourists (n= 139,164) visiting Kenya for less than one year, mostly up to 
four weeks were 1.2%/m for those who did not take prophylaxis and 0 .8% for those on 
CQ-P.176 In an earlier study o f ~ 42,000 travellers who took no prophylaxis, the risks per 
month for East and West Africa were 1.52% and 2.42%, respectively.177 For Peace Corps 
volunteers who took long term weekly chloroquine while living in several west African 
countries, the overall risk o f malaria acquisition was ~ 3.5%/m which probably 
corresponds to a risk o f 7%/month without prophylaxis, assuming a prophylactic efficacy 
of 50% for CQ.132
Deaths due to malaria have occurred in travellers who did not take or comply with 
prophylaxis or who took chloroquine alone. Given a case fatality rate in Europe o f 0.5- 
1%, the estimated risk of dying from malaria for travellers is approximately 1 in 4,000.177
1.10.4 Definition of prophylactic efficacy and effectiveness
When measured prospectively, the prophylactic efficacy (PEf) o f a given drug 
compares the risk o f malaria acquisition between placebo and the active drug. The PEf is 
the percent reduction o f malaria by the active drug and is computed by the formula PEf =
l - ( I d m g / I p i a c e b o ) »  I  is the malaria incidence, measured as the cumulative incidence 
(proportion) within a certain time span, or the incidence rate (number o f infections per 
person-year). The PEf has a point estimate and a 95% confidence interval (Cl). 
Retrospective studies have estimated the prophylactic effectiveness using the same 
formula whilst other studies have simply reported the effectiveness o f a given regimen 
e.g. the proportion o f individuals who remain parsite free after a given time period of  
unsupervised prophylaxis. There is no generally accepted cut o ff value that determines 
whether a given drug will be registered and recommended as prophylaxis. Clearly, the 
higher the PEf, particularly it's lower 95% Cl, and the lower the toxicity, the better. 
Prophylactic regimens will change over time as new drugs are registered, serious 
toxicities become apparent, and as the resistance patterns o f malaria change. A synopsis 
o f the PEf o f the main prophylactic regimens is presented below.
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1.10.5 Prophylactic efficacy and effectiveness of commonly used regimens
1.10.5.1 Chloroquine and Chloroquine/proguanil
Several small studies o f expatriates living in Africa have documented the poor 
prophylactic effectiveness o f  chloroquine against P. falciparum. In the early 1980s, a 
retrospective questionnaire study administered to 821 expatriates living in Dar Es Salaam 
showed that chloroquine was ineffective and associated with a malaria incidence rate of
17816.9/p-y, a rate similar to no prophylaxis. CQ/P was considerably better (2.2/p-y). In 
Cameroon, CQ/P was reasonably effective in expatriates. Over 18 months, nine (11.5%) 
o f 78 subjects developed falciparum malaria compared to 26 (50%) o f 52 subjects who 
took no prophylaxis (PO.OOOl) .179 CQ/P or proguanil alone were the best regimens used 
by expatriates living in Malawi; 8.5% o f users on these regimens developed malaria
1 90within one year compared to 22% for CQ alone. The largest published, retrospective 
series is o f 145,003 travellers to Kenya between 1985 and 1991.176 Using data from 
139,164 travellers who stayed for < 1 year, CQ/P prevented 72% (95% Cl 56-82) P. 
falciparum  infections compared to no prophylaxis; the corresponding figure for weekly 
mefloquine was 91% (95% Cl 85-94). Amongst US Peace Corps volunteers in West 
Africa on long term prophylaxis, CQ alone resulted in 3.1 to 3.8 malaria attacks/100 
person-months (p-m); the figures for CQ/P were 1.7 to 2.1/100 p-m .132 In a prospective 
study in 1992/93, CQ/P had a PEf of only 54% compared to placebo in malaria immune 
western Kenyans aged 9-14 years. 181 In 1992/93, amongst Italian soldiers (n=4,800) 
deployed to Mozambique, the incidence rate o f falciparum malaria was 17/1000 p-m in 
those taking CQ/P compared to 1.8/1000 p-m for those on mefloquine, a nine fold 
increase in risk.182 French soldiers (n=107) using CQ/P (administered as a daily, fixed 
dose combination) or doxycycline while on mission in an unspecified central African 
country for three months suffered an incidence rate o f falciparum malaria o f 3.1/100p-
1 83m. Most (87 o f 107) o f the malaria was in a group o f soldiers who had recently arrived. 
Their malaria incidence rate was 5.3/100p-m for CQ/P users and 6.3/100p-m for 
doxycycline recipients. Poor compliance was reported by ~  40% of the prophylactic 
failures. Difficult field conditions made the implementation o f personal protective 
measures (e.g. insect repellents, bed nets) problematic and contributed to the risk of 
acquiring malaria. A prospective trial o f CQ/P and atovaquone/proguanil (A/P) in western 
travellers has recently been conducted (See 1.10.5.4).
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Chloroquine alone as prophylaxis has little role. It may be used in areas o f P. 
vivax predominance and where there is no reported falciparum resistance. CQ/P may be 
used as in areas o f limited and low grade chloroquine resistance and for travellers with 
contraindications or intolerance to the other main regimens.
1.10.5.2 Mefloquine
Weekly mefloquine (250 mg in adults) provides very effective prophylaxis in 
areas where mefloquine resistance is not a problem. Efficacy and effectiveness exceeding 
90% have been reported in non immune Indonesians, and travellers to East and West
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Africa. Whilst prophylactic failures have been reported occasionally with weekly
MQ, its introduction in 1993 has resulted in a substantial fall in the number o f malaria 
cases of imported malaria into the UK from East Africa concomitant with declining use of  
CQ/P. A similar fall in malaria cases was seen in Peace Corps volunteers stationed in 
West Africa.185 In the mefloquine resistant areas o f SE Asia, mefloquine has been less 
effective.
Thai soldiers (n= 1,307), deployed on the Thai-Cambodian border for 22 weeks, 
had a malaria failure rate of 3.2 cases/100 p-m; 2.2 for P. falciparum, 1 for P. vivax. 
Compliance was high, averaging 91% over the course o f the study, but prophylactic 
failures due to poor compliance were calculated as 0.3/100 p-m (falciparum) and 0.2/100 
p-m (vivax) .186 At the time of prophylactic failure, 32 soldiers had serum MQ levels o f 26 
to 2,515 ng/ml with a mean o f 950 ng/ml. Nine had levels < 500 (< 391 whole blood) 
ng/ml, 23 > 500 ng/ml, and 16 had levels > 1,000 ng/ml.187 Halofantrine failed to cure (RI 
resistance) seven o f the 32 soldiers. All 7 RI failures had had serum MQ levels > 500 
ng/ml. The mean MQ IC50 o f those who failed halofantrine was significantly higher than 
that o f the halofantrine treatment successes: 23.8 ng/ml vs. 12.5 ng/ml. There was also a 
positive correlation between the MQ and halofantrine IC50S. These data demonstrate cross 
resistance between mefloquine and halofantrine and sound evidence o f  MQ resistance as 
the cause o f some o f these prophylaxis failures. Similarly, o f 2,289 Dutch marines 
stationed in Cambodia for six monthly tours o f duty, 59 developed 64 attacks o f malaria 
(P. falciparum n=42, P. vivax n=22), giving a cumulative incidence o f 2.6%.188 Most 
soldiers, 86.3% (n= 1,975) reported full compliance. Eight o f 11 falciparum isolates tested 
had evidence o f in vitro mefloquine resistance (methodological details not given). Malaria 
occurred during deployment {P. falciparum, n=31), and after return to Holland: (i) P.
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falciparum failures (n=l 1) 2-10 weeks, and (ii) P. vivax (n=22) 1-18 months after leaving 
Cambodia, consistent with data in returned UK travellers. 189 In non immune Indonesian 
soldiers stationed in north-east Irian Jaya for 13 weeks, mefloquine was highly effective 
at preventing falciparum and vivax malaria, achieving prophylactic efficacies o f 100% 
(87-100) and 100% (83-100), respectively.136 A prospective, comparative study with A/P 
has recently been reported (See 1.10.5.4). Mefloquine prophylaxis is recommended for 
Africa, Latin America, and parts o f Asia where there is chloroquine but no MQ 
resistance.
1.10.5.3 Doxycycline
Doxycycline is effective against drug resistant P. falciparum  and P. vivax malaria. 
It lacks appreciable causal activity and has no activity against liver hypnozoites.190 
Prophylactic studies have been conducted in SE Asia, New Guinea island, and Africa.
On the Thai-Burmese border, daily doxycycline (n=95) was compared to weekly 
chloroquine (n=93) in refugee children and adolescents aged 10-15 years. Doxycycline 
(100 mg/d) was administered to those > 40 kg and 50 mg/d to those < 40 kg for nine 
weeks. Doxycycline failures numbered 5 over 597 person-weeks; CQ failures were 31 
over 488 p-w .191 In another trial in the same population, standard [100 mg (n=66)] and 
half dose (n=77) doxycycline were compared to placebo (n=80) given over six months. 
Both regimens were more effective than placebo for preventing falciparum and vivax
109parasitaemia. The failure rate against P. falciparum was low ~ 0.2/100 p-w for both 
doxycycline regimens but the 100 mg dose was more effective at preventing vivax 
malaria (0.3 vs. 1.4/100 p-w). Two doxycycline (50 and 100 mg) regimens (n=243) were 
compared to one tablet o f weekly pyrimethamine 12.5 mg /dapsone 100 mg [Maloprim® 
(n=123)] in Thai soldiers deployed on the Thai-Cambodian border. 193 Drug 
administration was not supervised. Low rates o f compliance and corresponding low 
efficacy rates were documented for all three regimens over 17 weeks. Compliance was 
79% and 73% for the Maloprim® and doxycycline regimens, respectively. The 
cumulative failure rates for both malaria species were 19% (100 mg), 32.5% (50 mg), and 
52% (Maloprim®). The higher doxycycline dose was significantly better at preventing 
falciparum but not vivax malaria compared to the 50 mg regimen. In another trial o f 77 
Thai soldiers, conducted over 80 days, falciparum attack rates were low (3.9%) during the 
first 40 days but increased to 9.5% by study end. The P. vivax cumulative incidence was
54
1.3% at both time points. Declining doxycycline effectiveness was associated with poor 
compliance.194
In Cambodia, doxycycline combined with chloroquine (300 mg/w) was effective 
in Australian soldiers. Over two years, there were eight cases (Pf=2, Pv=6) o f malaria in 
600 men, giving a cumulative incidence o f 1.3% (0.65% over one year) .195 The French 
experience of doxycycline in Cambodia was similar. There were three cases o f malaria in 
703 soldiers stationed in south-west Cambodia for just over three months, giving an 
attack rate of 0.43%; 93% reported full compliance by questionnaire.196 In a randomised, 
double blind, placebo controlled trial, doxycycline had a protective efficacy o f 96.5% 
(81-100) against P. falciparum and 100% (83-100) against P. vivax in non immune
1 TAIndonesian soldiers in north east Irian Jaya. In Papua New Guinea (PNG), there were 
no cases o f P. falciparum  in 115 Australian soldiers on daily doxycycline (100 mg) who 
were exposed to malaria for up to six weeks. Prophylaxis was discontinued only three 
days after leaving the endemic area; 15 cases o f P. vivax occurred two to three weeks 
later.197 Daily doxycycline (100 mg) combined with low dose primaquine (7.5 mg/d) was 
given to 53 Australian soldiers two days before entering PNG and continued for three 
days after leaving. There were no cases o f malaria whist in PNG but three soldiers 
developed falciparum malaria three weeks after stopping prophylaxis and 15 developed 
vivax malaria between three and 40 weeks.198 The premature stopping o f doxycycline was 
a risk factor for malaria.
In Africa, doxycycline prophylaxis has been studied in Kenya, Somalia, and 
central Africa. In Kenya, doxycycline (50 mg/d or 100 mg/d) had a prophylactic efficacy 
of 84% (66-92%) and 92.6% (79.9-97.5%) in malaria immune children and adults, 
respectively.181 199 In Somalia, there were three cases o f malaria (Pf=l, Pv=2) in 900 
Australian soldiers who took doxycycline for four months, giving a cumulative incidence 
of 0.33%.195 However, during the deployment o f US forces to Somalia, doxycycline 
(n=52) appeared less effective than mefloquine (n=344) for preventing malaria with 5.49 
(95% Cl 1.78-12.82) failures/person-weeks vs. 1.15 (95% Cl 0.03-6.41) for mefloquine. 
Although this difference was not statistically significant, the proportion o f soldiers 
reporting full compliance was significantly less (P < 0.0001) in the doxycycline recipients 
(81%) compared to those taking MQ (98%).200 Soldiers were at an increased risk of 
developing malaria if  they did not fully comply with prophylaxis (2.4 fold), did not roll
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down their sleeves in the evening (2.2 fold), or who did not use bed nets (2.6 fold). Some 
prophylactic failures occurred despite adequate drug levels o f mefloquine or 
doxycycline.201 Of the 13 mefloquine recipients who developed malaria, eight had a 
CMQ:MQ ratio > 2, and five had serum MQ levels > 620 ng/ml, o f whom one had a level 
of 1,067 ng/ml. Of the 20 doxycycline failures, only 10 had measurable levels. Five had 
very low levels, 0.1 ng/ml, and five had levels ranging from 1 to 7.5 ng/ml, consistent 
with compliance. In a follow up study of malaria that developed in 106 US Marines who 
had returned to the USA from Somalia, 97 (87%) had P. vivax, 8 (7%) P. falciparum , 6 
(5%) mixed vivax/falciparum infections, and 1 P. malariae. Compliance for the necessary 
four weeks post return was reported by only 56%. A surprising finding was that only half 
of the soldiers had received sufficient doxycycline or mefloquine or primaquine to 
complete prophylaxis. In French soldiers deployed to Gabon and the Central African 
Republic, the effectiveness o f daily doxycycline (as hyclate salt) was similar to that of 
daily CQ/P despite the fact that doxycycline had superior prophylactic efficacy. The 
malaria attack rates (AR) over four months were 1/171 (0.6%) for doxycycline and 
13/270 (4.8%) for CQ/P, giving an eight fold increased risk o f acquiring malaria on 
CQ/P. However, withdrawals because of gastrointestinal upset were 6.4% for doxycycline 
and none for the CQ/P group, giving an adjusted AR of 7% vs. 4.8%, respectively 
(P=0.3).203
Doxycycline is recommended for use in areas o f multidrug resistant malaria, and 
as an alternative for individuals unable to take mefloquine or atovaquone/proguanil.
1.10.5.4 Atovaquone/proguanil
This fixed dose combination comprises atovaquone 250 mg and proguanil 100 mg 
(A/P) and has recently been introduced as a daily prophylactic drug. A/P has the 
advantage over other antimalarials because it processes causal prophylactic activity 
allowing prophylaxis to start one day before entry to and finish one week after leaving the 
endemic area.
In clinical trials A/P had high rates o f protective efficacy 98% (91.9-99.9) in 
malaria immune Africans from Kenya, Gabon, and Zambia.204 205 206 One trial has 
assessed the prophylactic efficacy o f A/P (n=148) relative to placebo (n=149) in Papuan 
adults with limited malaria acquired immunity. In Papua, the PEf was 96 (72-99)% and 
84 (44-95)% against falciparum and vivax parasitaemia, respectively.207 Two trials have
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also been conducted in western travellers comparing A/P with either CQ/P or 
mefloquine. Travellers in both studies spent a mean o f 22 weeks in the endemic 
areas; the majority travelled to Africa 63% (CQ/P study) and 79% (MQ study). A/P was 
effective in both studies. Of the 501 A/P recipients (CQ/P study), one (0.2%) developed 
P. ovale and three (0.6%) o f 507 CQ/P recipients developed P. falciparum. In the A/P- 
MQ study, there were no cases o f prophylaxis failure with either regimen.
A/P is recommended for prophylaxis against multidrug resistant falciparum 
malaria for short trips and for travellers who cannot tolerate doxycycline or mefloquine.
1.10.6 Adverse effects of prophylactic regimens
Drug related toxicity is a crucial element for recommending a particular 
prophylactic drug. Clinicians know that patients will not take a drug that makes them feel 
unwell. This is particularly true for the healthy travellers for whom the risk-benefit ratio 
requires both very safe and highly tolerable regimens. Rare toxicity may not be evident 
from randomised trials. Indeed, approximately 100,000 subjects would be needed in such 
trials to detect a toxicity rate of 1 in 10,000 .21°
1.10.6.1 Chloroquine and chloroquine/proguanil
Chloroquine, alone or combined with proguanil, has been in use for many years. It
is generally well tolerated, and is considered safe in pregnancy. Commonly reported
symptoms are generally mild and include gastrointestinal upset, headache, malaise,
dizziness, visual disturbance, mouth ulcers, itching, and insomnia. In one open label,
prospective study in Scandinavian travellers, adverse effects reporting rates associated
with CQ/P were low and considered mild: nausea (3%), diarrhoea (2%), and dizziness 
211(1%). Retrospective, post travel studies have generally recorded considerably higher 
rates. The large series o f Steffen et al reported the side effects o f several prophylactic 
regimens by questionnaire o f 145,003 travellers to Kenya most o f whom (97.6%) stayed 
for up to 4 weeks.176
Non serious side effects were assessed in 89,902 travellers who used no 
prophylaxis (n=4,026), CQ 300 mg weekly (n=3,354), CQ 600 mg weekly (n=3,646), 
CQ/P (n=20,150), sulfadoxine/pyrimethamine (n=8,673), and mefloquine (n=50,053). 
Side effects were reported frequently by users o f all prophylactic regimens and by 5.3% 
of travellers not on prophylaxis. The corrected rates (reported rate less 5.3) were 18.5% 
(CQ300), 17.2% (CQ600), 30.1% (CQ/P), 11.6% (S/P) and 18.7% for mefloquine.
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Overall, ~  50% of side effects were considered subjectively mild, 36-40%, moderate, and 
10-14% severe. Nausea was the commonest side effect for all regimens, reported by 11- 
19% of the CQ regimens and 12% by the MQ recipients. The rates for nausea (18.8%) 
and for mouth ulcers (7.9%) were the reasons for the overall excess of side effects in the 
CQ/P group compared to the other regimens. Dizziness was reported by more mefloquine 
(7.6%) than by chloroquine (5-6%) users, whereas the opposite trend was noted for 
insomnia. No differences were found for depression and headaches. Serious 
neuropsychiatric side effects, consisting o f convulsions, acute psychosis, and severe 
vertigo, were reported rarely by the CQ, CQ/P, and MQ groups. The risk of any o f these 
reactions was estimated as 1 in 13,600 for CQ and 1 in 10,600 for MQ.
In a telephone survey o f returning British travellers who had used prophylaxis for 
a median o f seven weeks, the reporting o f any side effect was similar for CQ/P (n= 1,181)
919and MQ (n=l,214) users, some 40%. Most side effects were considered 'trivial' and did 
not interfere with daily activities. Mild GI upset was reported by more o f the CQ/P group: 
16.3% vs. 12.5% (P=0.009) but the reporting o f any neuropsychiatric (NP) event was 
more likely in the MQ group: 333 (27%) vs. 189 (16%) RR=1.7 (1.5-2). There were 
eleven travellers, ten women and one man, who reported disabling neuropsychiatric side 
effects, defined as preventing the traveller from undertaking the activity for which she/he 
had made the journey. One traveller with a family history o f  epilepsy, considered a 
contraindication by the authors, was excluded from the analysis. Reported disabling NP 
rates were 0.7% (n=9) for MQ compared to 1 (0.08%) CQ/P users (P=0.02). These 
findings were broadly similar to a postal survey o f visitors to the Kruger National Park in 
South Africa, an area o f chloroquine resistance. Travellers on CQ/P (n=2,488) reported 
significantly more nausea (15.1% vs. 12.2%), diarrhoea (6.3% vs. 3.7%) and mouth 
ulcers (2.9% vs. 0.5%). Significantly more MQ (n= 1,300) recipients reported 
neuropsychiatric side effects: light headedness (7.5% vs. 4.8%), vivid dreams (2.8% vs. 
1.7%), depression (2.7% vs. 1%), and anxiety (0.5% vs. 0.01%).213 Mouth ulcers were 
also problematic in a cohort study of 470 British soldiers in Belize; 37% (142/382) of 
CQ/P users reported mouth ulcers compared to 24% (21/88) who took proguanil alone 
[RR=1.56 (95% Cl 1.05-2.31)].214
There has been experience with the fixed combination of chloroquine and 
proguanil. This combination is used in several European countries, notably France and
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Switzerland. CQ/P was well tolerated by 194 French travellers.215 Gastrointestinal side 
effects were the most commonly reported side effects, affecting -10% of travellers. Non 
serious neuropsychiatric effects were reported by 2%, a significantly lower rate compared 
to the mefloquine users, 11.5% (n=l 83).
In a cohort o f French soldiers, none o f the CQ/P users (n=270) stopped their 
prophylaxis compared to 11 (6.4%) o f 171 soldiers on doxycycline hyclate.203 It was felt 
that the formulation o f the doxycycline was a factor in this GI intolerance. By contrast, 
CQ/P was significantly less well tolerated and less well complied with than doxycycline 
monohydrate in 522 French soldiers deployed to Gabon or Chad.216 The following side 
effects were reported more frequently (P < 0.05) in the CQ/P arm vs. the doxycycline 
arm: (i) epigastralgia, (ii) diarrhoea, (iii) mouth ulcers, (iv) urticaria, (v) sun sensitisation, 
(vi) skin desquamation, (vii) pruritus, and (viii) skin rashes (morphologies not specified). 
Despite the poorer tolerability, there were no withdrawals from the CQ/P group but 15 
from the doxycycline group because of drug intolerance [gastrointestinal effects (n=9), 
headache (n=5), and skin rash (n=l)]. However, the authors caution that withdrawal 
should not be viewed as an indicator o f doxycycline tolerability for several reasons: (i) 
the soldiers knew which prophylaxis they were taking, (ii) they were also aware o f the 
previous poor gastrointestinal tolerability experienced by French soldiers, and so were 
more anxious about possible doxycycline toxicity, (iii) there was a bias in favour of 
stopping doxycycline because CQ/P could be used as an alternative whereas no such 
alternative existed with the CQ/P group. Of interest is that skin sensitisation was more 
common in the CQ/P than the doxycycline recipients, a finding consistent with a study in 
travellers from Switzerland, Germany, and Israel.217
As prophylaxis, very few serious adverse reactions have been reported with CQ. 
Generalised convulsions have been reported rarely in travellers.213 In a case series o f four 
women who developed clonic-tonic fits, one had a past history o f tonic-clonic and 
complex partial seizures, and another a history o f absence seizures. The latter and another 
woman had EEG evidence of a reduced seizure threshold.218
Chloroquine induced skin rashes are rare and have included urticaria, lichen 
planus, photosensitivity, a pustular eruption, bullous pemphigoid, toxic epidermal 
necrolysis, exfoliate dermatitis, and exacerbation o f psoriasis 219 220 221 222 223 Deafness
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has been reported rarely with chloroquine generally in association with long term use in 
rheumatology patients, and following intramuscular injection for malaria.224 225
Contraindications to CQ prophylaxis are (i) epilepsy, (ii) known allergy, (iii) 
severe renal disease, (iv) severe hepatic disease, and (v) a history o f generalised psoriasis
1 / i n
(WHO recommendation). The prophylactic dose of CQ should be reduced in patients 
with mild or moderate renal failure to avoid drug accumulation.226 Chloroquine should 
not be used in patients severe renal failure (serum creatinine > 700 pmol/L). Data are 
lacking on the optimal CQ prophylactic dose in liver impairment. In 'mild' liver disease, 
standard CQ dose appears to be safe.227
Chloroquine is listed as a drug that can be used in patients with acute porphyria 
(Cardiff Porphyria Service: www.uwcm.ac.uk. accessed January 2003). However, it is 
considered hazardous in patients with porphyria cutanea tarda at the doses used for 
treatment or prophylaxis because severe toxicity may be caused by the mobilisation of 
porphyrins. The question of chloroquine exacerbating psoriasis remains unanswered 
because psoriasis fluctuates naturally. Chloroquine has been used successfully for patients 
with psoriatic arthritis 228 Never the less, there have been a number o f case reports of 
exacerbations o f psoriasis coincident with CQ as antimalarial prophylaxis, and CQ or 
hydroxyCQ as treatment for rheumatoid and psoriatic arthritis. For clinicians, 
psoriasis should be viewed as contraindication to CQ prophylaxis but as a relative 
contraindication for treatment.
1.10.6.2 Mefloquine
The prophylactic dose is 250 mg weekly (adults) and 5 mg/kg for children; the 
recommended treatment dose is 15 mg/kg or 25 mg/kg in areas o f MQ resistance.
As treatment, MQ tolerability is generally good. Several dose related symptoms 
are note worthy such as anorexia, nausea, and vomiting, dizziness, inability to walk 
unaided, and insomnia.231 Early, MQ induced vomiting is another significant problem of 
treatment especially in young children and adults > 5 0  231 232 233 T h e  to l e r a b i ]i t y  o f
mefloquine is improved appreciably by splitting the higher dose (15 followed by 10 
mg/kg) and delaying the administration dose to the second day o f treatment in a three day 
regimen with artesunate.234
As prophylaxis, the proportion o f travellers reporting any side effect varies 
considerably between trials but has ranged between 18-40% in the larger retrospective,
60
questionnaire studies. The majority (~ 90%) are, subjectively, o f mild or moderate 
severity and self limiting e.g. nausea, diarrhoea, headache, strange dreams, insomnia, 
dizziness, and mood changes. Much attention has focussed on the NP effects of 
mefloquine. A neuropsychiatric event describes any central nervous system (CNS) or 
psychiatric symptom. A minor NP event includes headache, dizziness, light headedness, 
paraesthesiae, insomnia, vivid and unpleasant dreams, irritability, and nervousness. A  
serious NP event encompasses the following principal diagnoses: convulsion, disturbance 
o f consciousness, inability to walk unaided due to vertigo or ataxia, psychosis, disorder of 
affect, acute neurosis, and acute confusion. Predisposing factors are a past history of  
neuropsychiatric disorders, recent (within two months) MQ exposure e.g. treating a MQ 
prophylactic failure with MQ, previous MQ related NP event, previous treatment with 
psychotropic drugs, and MQ used in the recovery phase o f severe malaria. A family 
history o f epilepsy has been reported by some travellers who developed fits while on MQ 
prophylaxis but it is unclear if  this is a risk factor. Data on NP AEs associated with MQ 
prophylaxis come from studies o f different study designs o f tourists and soldiers. Reports
O'X'7to the manufacturer as part of pharmacovigilance complement formal trials. Essential 
points from these studies are reviews are: (i) many (40%) NP side effects occur soon after 
the first dose and 75% are manifest by the third dose, (ii) most are o f mild or moderate 
severity and resolve completely, (iii) some require medical management including 
hospitalisation, (iv) less than 2% of patients have sequelae, (v) women are more likely to 
experience NP AEs than men, (vi) MQ in soldiers (fit, young men) is well tolerated, 
including the loading dose o f MQ (250mg/d x 3d), (vii) in prospective studies, MQ 
related NP side effects were broadly similar to other antimalarials or placebo, (vii) long 
term MQ prophylaxis is well tolerated, and (viii) the risk o f serious NP AE during 
prophylaxis is estimated to be 1 in 10,600 for MQ and 1/13,600 for CQ.135 137 176 177 188 200 
235 238 239 240 ^  a  m e ta _analy sis o f controlled trials, mefloquine users were more likely to 
withdraw from studies compared to placebo but not when compared to other prophylactic
„  169regimens.
There are limited data assessing psychomotor function, motor function, action 
requiring fine co-ordination, and balance and hearing. Boudreau et al found no 
compromise o f performance of American soldiers who took weekly MQ (preceded by the 
loading dose) or chloroquine as prophylaxis. Sleep disturbances, increased dream activity,
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and depressed feelings were detected in the MQ group.135 In a double blind, randomised, 
cross over, placebo controlled study o f 23 Swiss trainee pilots (mean age 27), MQ was 
given as a loading dose, followed by weekly dosing for three weeks. This regimen was 
tolerated by all subjects except one who complained o f dizziness, diarrhoea, and flu like 
symptoms during the loading dose phase; he was withdrawn from the study. There were 
no significant differences in flying performance, psychomotor functions, and postural 
sway between the two arms. Poorer sleep quality was reported by the MQ users who had 
a lower mean reduction in sleep time o f 34 minutes that was not statistically significant. 
Similar findings were reported in another placebo controlled trial o f MQ prophylaxis and 
the effect o f alcohol driving car. There was no impairment o f driving in a cohort o f young 
volunteers who had blood levels o f alcohol o f between 0.3-0.5 mg/ml (the legal limit in 
many countries is 0.8 mg/ml).241 In 10 volunteers, MQ had no effect on audiometry and 
vestibular functions assessed using posturography and the recording o f nystagmus.242 
There is one report o f impaired hearing in three travellers who took MQ as 
prophylaxis.243
Two studies have examined tolerability o f long term prophylaxis. Mefloquine was 
well tolerated in 2,289 Dutch Marines stationed in Cambodia for six months.188 One 
battalion o f 754 was given a loading dose o f mefloquine, 250 mg daily for three days. 
Seven (0.3%) sought medical care for serious adverse events: convulsions (n=2), 
myoclonus (n=l), severe dizziness (n=2), and skin rash (n=2). Six changed to 
doxycycline and one was given MQ bi-weekly with good effect. By questionnaire, 609 
(30.2%) o f 2,015 soldiers reported voluntarily 820 complaints; these were mostly 
headache, difficulty in concentration, weakness, dizziness, and nausea. Mefloquine taken 
weekly was also well tolerated by 802 American Peace Corps volunteers o f whom 152 
used mefloquine for more than one year.133 The reporting o f side effects by volunteers 
decreased significantly over time from 44% after 4 months use to 19% after more than 
one year o f use, suggesting that mild symptoms were well tolerated. Only 7 (0.9%) 
stopped prophylaxis because o f MQ related toxicity. These data show that MQ 
tolerability was acceptable over the medium to long term.
Cutaneous toxicity with mefloquine as treatment or prophylaxis is rare. In a 
review o f published data from 1983-1997, only 74 cases o f any skin reaction were 
reported, making skin toxicity rare. These reactions included itching, red maculopapular
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rashes, urticaria, cutaneous vasculitis, exfoliate dermatitis, SJS, toxic epidermal 
necrolysis, and facial bullous lesions. Maculopapular rashes (30%) and pruritus (4-10%) 
were two most commonly reported reactions.244 Six cases [prophylaxis (n=3), treatment 
(n=3)] o f severe and three o f mild itching occurred in those using Fansimef (MQ+S/P). 
MQ is not generally associated with cardiovascular toxicity. Reports o f sinus bradycardia 
and sinus arrhythmia are more likely to be related to resolution of malaria, especially in 
young fit individuals. There have been reports o f complete AV block with mefloquine 
treatment and atrial flutter with 1 to 1 conduction, and AV conduction through an 
aberrant pathway with mefloquine as prophylaxis.245 246 247 Acute intravascular 
haemolysis has been reported with malaria treatment in expatriate Europeans.248 249 
Agranulocytosis has also been reported. MQ causes transient elevation of
transaminases but is rarely associated with hepatitis.251
Mefloquine should not be given to individuals with known allergies to mefloquine 
or quinine nor to those with previous MQ related, serious toxicity. Prophylactic 
contraindications include: (i) epilepsy, (ii) psychiatric disease e.g. depression, bipolar 
affective disorder, any psychotic disease, severe anxiety neurosis, (iii) the first trimester 
of pregnancy (women should avoid becoming pregnant for 3 months post MQ use), and
(iv) severe hepatic disease. A family history o f epilepsy is not considered a
99 7contraindication. Renal failure is not a contraindication to MQ prophylaxis; MQ PK 
values were similar to normal volunteers.252 Halofantrine should not be used to treat 
mefloquine prophylaxis failures because o f the risk o f cardiotoxicity. Treatment 
contraindications are: (i) epilepsy, (ii) psychiatric disease, (iii) mefloquine treatment 
within the past two months, (iv) the recovery phase o f severe malaria, (v) pregnant 
women in the first trimester (unless no other choice is available), and (iv) concurrent 
halofantrine treatment. Mefloquine as treatment or prophylaxis is not recommended for 
persons performing activities requiring fine co-ordination and spatial discrimination e.g. 
pilots. On the question o f individuals with cardiac disease, the BNF advises caution.227
1.10.6.3 MQ use in pregnancy and breast feeding women
Mefloquine prophylaxis after the first trimester was highly effective in Malawi
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and in western Thailand. As treatment, MQ alone or in combination with
artesunate has been used on the Thai-Burmese border because multidrug resistant P. 
falciparum limits therapeutic choice.256 However, in a retrospective study, MQ alone as
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treatment was associated with a higher risk o f still birth compared to either quinine (Q) 
monotherapy or other antimalarial drugs (OT).257 The proportions o f still births were (i) 
9/200 (4.5%) MQ recipients vs. 10/633 (1.6%) Q recipients, OR=4.72 (95% Cl 1.7-12.7), 
vs. 12/873 (1.4%) o f women who received other drugs, OR=5.1 (95% Cl 2-13.1). 
Mefloquine was not associated with an increased risk o f abortion, low birth weight, 
neonatal neurological retardation or congenital malformations. Interestingly, the 
prospective, prophylactic study o f 159 women (weekly MQ after week 24 o f gestation) 
found a non significant increased risk o f still birth in the MQ recipients: 7% vs. 2.6% 
[RR=2.63 (95% Cl 0.86-8.08)].255 This result may have been due to an inadequate sample 
size and does not exclude the possibility o f a positive association between mefloquine and 
stillbirth, especially in view o f the later, retrospective, treatment study. In Malawi, the 
rate o f still births with mefloquine (750 mg, followed by 250 mg MQ weekly) was 3.6% 
(37/1,015), a rate similar to that o f chloroquine recipients, 3.8% (119/3,132).253 
Approximately 60% of women in both arms reported side effects, notably, itching, 
dizziness, and GI upset. The MQ recipients were more likely to complain o f dizziness but 
of less itching (details not given). One MQ recipient developed self limiting, acute 
confusion [0.09% (95% Cl 0-0.55)].
In a post marketing survey of 1,627 Western woman who had been exposed to 
mefloquine pre or post pregnancy, there were 32 babies with congenital malformations, 
and 79 women had spontaneous abortions. All congenital abnormalities occurred in 
women who had taken mefloquine before becoming pregnant or within the first trimester
co
o f pregnancy. In a retrospective study o f accidental MQ exposure as prophylaxis in US 
Servicewomen (n=72), spontaneous abortions numbered 12; all occurred between 6 to 12 
weeks o f gestation. In the analysis, the authors excluded women with an unknown 
pregnancy (n=19) or foetal (n=17) outcome, giving an abortion rate o f 12/36 [33.3% 
(95% Cl 19.5 - 49.8)]. There were no congenital abnormalities in the 23 live births and no 
stillbirths.259
Mefloquine as prophylaxis or treatment in pregnancy requires careful assessment. 
Although the risk benefit ratio is difficult to define, MQ use should clearly be beneficial. 
MQ prophylaxis should not be used in the first trimester unless there is a pressing need to 
travel to a malaria endemic area. In fact the WHO advises pregnant women not to travel 
to malaria endemic areas. 167 In view of the limited data suggesting a risk o f congenital
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abnormalities in women exposed to MQ before they become pregnant, the 
recommendation that pregnancy should be avoided for three months after the end o f MQ 
prophylaxis should be followed. Mefloquine is secreted into breast milk in small amounts, 
the activity of which is unknown. Circumstantial evidence suggests that adverse effects 
do not occur in breast-fed infants whose mothers are taking mefloquine (International 
Standard Prescribing Information. Roche, May 1999). Mefloquine use on the Thai- 
Burmese border has not been associated with apparent ill effects in breast fed infants. (R. 
McGready, personal communication).
1.10.6.4 Doxycycline
Doxycycline prophylaxis or treatment is generally well tolerated and serious 
toxicity is rare. In placebo controlled trials, the overall tolerability of doxycycline has 
been comparable or even better than placebo. In Irian Jaya, Indonesian soldiers on 
doxycycline reported any symptom less frequently than placebo recipients (rate ratio D:P 
for all symptoms = 0.64, P  < 0.001) because the latter reported significantly more mild 
CNS symptoms e.g. poor sleep, dizziness, and headache (detailed frequencies o f each 
symptom are not stated in the paper). Although the doxycycline recipients reported less 
frequently any GI symptom, the D:P rate ratio was not significant.136 Doxycycline 
recipients reported nausea if they consumed doxycycline without food, a finding 
consistent with other studies.195 261 In this study, doxycycline was better tolerated than 
mefloquine. Three other placebo controlled trials have reported tolerability data in less 
detail. In Kenyan children, the mean number o f reported symptoms per subject [nausea 
(3.3 vs. 4.9), abdominal pain (7 vs. 8), diarrhoea (1.2 vs. 1), fever (5.3 vs. 5.8), headache 
(7 vs. 6)] were similar between placebo and doxycycline arms.181 In another trial in 
Kenyan adults, the tolerability o f doxycycline was similar to that o f placebo but one 
female on doxycycline had repeated episodes o f vaginal candidiasis and was withdrawn 
from the study.199 In Thai refugees o f all ages the reporting frequency o f any GI symptom 
was highest in the 100 mg doxycycline group (49/p-y); this frequency was significantly 
higher than the 50 mg group (20/p-y) but not compared to placebo (32/p-y). The placebo 
group reported more fever, headache, and dizziness compared to doxycycline.192
In 623 travellers, participating in a double blind comparison with the three other 
main prophylactic drugs and answering a symptoms questionnaire, the doxycycline group 
(n=153) tolerated doxycycline monohydrate well. Although this study was not
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sufficiently powered to detect small differences in reported symptoms between the arms, 
certain inferences can be drawn. Moderate gastrointestinal symptoms (9 vs. 20%, 
P=0.0006) and moderate skin symptoms, defined as itching, or abnormal reddening of
217skin (3 vs. 8%, P=0.08) were reported less frequently compared to the CQ/P group.
In a retrospective questionnaire o f 383 Australian travellers (male=200), who used 
doxycycline for a mean o f 4 weeks, a total o f 82 (21.4%) reported symptoms that were 
considered by the travellers to be drug related; 25 (6.5%) reported these as troublesome 
(interfered with normal activity), and 22 (5.7%) stopped doxycycline.262 The specific 
reasons for stopping doxycycline were not documented. Two symptoms of note were 
vaginal itch (as a proxy for vaginal thrush), reported by 17 (9.3%) women, and red skin, 
consistent with mild photosensitivity, that was reported by 22 (5.7%) travellers. 
Abdominal pain, nausea or vomiting, and diarrhoea were reported by some 8%, 15%, and 
12%, respectively.
Doxycycline induced upper and or lower gastrointestinal symptoms are important 
side effects that have resulted in discontinuation o f prophylaxis: 3 and 6.4% in two 
studies o f French soldiers. Upper GI intolerance is commonly reported, affecting 
between 10 to 35% of subjects.198 200 203 216 Studies o f doxycycline for the prevention of
9A 1traveller's diarrhoea have reported broadly similar rates (4-12%) o f upper GI upset. 
Heartburn secondary to oesophagitis is well described and may be reduced if  doxycycline 
is taken with meals and not before sleep.263 264 Oesophageal ulceration causing severe 
hiccups, heartburn, and interference with sleep, was reported in a 51 years old man 
following doxycycline as adjunct treatment for malaria.265 Doxycycline induced diarrhoea 
was reported by ~ 18 and ~ 20% of French soldiers, a rate higher than the 3% reported in 
American outpatients prescribed short course doxycycline. In a double blind, double 
dummy study comparing doxycycline with mefloquine in soldiers on exercise in 
Thailand, rates o f diarrhoea in both groups was similar, 49 (58/119) and 48 (64/134)%, 
respectively. The authors concluded that doxycycline in Thailand, where many o f the 
common pathogens causing traveller's diarrhoea are resistant to tetracyclines, doxycycline 
conferred no benefit in preventing diarrhoea but did not also increase risk o f diarrhoea.267 
Antibiotic induced colitis due to Clostridium difficile is a well recognised complication of 
antibiotic use.268 Laboratory confirmed C. difficile diarrhoea secondary to doxycycline as 
prophylaxis for malaria was reported in three Australian travellers. One stopped
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prophylaxis but the others continued doxycycline despite the diarrhoea.269 The risk of 
acquiring C. difficile diarrhoea during doxycycline prophylaxis is unknown.
Doxycycline enhances the phototoxicity of sunlight. This photosensitive reaction 
is an exaggerated sunburn response that is dose dependent and results in skin redness, and 
blistering, especially in fair skinned individuals, after excessive exposure to sunlight.270 
The reported incidence o f photosensitivity in doxycycline users varies. In a retrospective 
questionnaire, 22 (5.7%) o f 383 Australian travellers reported 'red skin'.262 Mild 
photosensitivity occurred in 4.5% o f 125 Australian soldiers taking 50 mg o f doxycycline
107daily and weekly CQ for just under 13 weeks. Doxycycline caused photosensitivity in 
21.2% (n=52) American soldiers compared to 5.2% (n=344) on mefloquine (P <0.01) but 
this does not appear to have resulted in drug withdrawal.200 Photosensitivity was reported 
by five o f seven Caucasian men who were exposed to intense sunlight on a sailing 
holiday. They took 100 mg o f doxycycline daily to prevent travellers' diarrhoea. These 
five complained o f severe pruritus and stinging that recurred within minutes of 
reexposure to the sun. Six developed nail discoloration which progressed to photo­
onycholysis (nail separation) in five.271 Photo-onycholysis is a well recognised but rare
777reaction of the tetracyclines. Non severe, doxycycline induced skin rashes have 
included toxic erythema, urticaria, and fixed drug eruptions.273 274 Data are few on the 
risk o f developing a non severe rash with doxycycline; it was 4% in a study o f 113 
American outpatients. Severe cutaneous reactions are rare and include erythema 
multiforme, toxic epidermal necrolysis, vasculitis, and a generalised pustulosis.
Neurological toxicity is unusual but light-headedness (a minor NP event) was 
significantly more common in doxycycline recipients (19.2%) compared to those on 
mefloquine (10.5%).200 As a class, severe tetracycline induced CNS toxicity is rare. 
Benign intracranial hypertension has been reported in five women on long term 
tetracycline (250 mg daily) for acne, and in two female travellers on doxycycline
• 277 278prophylaxis. In the travellers, appropriate management resulted in the return of 
normal vision in one woman but the other woman developed optic atrophy with 
consequential reduced central acuity, and poor colour and peripheral vision. Her loss of 
vision was estimated at 70%.
Longitudinal data on the use o f the tetracyclines for treating acne have been 
summarised in early reviews at a time when doxycycline was not commonly used.279 280
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All tetracyclines were well tolerated with a small excess o f reported symptoms compared 
to placebo (7.9% vs. 0.9%). Demeclocycline, the tetracycline with the greatest phototoxic 
potential, caused all the cases o f photosensitivity, and accounted for some 40% of all 
reported toxicity. In a clinical series of 130 women who were taking tetracycline for acne, 
16 (12.3%) developed vaginal Candida; a doubling o f the background rate o f some 6% 
that was found in a study o f non diabetic, non pregnant women not on antibiotics.281 
Candidiasis developed after a mean o f seven weeks (range 1-20). Ten o f the 16 restarted 
tetracycline two o f whom had a recurrence.
Contraindications to doxycycline use include: (i) pregnancy, (ii) breast feeding, 
(iii) children under 12 years (< 8 in the US literature), (iv) a history o f tetracycline 
allergy, (v) severe hepatic disease, and (vi) systemic lupus erythematosus. Doxycycline is 
not contraindicated in renal disease. Travellers should be advised to use sunscreen in 
sunny environments. Women on the combined oral contraceptive pill should be warned of 
the theoretical risk o f contraceptive failure due to functional impairment o f bacteria that 
are involved in the recycling o f ethinyloestradiol from the large bowel. The BNF states 
this risk only applies to a short course o f doxycycline and that additional contraceptive 
measures should be used. However, these additional measures are not needed if  
doxycycline use exceeds three weeks.227
1.10.6.5 Atovaquone/proguanil
Atovaquone/proguanil is well tolerated as treatment or prophylaxis. The most 
commonly reported adverse events in clinical trials have been anorexia, nausea, vomiting, 
dyspepsia, abdominal pain, diarrhoea, headache, and coughing. The frequencies o f some 
o f these symptoms were similar to other antimalarials (treatment or prophylaxis) or 
placebo (prophylaxis). However, in one treatment trial o f Thai adults, vomiting occurred 
in 14 o f 91 A/P recipients of whom 13 (14.3%) required retreatment; this compared to 2 
of 91 MQ patients, none o f whom required retreatment (P < 0.001).282 Vomiting was also 
a frequent symptom in 63 treated Gabonese adults (29%) and 25 travellers (44%).283 284 
From pooled data, overall rates o f early vomiting (within one hour) were 8% in adults and 
11% in children. However, repeat vomiting after retreatment was low (< 1%).285 As
lo r
treatment, transient elevation o f liver enzymes has been documented.
Two prophylactic studies in travellers have compared A/P with CQ/P or MQ. 
Overall, A/P was better tolerated than either comparator regimen 208 209 The majority of
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reported symptoms were o f mild severity in both studies. GI complaints (nausea, 
vomiting, and abdominal pain) were reported by significantly more o f the 511 CQ/P 
recipients (20%) compared to 12% of the 511 A/P recipients. Rates o f mild/moderate 
neuropsychiatric side effects (headache, dizziness, abnormal dreams) were similar 
between both groups. One CQ/P recipient had a convulsion. One A/P recipient developed 
an 'allergic reaction' that required study withdrawal. No further details are given but it 
must be assumed this was a serious A/P related adverse event. In the A/P-MQ study, rates 
o f GI symptoms in both groups were similar [16% (A/P, n=493)] versus 19% [MQ, 
n=483)]. MQ recipients had significantly higher rates o f NP complaints (strange vivid 
dreams, insomnia, dizziness/vertigo, anxiety, and depression). For both groups, the 
majority o f AEs were mild. Moderate (interfered with daily activity) or severe (medical 
advice sought) AEs that were considered drug related and resulted in drug discontinuation 
numbered 6 (1.2%) in A/P group and 24 (4.9%) in the MQ group (P=0.001); 19 o f the 24 
MQ withdrawals were due to NP events. A/P was also well tolerated in adult transmigrasi 
who reported symptoms with similar frequencies compared to placebo recipients except 
for stomatitis (0.8/p-y vs. 0.01/p-y) and back pain (1.1/p-y vs. 0.7/p-y). Overall, a high 
proportion in both groups (A/P-94%, placebo-91%) reported at least one symptom over 
20  weeks.207
A/P should be taken with food to reduce GI upset and increase drug levels. 
Contraindications to A/P use include: (i) pregnancy (lack o f safety data), (ii) known 
allergy or severe toxicity to either component, (iii) severe renal disease (defined as < 30 
ml/min by the manufacturer) for both prophylaxis and treatment. A/P may accumulate if  
used as prophylaxis in severe renal disease (www.gsk.com accessed July 2002). Proguanil 
may cause a megaloblastic bone marrow toxicity in renal failure patients. There are no 
data of A/P use in liver disease.
1.10.7 Perspective on antimalarial chemoprophylactic toxicity
In prescribing prophylaxis, clinicians need to take into account the malaria 
resistance patterns, potential drug toxicity, drug contraindications, ease o f use 
(compliance), and the probability that a given regimen might need to be changed whilst 
the traveller is overseas for a short or long stay. Several trials have assessed some o f these 
issues but have used different definitions o f adverse events, and sample sizes. This makes 
direct comparisons difficult.
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Drug withdrawal rates in soldiers have been reported in prospective studies and 
have been generally low (< 7%), for the three main regimens: doxycycline, CQ/P, and 
MQ. Rates o f doxycycline discontinuation have been 0.6% (n=900), 1.7% (n=600), 3.2% 
(n=125), and 5.6% (n=53) in Australian soldiers, 6.4% in 171 French soldiers, 3.8% of 52 
American soldiers, and 0% (n=486) and 2.6% (n=77) Thai soldiers.193 194 197 198 200 203 
Mefloquine discontinuation rates were 0.3% of 344 American soldiers, 0% in 750 Thai 
soldiers, and 1.6% of 1,580 Italian soldiers, and 4.9% in travellers.182 186 200 209 Only 1.4% 
(54/3,760) o f Italian soldiers stopped CQ/P prophylaxis whilst deployed in Somalia.182 In
9HR OOQtwo studies o f travellers, rates o f withdrawal for A/P were low at 0.8 and 1.2%. One 
of 148 (0.7%) adult transmigrasi withdrew from A/P prophylaxis because o f the 
development of a serious cutaneous reaction which was thought to be possibly drug 
related.207
An important study o f malaria prophylaxis has been published recently in 
travellers.217 Its importance lies in the fact that the four main regimens are compared 
directly. Although the study did not achieve its stated sample size, it has still provided 
important comparative data. Furthermore, the study was a randomised, double blind, 
study with a placebo run-in phase. The main outcome measures were the reporting rates 
of adverse events, assessed subjectively. Of 623 recruited non-immune travellers (~ 50% 
female) to sub-Saharan Africa: 153 each received either doxycycline, mefloquine, or the 
fixed combination chloroquine and proguanil, and 164 received A/P.
Overall, many travellers reported adverse events, even in the placebo group. The 
CQ/P arm had the highest proportion o f mild to moderate adverse events: 69/153, 45% 
(95% Cl 37%-53%), followed by mefloquine: 64/153, 42% (34%-50%), doxycycline: 
51/153, 33% (26%-41%), and atovaquone and proguanil: 53/164, 32% (25%-40%); 
/M).048 (3 degrees o f freedom). The MQ (12%) and CQP (11%) recipients tended to 
report higher rates o f more severe events than the A/P (7%), or doxycycline (6%) 
recipients (P= 0.137, 3 degrees o f  freedom). Neuropsychiatric adverse events were 
significantly higher in the mefloquine group: 37% vs. 30% for CQ/P vs. 24% for 
doxycycline, vs. 20% for A/P (P=0.003). The highest proportion o f moderate or severe 
skin problems were reported in the CQ/P arm: 8% vs. 3% (doxycycline) vs. 2% (A/P) vs. 
1% (MQ), P=0.013. Women reported significantly more neuropsychiatric,
gastrointestinal, and skin problems than men.
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A total o f 22 participants withdrew from the study because of adverse events or 
because allocation concealment had to be broken. Although rates were low, and 
differences did not achieve statistical significance (P=0.42), they appear to be least in the 
A/P group (n=3) 2% (0-4%) vs. 3% (0-6%) for doxycycline (n=5) vs. 4% (1-8%) for MQ 
(n=6 ), and 5% (2-9%) for the CQ/P group (n=8). The grade o f adverse event was known 
in 18 subjects. AEs were mild in five participants, moderate in eight, and severe in five.
This study confirmed the low rates o f withdrawal from prophylaxis o f any 
regimen but that A/P and doxycycline appeared to be better tolerated than MQ and CQ/P. 
Of interest was the high rate o f reported skin reactions with CQ/P. These were chiefly 
photosensitivity (other diagnoses were not stated), a side effect that is emphasised for 
doxycycline. In long term users o f prophylaxis, adverse events are generally reported 
most often in the early phase o f prophylaxis and stabilise over time. Withdrawal rates 
for long term mefloquine users were low in Dutch marines (0.3%), and American Peace 
corps workers (0.7%).133188
Taken together, these data show that drug withdrawal rates due to adverse events 
or drug toxicity (where causality has been established) are low. The majority o f travellers 
and soldiers tolerate the different prophylactic regimens.
1.11 Pharmacology of chloroquine
Chloroquine, developed in the 1930’s, has been the standard antimalarial drug for 
the past 50 years. It is also used for treating rheumatoid arthritis, exploiting its intrinsic 
anti inflammatory properties, and amoebic liver abscess. Standard dose CQ for the 
treatment o f all malaria species is 10 mg/kg once on Days 0 and 1, and 5 mg/kg on Day 2. 
The dose for prophylaxis for adults is 300 mg o f CQ base per week.
1.11.1 Mechanism of action
Chloroquine is a mix o f two enantiomers. The CQ (-) enantiomer is less active 
than CQ (+) against CQ resistant strains in vitro.2** MonodesethylCQ, the main CQ 
metabolite, has less antimalarial activity than CQ. Chloroquine is concentrated in the 
acidic food vacuole o f parasitised red cells where it interferes with haem polymerisation, 
a natural detoxifying process for the parasite. The anti inflammatory effects are due to the 
inhibition o f TNF-alpha release from macrophages and the attenuation o f TNF release by 
glycosylphosphatidylinositol (GPI), the putative malaria 'toxin'.289
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1.11.2 Pharmacokinetics
1.11.2.1 Absorption
Chloroquine is rapidly absorbed when administered orally, by subcutaneous, or 
intramuscular injection, and by intravenous infusion.83 The Tmax after the first oral dose is
2-5h, and 5 lh after 25 mg/kg taken over 48 h.148 Oral bioavailability is high (~ 80%) and 
is increased with food but reduced in kwashiorkor.80 There is wide interindividual 
absorption o f CQ which varies two to six fold for plasma and up to 11 fold for whole 
blood.83
1.11.2.2 Distribution
Chloroquine has a large volume o f distribution because o f extensive binding to 
tissues. Just under two thirds (58-64%) o f CQ binds to protein. Because equilibration is 
slow compared to absorption, there is a tendency to develop transiently high and, 
potentially, toxic peak concentrations after parenteral administration. Chloroquine must 
never be given by bolus iv injection.146
1.11.2.3 Metabolism
About 50% of chloroquine is metabolised in the liver to monodesethylchloroquine 
(DCQ) and several secondary metabolites.
1.11.2.4 Excretion
Urinary excretion is the main mechanism o f elimination; a mean o f 42-47% of 
chloroquine is excreted unchanged and 7-12% is excreted as DCQ. The terminal half life 
o f chloroquine is long; low concentrations of CQ persist for 1-2 months. Following CQ 
prophylaxis, half life estimations were 45-55 days (CQ) and 59-67 days (DCQ) with 
mean residence times o f 20 and 35 days, respectively.290 In one study o f Nigerian children 
treated with standard dose CQ, the mean plasma CQ levels on Day 7 were 38% those of 
Day 3, giving a half life o f 3-4 days during the first week.291 Renal failure significantly 
prolongs the elimination half life, increases the AUC, and is also associated with less 
conversion o f CQ to DCQ.226 Dose reduction is required only for prophylaxis. PK 
parameters differ between healthy subjects and malaria patients. In one Thai study, 
patients with vivax malaria had a significantly higher Cmax, AUC28days, and longer T>/2p than 
healthy controls.292
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1.11.3 Toxicity
Chloroquine is usually very well tolerated when used for malaria treatment or 
prophylaxis (see above). More toxicity is associated with the higher doses used over 
prolonged periods for rheumatic diseases. Commonly reported symptoms include 
headache, malaise, dizziness, blurred vision, difficulty focussing, mild GI upset, and 
itching. Itching is more common in African patients and may affect up to ~ 50% of
• 293 • • •patients. Itching is described as a widespread prickling sensation mostly affecting the 
palms, soles, perineal region, and scalp. It starts within 7 to 30 hours after the first dose of 
CQ, reaches a peak o f intensity between 4 to 12 hours later, and lasts up to 48 hours. 
Antihistamine treatment is not usually very effective.294 By contrast, a retrospective study 
of Thai or Burmese patients with vivax malaria found itching was uncommon, affecting ~  
2% (23/1189), mild in severity, and responded to antihistamine treatment.295 Less 
common side effects include lightening o f skin colour, rashes, reversible hair bleaching, 
and hair loss.296 ECG effects have been documented in three volunteers given prophylaxis 
followed by a therapeutic dose (25 mg/kg total dose). The ECG changes recorded were 
prolongation o f the QTc interval, and a reduction in the height o f the T wave.297 Postural 
hypotension has also been reported. Severe toxicity such as neuromyopathy, toxic 
epidermal necrolysis, bone marrow toxicity, and retinopathy is rare.298 299 300 301 
Irreversible CQ induced retinopathy is a complication o f long-term, high-dosage therapy. 
Cumulative doses o f lg  base/kg body weight or 50-100 g base total have been associated 
with retinal damage.302 At malaria prophylactic doses, potential eye toxicity is a 
significant concern only for long term (> 5 years) users. Patients may complain of 
temporal scotomas (words disappear when reading, only half an object is seen), and misty 
vision. Retinal signs include: pale optic disc, arteriolar narrowing, peripheral retinal 
depigmentation, macular oedema, retinal granularity and oedema, and retinal pigmentary 
changes consisting o f a circle o f pigmentation and central pallor, the so called ’doughnut' 
or 'bull's eye' macula. CQ induced, punctate corneal opacities occur in 30-70% of 
rheumatology patients within a few weeks o f treatment; they do not correlate with retinal 
changes. Symptoms are manifest in 50% and comprise photophobia, visual halos around 
lights, and blurred vision 219 Case reports have documented hearing loss in association 
with long term chloroquine or hydroxychloroquine use.224 303
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1.11.4 Overdose toxicity
Chloroquine has a low safety margin; a one time dose o f 30 mg/kg may be 
lethal.304 Severe clinical features are o f rapid onset (1-3 hours), such as vomiting, 
drowsiness, convulsions, visual disturbances, hypokalaemia, (serum K+ < 3mmol/L), 
shock, cardiorespiratory arrest, and death. The case fatality rate (CFR) is 10-30%. 
Diazepam is a specific antidote.
1.11.5 Use in pregnancy and breast feeding women
Chloroquine is considered safe for use as treatment and prophylaxis throughout 
pregnancy.253 306 307 308 Two small case series (n=21, n=35) have reported normal visual 
fields and slit light examinations in children who were exposed to CQ or hydroxyCQ (for 
maternal rheumatoid arthritis or SLE) in utero for time periods o f one to nine months. 
Eight children were also breast fed.309 310
Chloroquine is excreted into breast milk in small quantities and has mean Ti/2p of 
8.8 days. The estimated fraction o f the maternal dose that a breast feeding baby would 
receive was 0.7% of the daily dose and 4.2% over nine days.311312 CQ can be safely given 
to breast feeding mothers.
1.11.6 Drug interactions, cautions, and contraindications
Several drug interactions are important. Antacids reduce CQ absorption, and 
cimetidine inhibits CQ metabolism resulting in increased concentrations. CQ increases 
the risk o f ventricular arrhythmias with concurrent amiodarone use. HydroxyCQ 
increases the concentration o f digoxin; this may also apply to CQ. Cyclosporin 
concentrations are increased by chloroquine. In practice, there are few contraindications 
to using chloroquine: known allergy, or unacceptable toxicity from previous use (see also 
1.26.1). Chloroquine may increase the symptoms o f myasthenia gravis.
1.12 Pharmacology of doxycycline
Doxycycline, a tetracycline, is a well established antibiotic that is used to treat a 
variety o f infections e.g. scrub typhus, bacterial exacerbation o f chronic bronchitis, and 
brucellosis. Doxycycline is a standard malaria prophylactic drug. It is also used in 
combination for treating falciparum malaria and has replaced tetracycline because o f its 
twice daily dosing and low cost (US$ ~ 3/100 generic capsules in Indonesia).
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1.12.1 Mechanism of action
The tetracyclines are bacteriostatic antibiotics; they inhibit ribosomal protein 
synthesis. In malaria parasites, tetracycline is believed to act in the parasite 
mitochondrion where it inhibits dihydroorotate dehydrogenase, an electron transport 
enzyme important for pyrimidine synthesis.313 314 Doxycycline has also been shown to 
inhibit the production o f nucleoside- (e.g. ATP) and deoxynucleoside 5'- (e.g. dATP)
315 •triphosphates which are required for malaria parasite DNA replication. Doxycyclme 
acts principally against the asexual forms o f the malaria parasite. Causal activity is not 
consistent and there is no hypnozoite activity.190 In vitro, the mean (95% Cl) IC50 of 
doxycycline against African isolates o f P. falciparum  was high, 11.3 (9.5-13.4) pmol, 
reflecting its weak activity.316 The IC50S between CQ sensitive and resistant stains o f P. 
falciparum were similar. These findings were consistent with an in vitro study o f Thai 
isolates.317
1.12.2 Pharmacokinetics
1.12.2.1 Absorption
Absorption is rapid from the duodenum after oral administration and is linearly 
related to dose; bioavailability is 95%.318 After a single oral dose o f 100 or 200 mg, the 
Cmax was 1.7-5.7 mg/L, and the Tmax 2-3.5 hrs. Unlike tetracycline, the absorption of 
doxycycline is not greatly affected by food or milk.
1.12.2.2 Distribution
Doxycycline is lipophilic and widely distributed in tissues. The Vd is ~ 53-134 
L/kg and the volume o f the central compartment is 22 L/kg. The variation in Vd values is 
partly due to the different doxycycline salts studied. The highest tissue concentrations are 
found in the liver, kidneys, and digestive tract. The tissue to serum ratio is 2:1 and is 
stable over time. Plasma protein binding is between 80-90% and is reduced in children 
with malnutrition; the latter results in increased total and non renal elimination, a decrease 
in the AUC, and a shortening of the T i/2p.
1.12.2.3 Metabolism
Metabolism o f doxycycline occurs in the liver, as evidenced by a decrease in the 
AUC with the concomitant administration o f rifampicin, a known inducer o f cytochrome 
P450. However, no doxycycline metabolites have been found in blood, urine, or faeces.
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1.12.2.4 Excretion
Doxycycline excretion is via the GI tract (60-70%) and the kidneys (30-40%). 
Renal clearance (mix o f glomerular filtration o f unbound doxycycline and renal 
absorption) is ~  2L/h and is enhanced by alkalinisation. Faecal elimination is primarily 
through gut wall diffusion; biliary excretion contributes to a lesser extent. Intraintestinal 
doxycycline is chelated with calcium and magnesium ions which render it unabsorbable 
and less potent as an antibiotic. Non chelated doxycycline is reabsorbed and is recycled 
(enterohepatic cycling). The elimination half life is 15-25 hours; it is unchanged in the 
elderly and dose reduction is not necessary. In all degrees of renal failure, the AUC and 
half life remain the same or are slightly increased. Drug accumulation has not occurred 
with repeat dosing because decreased protein binding results in increased clearance via 
the liver and gut.
1.12.3 Toxicity
At recommended doses for prophylaxis, treatment, and in combination with 
antimalarial drugs, doxycycline is well tolerated (see above).
1.12.4 Overdose toxicity
There are few data on the overdose toxicity o f doxycycline. Reported symptoms 
include nausea, vomiting and abdominal pain. Severe toxicity is thought unlikely. One 
case report describes a male who took 1 gm o f doxycycline daily for 12 years. He 
developed hepatic dysfunction (hepatic necrosis and cholestasis), grey/blue patches on his 
shins, anaemia, leukopenia, and Wenckebach phenomenon on ECG. These effects were 
reversible.319
1.12.5 Use in pregnancy and breast feeding women
Tetracyclines should not be used in pregnancy (see below). Little published data 
exist on tetracycline excretion into breast milk. Minocycline concentration peaked at 0.8 
mg/L following 200 mg, representing 25% and 75% o f the measured levels in amniotic 
fluid and the umbilical cord, respectively. The amount of tetracyclines absorbed by the 
breast fed infant is considered small because o f chelation with calcium (Ca2+) ions in 
breast milk.
1.12.6 Drug interactions, cautions, and contraindications
Significant interactions include anticonvulsants (increased metabolism, reduced 
blood levels, shortened Ti/2p), wine (reduced AUC), beer (delayed absorption, increased
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Ti/2p), antacids (reduced absorption), ferrous salts (reduced absorption), and rifampicin 
(increased clearance). The dose o f doxycycline should be increased if  co prescribed with 
anticonvulsants.320
Known tetracycline allergy is a contraindication. Tetracyclines cause brown 
discoloration and abnormalities o f bone growth during periods o f tooth formation. They 
cross the placenta and have caused foetal abnormalities in animals. Therefore, they are 
contraindicated during pregnancy, breast feeding, and in children less than 12 years (< 8 
in the US). Doxycycline is listed by the British National Formulary as a drug that is 
unsafe for use in acute porphyria and should not be used.227 Exacerbation o f SLE has 
been described with the tetracyclines and should not be used. Data on the use of 
doxycycline in patients with liver disease are lacking. However, as a class, tetracyclines 
can be hepatotoxic and should not be used in such patients. Intravenous tetracycline is 
contraindicated because it has caused acute liver necrosis and death in pregnant and non 
pregnant adults.321 322
1.12.7 Tetracyclines alone for the treatment of P. falciparum and P. vivax
There are few data on the treatment o f P. falciparum  and P. vivax with 
doxycycline or tetracycline. Both drugs have modest activity against both species. In 
experimentally induced malaria infections in non immune American volunteers, seven 
days o f doxycycline (100 mg bid) cured 9/9 men with low parasitaemic P. falciparum  
malaria whereas five days o f doxycycline resulted in 4/4 cases o f recrudescence that 
occurred between 19 to 27 days.323 In the same study, Chesson strain vivax malaria (the 
New Guinea strain) was treated with tetracycline or doxycycline. Twelve American 
volunteers were given tetracycline as 2 gm daily for seven (n=4) or 14 days (n=2), and 4 
gm daily for seven days (n=6). All cleared their parasites but eleven had recurrent vivax 
parasitaemia between Days 21 to 44; the twelfth man was given primaquine on Day 33. 
Doxycycline was given to two men (100 mg bid x 4 or 6 days) with similar results. In 
another volunteer study, tetracycline was given to 29 volunteers in doses o f 250 mg qid 
for 3% (n=3), 5 (n=6) or 7 days (n=20). All three (3 lA d regimen) and one from each other 
group had parasite recrudescence.324
Tetracycline (250 mg qid for 10 days) cured 12 o f 16 asymptomatic, low 
parasitaemic, P. falciparum patients o f whom four had recently failed chloroquine (RI
T9 ^resistant). The other four developed symptomatic disease within 72 hours and had to be
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given rescue treatment. Malaysian children, aged two months to eight years, with 
chloroquine resistant falciparum malaria had a higher cure rate when treated with seven 
days o f doxycycline (4 mg/kg) compared to four days: 22/26 (84.6%) vs. 4/9 (44.4%), 
P=0.01.326 Five Gambian children aged VA to 5 years cleared their parasites with high 
doses o f tetracycline, 125 or 250 mg qid for five days.327 In all these studies, tetracycline 
and doxycycline produced slow parasite (PCT) and fever (FCT) clearance times against 
both malaria species. The PCTs and FCTs for P. falciparum ranged from 4 to 8 and 1 to 8 
days, respectively; corresponding figures for P. vivax were 4 to 10 and 4 to 9 days, 
respectively.
1.12.8 Use of the tetracyclines as adjunct treatment of P. falciparum 
malaria
A number o f studies have reported the use of tetracycline or doxycycline in 
combination with standard antimalarials achieving efficacious cure rates of ~ 95%. 
Twenty nine (96.6%) o f thirty Thai adults were cured by three days o f quinine and ten 
days o f tetracycline.325 Similar results also from Thailand were obtained in other studies 
that used seven days o f tetracycline or doxycycline combined with quinine (3 or 7d), 
mefloquine (25 mg/kg total dose), or amodiaquine.158 159 160 161 162 In Gabon, doxycycline 
for three days combined with one day o f quinine (3 doses) resulted in a cure rate o f 91% 
(32/35) compared to 38% (14/37) for quinine alone; all treatment failures were RI.328 The 
corresponding figures for doxycycline/CQ and CQ alone were 75% (27/36) and 36% 
(15/42) in two other studies.163 164 However, a clinical trial o f Thai adults with falciparum 
malaria assessing the efficacy o f chloroquine with tetracycline against falciparum malaria 
was prematurely abandoned because two patients with RIII resistance became seriously 
ill with high fever and rising parasite counts. The investigators concluded that this 
combination was potentially dangerous and recommended against its use for treating
19Qchloroquine resistant falciparum malaria.
1.13 Pharmacology of Azithromycin
Azithromycin is an azalide antibiotic with a similar structure to erythromycin and 
clarithromycin.330 It has broad antimicrobial activity and is used to treat a number of 
infections, including community-acquired pneumonia, travellers' diarrhoea, trachoma, 
genital Chlamydia trachomatis, and Mycobacterium avium-intracellulare complex
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(MAC). The dose o f azithromycin varies with the clinical indication but for routine use, 
the adult dose is 1.5 gm given taken over three days.
1.13.1 Mechanism of action
Azithromycin inhibits ribosomal protein synthesis in bacteria, resulting in a 
predominantly bacteriostatic effect. A post antibiotic effect o f several hours has been 
demonstrated against respiratory bacteria. In malaria parasites, protein synthesis is also 
inhibited but the precise details are unknown. Like doxycycline, azithromycin results in a 
reduced production o f nucleoside-5'-triphosphates and 2'-deoxynucleoside-5'- 
triphosphates.315
In vitro, azithromycin has weak antimalarial activity against CQ resistant and 
sensitive P. falciparum , comparable to the other antimalarial antibiotics. In one in 
vitro experiment, the MIC was higher at 48 h (6.2 and 8.7 pg/ml) compared to 96 h (0.08 
and 0.04 pg/ml) for two falciparum isolates. The marked reduction in the MIC values 
between the first and second asexual erythrocytic cycles suggests a slow onset of 
action.333 An additive or synergistic effect was seen with chloroquine and quinine.334
1.13.2 Pharmacokinetics
The PK profile o f azithromycin is one o f rapid absorption, extensive tissue uptake, 
followed by slow release that results in a long half life. Compared to erythromycin, 
azithromycin has lower serum and AUC values, greater tissue penetration, and a longer 
terminal half life.
1.13.2.1 Absorption
Azithromycin is absorbed rapidly from the gastrointestinal tract, reaching peak 
plasma concentrations after approximately IVi hours. In studies o f different regimens of 
orally administered azithromycin to healthy adult volunteers (e.g. 500 mg on Day 0, 
followed by 250 mg/d x 4 or 9d, 500 mg once only on Day 0), the measured 
pharmacokinetic parameters were: (i) a low bioavailability o f 37% (probably related to 
incomplete absorption), (ii) Cmax 0.41-0.5 mg/L, (iii) Tmax 2.2-2.5 hours, (iv) a mean 
serum concentration at 24 hours o f 0.05 mg/L, (v) a Tma ~ 4 hr, (vi) mean T 1/2(3 ~ 57 and 
68 h (the Ti/2p depended on when sampling was done), (vii) half lives in tissues were 2.3 
days (prostate), and 3.2 days (tonsils), (viii) AUC0-72 = 4.3 mg/Lh (stat dose only), (ix) 
AUCo-24 = 2.6 mg/Lh, (x) AUC0-4 = 3.39 mg/Lh, (xi) Vd = 31 L/kg, (xii) tissue:serum 
ratio > 100 at 12 h, and (xi) a high plasma clearance o f 630 ml/min. Compared to
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young volunteers, older subjects had (i) a significantly slower TmaX (3.8 vs. 2.5 h post first 
dose), and (ii) a significantly higher AUC on Day 5 (2.7 vs. 2.1 mg/Lh) but not Day 1 
(3.8 vs. 2.5 mg/Lh).
1.13.2.2 Distribution
Azithromycin is widely distributed in tissues. Protein binding is mostly to ai-acid 
glycoprotein and is inversely related to the serum concentration. Binding is ~ 50% and 
7.1% at serum concentrations o f  0.02-0.05 and 1 mg/L, respectively. Its high tissue 
(intracellular) penetration is a therapeutic advantage against intracellular pathogens like 
Chlamydia and Toxoplasma species. There is also high penetration into white blood cells 
and macrophages but there are no data on its penetration into normal or parasitised red 
cells.
1.13.2.3 Metabolism
Azithromycin is metabolised in the liver but not by the cytochrome P450 
isoenzymes. The main metabolic reaction is N-demethylation o f the desosamine sugar of 
the macrolide ring; others include O-demethylation, hydrolysis, and hydroxylation. There 
is no significant interaction with theophylline, digoxin, and warfarin.
1.13.2.4 Excretion
Biliary excretion o f mostly unchanged drug is the main route o f elimination; ~ 6% 
of an oral dose appears unchanged in urine. In mild to moderate renal failure (GFR 10 - 
80 ml/min), the Cum and AUC0-120 increased modestly by 5.1 and 4.2%, respectively; 
corresponding values in severe renal failure (GFR < 1 0  ml/min) were 61% and 35%. In 
mild or moderate hepatic impairment, PK differences with normal volunteers were 
inconsistent. The Ti/2p was increased modestly in volunteers with moderate hepatic 
impairment. Dose reduction in mild or moderate renal or hepatic disease is unnecessary.
1.13.3 Toxicity
Standard dose azithromycin, administered over 3 to 5 days to children (30 mg/kg 
total dose) or adults (1.5 gm total dose), is well tolerated. A total o f 12% report any 
symptom. Less than 10% of patients report any gastrointestinal symptom [nausea or 
vomiting (3.4%), abdominal pain (2.5%), diarrhoea (3.6%)]. The majority o f patients, 
93%, reported mild or moderate side effects. Unacceptable toxicity resulted in drug 
discontinuation in 0.7-1.3% o f azithromycin treated patients.337 338 339 340 This tolerability
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is comparable or better than other antibiotics that were used for the same clinical 
indications.341 342 343 344 High dose azithromycin e.g. 1 gm for adult genital chlamydia, 20 
mg/kg in paediatric trachoma, is also well tolerated.345 346 However, tolerability is worse 
when azithromycin is used for longer periods against MAC in both AIDS and non-AIDS 
patients.347 348 349 350 Doses o f 1.2 gm weekly or 300-600 mg/day are associated 
frequently with side effects, especially GI symptoms. In a study o f MAC prophylaxis, 1.2 
gm of azithromycin was administered weekly to 85 patients for a mean o f 400 (30-985) 
days. Seventy one (78.9%) reported at least one GI symptom, a 2-4 fold increase 
compared to placebo. GI intolerance resulted in six (7%) patient withdrawals at a median 
time o f 112 days.348
Several small studies (total n 46 patients), have identified reversible hearing loss 
as an important side effect in 13-17% of patients with AIDS or non-AIDS related MAC. 
Audiogram confirmed hearing loss has usually been in the speech frequency range and 
lasted between two and eleven weeks. There is, however, one published report
o f irreversible, high frequency hearing loss in a 37 years old woman who took 750 mg of 
azithromycin.353
In the Kenyan prophylaxis study, both azithromycin groups (250 mg/d or lgm/w) 
reported symptoms that were similar to the placebo group. There was also no evidence of 
toxicity on routine clinical haematological or biochemical testing.199 In large clinical 
series, changes in haematological and biochemical parameters have been unremarkable. 
Transient neutropenia (1.5%) and transient, mild elevations o f liver transaminases (1.5- 
1.7%), alkaline phosphatase (0.3%), bilirubin (0.7%) have been reported in a minority of 
patients. Significant hepatotoxicity has occurred rarely e.g. hepatitis as part o f a systemic 
hypersensitivity syndrome, and cholestasis.354 355 Serious azithromycin related toxicity 
e.g. pseudomembranous colitis, erythema multiforme, Churg-Strauss syndrome, 
cutaneous vasculitis, pustular rash, Henock-Schonlein purpura, and anaphylaxis is also
337 338 339 356rare. Anaphylaxis may reappear after apparent successful treatment without
reexposure to the drug. Therefore, treatment for anaphylaxis may be required for several 
days. There are no published data on azithromycin overdose.
1.13.4 Use in pregnancy and breast feeding women
Azithromycin is not licensed for use in pregnancy but there is accumulating 
experience with the treatment o f genital Chlamydia trachomatis. Azithromycin is well
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tolerated and has not caused untoward toxicity for both mother and foetus. 
Azithromycin is excreted into breast milk in small amounts but its effect on infants is 
unknown.359 Breast feeding should not, therefore, be considered a contraindication.
1.13.5 Drug interactions, cautions, and contraindications
Antacids reduce the absorption o f azithromycin. Because azithromycin is not 
metabolised by cytochrome P450, there are far fewer metabolic interactions compared to 
erythromycin e.g. theophylline, fluconazole, carbamazepine, and cyclosporine. Nelfinavir 
increases azithromycin serum concentrations. There is also no significant interaction with 
warfarin (dispacement from protein binding). Azithromycin has few contraindications; 
namely, known macrolide allergy, and severe liver disease. Caution should be exercised 
in patients with mild hepatic or renal impairment but dose reduction is unnecessary. There 
are no dose recommendations for patients with severe renal disease. Because the safety 
database in pregnancy is limited, azithromycin cannot yet be recommended. Never the 
less, azithromycin can be used if  there are no safer alternative drugs.
1.13.6 Antimalarial activity
1.13.6.1 Preclinical studies
Against blood forms o f P. berghei in mice, azithromycin was more active than 
erythromycin and its activity was increased by chloroquine.360 Azithromycin was more 
potent than doxycycline in a murine experiment o f causal prophylaxis against P. yoelii; 
the effect was dose dependent.361 In mice and monkey experiments, azithromycin had 
schizonticidal activity against P. berghei and CQ resistant P. falciparum , respectively. It 
also enhanced the antimalarial activity o f quinine, halofantrine, and artemisinin.
1.13.6.2 Clinical studies
Two human challenge experiments demonstrated a prophylactic effect of 
azithromycin and its causal activity. Four volunteers were given supervised azithromycin 
for 7 days (500 mg on Day -2, then 250 mg/d for Days -1 to +5). Mosquito challenge with 
a chloroquine resistant strain o f P. falciparum  was done on Day 0. Three volunteers 
remained malaria free; the one who developed malaria did not have measurable 
azithromycin serum levels, consistent with poor absorption. Fifteen control subjects, who 
did not receive azithromycin, developed malaria 9 to 12 days after sporozoite 
challenge.363 In the second study, a prophylactic effect against the initial 7 day period of 
solely liver infection was determined by loading subjects with azithromycin prior to
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malaria challenge on Day 0 and giving azithromycin for 7 days after challenge. The 
regimen was 500 mg on Day -14, followed by 250 mg/d from Day -13 to Day +7. Four of 
10 subjects did not develop patent parasitaemia. In a second cohort (n=10), azithromycin 
was continued for 28 days after challenge. None o f the 10 subjects became infected. For 
each cohort, two concomitantly challenged control subjects did not receive azithromycin 
and all developed patent parasitaemia on Days 9 to 13.364 Azithromycin was partially 
effective against liver parasites and highly effective against blood stage parasites.
When azithromycin was used for treating Gambian children with trachoma, there 
was a coincidental reduction in spleen rates, parasite counts, and the number o f episodes 
of febrile parasitaemia due to P. falciparum. A placebo controlled prophylactic study 
against P. falciparum  was conducted over ten weeks in Kenyan adults from western 
Kenya. Daily (250 mg) or weekly (1 gm) azithromycin, and daily doxycycline (100 mg) 
were tested. Using cumulative incidence, the prophylactic efficacies were: (i) daily 
azithromycin 83% (68-91), (ii) weekly azithromycin 64.2% (41.1-77.1), and (iii) 
doxycycline 92.6% (79.9-97.5).199 Although the PEfs o f azithromycin were not 
significantly different, these data suggest that daily dosing was better than weekly dosing.
1.14 Rationale for the chloroquine doxycycline study
This study was undertaken as a joint collaborative effort between the Indonesian 
Ministy o f Health, the Indonesian Navy, and NAMRU-2. At the time, the first line drug 
for malaria was chloroquine for all provinces o f Indonesia. SP was the second line choice 
for chloroquine resistant P. falciparum  and there was no official second line choice for 
chloroquine resistant P. vivax. Aside from CQ and SP, only primaquine, quinine, 
mefloquine and Fansimef were registered in Indonesia at the time o f the study. Well 
known antibiotics e.g. the tetracyclines, the penicillins, co-trimoxazole, chloramphenicol 
were also registered.
By 1995, it was clear that Indonesia had areas o f multidrug resistant P. falciparum  
as well as CRPV. Other parts o f south east Asia were also known to harbour multidrug 
resistant malaria; the best well characterised area was, and still is, the western border of 
Thailand. Standard (15 mg/kg) and high (25 mg/kg) dose mefloquine had become 
ineffective, the latter falling to about 60% efficacy by 1994.94 In 1993, three days o f  
artesunate plus high dose mefloquine had achieved a cure rate o f some 98%. 156 This
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combination subsequently rescued mefloquine and is currently (2005) the first line 
treatment for drug resistant P. falciparum.
The predominant view regarding the treatment o f malaria in 1995 was still to use 
monotherapy. Experience with combinations like artesunate plus mefloquine or standard 
antimalarial drugs with antibiotics had been limited mostly to the research setting. In 
addition, quinine alone or in combination with tetracycline sufficed for drug resistant 
malaria. Although artesunate and other artemisinins had been used in China for many 
years, there appears to have been a reluctance to embrace this class o f drugs in the 1990s. 
This is certainly also the case for Indonesia. It is also fair to point out that although the 
problem of drug resistance was known, effective and long lasting solutions were not 
obvious. The failed experience o f Fansimef in Thailand may have also dampened the 
enthusiasm for using drug combinations and there were no longitudinal studies which 
showed convincingly that a given combination had held resistance in check and / or 
reduced malaria transmission. This information only became widely available in 2000 
when the experience from the Thai Burmese border was published.94
Therefore, for the Indonesian Ministry o f Health, options were limited. 
Mefloquine was expensive, associated with unpleasant side effects that might limit 
acceptability by the population, and not registered in Indonesia. Halofantrine was also 
expensive and unregistered, and at this time reports were emerging o f fatal cardiotoxicity, 
rendering a poor choice for widespread use. Atovaquone / proguanil have never been 
registered in Indonesia and had only been registered in early 1990s in other countries. 
Cost precluded its widespread use despite its good efficacy and tolerability. The question 
of using artemisinins was never debated as a serious option because little was known 
about this class o f drugs and they were not widely available. Amodiaquine, a drug widely 
used in Africa, has never been used as drug policy in Indonesia and was, therefore, never 
considered an option.
Clearly, an easy and readily applicable option would be to use drugs that were 
well characterised, inexpensive, registered and widely available in Indonesia. One option 
was to examine the possible benefit o f adding doxycycline to chloroquine for both 
falciparum and vivax malaria, cogniscent that this combination could not be used in 
children under 8 years or in pregnant women. There was adequate documentation from 
Asia, mostly Thailand, and Africa that tetracycline and doxycycline increased cure rates
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when combined to chloroquine and quinine. The cost o f this combination for an adult 
would increase the total cost to about 50 US cents, a not unreasonable price. Therefore, 
this combination was chosen and tested in adult patients.
1.15 Rationale for the azithromycin prophylaxis study
The azithromycin prophylaxis study was part o f a drug registration project that 
was a partnership between Pfizer, the US Army, US Navy, the Indonesian Army, and the 
Indonesian Ministry o f Health. At the time o f the study, there were three widely available 
and internationally registered drugs for malaria: chloroquine/proguanil, doxycycline, and 
mefloquine. Atovaquone / proguanil was in development and was registered as a 
prophylactic in 1998.
With only three prophylactic drugs, there was certainly a need for more and better 
drugs. The usefulness o f chloroquine/proguanil is severely limited by the spread of 
chloroquine resistance that continues. This combination had already been relegated to 
second choice by 1995 and is currently not recommended by some countries. Although 
never formally tested in Indonesia, its prophylactic efficacy is likely to be very low, 
possibly no better than placebo in north east Papua. Mefloquine is certainly efficacious in 
areas where there is high sensitivity to this drug but there is a cloud over its tolerability 
and a perception that is not well tolerated despite the documented evidence. Doxycycline 
is highly effective and generally well tolerated but its clinical indication does not include 
small children or pregnant women. The antimalarial properties o f azithromycin were well 
described in animal work, human challenge experiments, indirect field experience in 
trachoma treatment, and a prophylactic study in malaria immune Kenyans.
Azithromycin is registered for use in adults and children down to the age o f six 
months. For use in pregnancy, the US FDA classifies azithromycin as a B drug 
(reproduction studies show no evidence o f harm to the fetus but adequate and well 
controlled trials in pregnancy are lacking). Azithromycin has been used to treat sexually 
transmitted diseases in pregnant women without apparent untoward effects for both 
mother and foetus but experience is still young. Azithromycin is secreted into breast 
milk in small amounts and can be given to breast feeding mothers.
Malaria chemoprophylaxis and has traditionally been the domain o f non immune 
travellers but there is currently increasing interest in prophylaxis and intermittent 
preventative treatment in pregnant women in malaria endemic countries. For drug
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registration, demonstrating high prophylactic efficacy in a non immune population is 
better than trials conducted in malaria immune individuals. Indeed, this was the request of  
the US FDA for this study (D. Braitman, personal communication). Therefore, if  the 
measured prophylactic efficacy o f azithromycin in a population o f low or no immunity 
were high against P. falciparum  malaria, and its tolerability good, then azithromycin 
would be a substantial addition to the small number o f antimalarial prophylactic drugs 
currently available. Azithromycin could be used in individuals o f all ages, breast feeding 
mothers, and in those with certain illnesses e.g. epilepsy, mild to moderate renal failure, 
depression, other major psychiatric illnesses, and those with doxycycline induced 
photosensitivity. There is a potential role for azithromycin in pregnant women but more 
safety data are required before this recommendation can be made.
The decision to allow azithromycin to be used in Indonesia was made by the 
Indonesian National Ethics Review Committee and the Indonesian Army Ethics 
committee. There was less enthusiasm from the Ministry o f Health because the likely 
high cost o f the drug would have precluded its widespread use. However, the Indonesian 
Army was keen have another prophylactic option and were happy to have close ties with 
the US Navy. Cost was less o f an issue (See also Ethical Issues in the Discussion section).
1.16 Study aims
The aims o f the studies were to assess: (i) azithromycin as a potential antimalarial 
prophylactic drug, and (ii) the combination of chloroquine and doxycycline as alternative 
therapy to chloroquine against chloroquine resistant P. falciparum  and P. vivax.
1.17 Study objectives
The objectives were to: (i) measure the prophylactic efficacy o f azithromycin and 
doxycycline relative to placebo for preventing P. falciparum  and P. vivax parasitaemia, 
and (ii) evaluate the efficacy and tolerability o f chloroquine combined with doxycycline 
for treating acute, uncomplicated P. falciparum  and P. vivax.
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Chapter 2 - Materials and Methods
2.1 Study site - Jayapura and Arso region
2.1.1 General description
Irian Jaya, renamed Papua in 2000, forms the western half o f New Guinea island 
(Appendix 2). It is geographically diverse with central highlands that peak at ~ 5000m, 
lowlands, and areas o f dense tropical forestation. Jayapura is the provincial capital and is 
located on the north east coast. Jayapura has a population o f 210,000. The Greater 
Jayapura area extends for approximately 60 km around the city centre and includes 
several small towns [Abepura (population o f 46,000), Sentani (pop. 30,000)], and several 
transmigrant settlements. There is one public (Rumah Sakit Umum) and two military 
hospitals. The RSU has 373 beds, and functions as a regional referral centre. Annual 
visits to the hospital total approximately 130,000 outpatients, with almost 14,000 
inpatients. There are also several government and private medical clinics, laboratories, 
and pharmacies located in the area. Antimalarial and other drugs may be purchased easily 
without a prescription.
The Arso region is a rural area situated south east o f Jayapura. It is a low land 
swamp that is surrounded by forested hills. The plain stretches south for 50 km from 
Sudarso bay in the north and is between 20-40 km in breadth. Several small tributaries of  
the Tami river cross the plain. Arso is hot and wet all year round. Temperatures range 
from 20°C to 35°C. The relative humidity is usually approximately 80%. Total annual 
rainfall is estimated at 3,400 mm (134 inches). It is highest during November and March; 
there is no dry season. The northern part consists mostly o f forested areas ('hutan') and a 
large palm oil plantation o f some 10,000 hectares dominates the extreme south o f the 
plain. Local Irianese and transmigrasi (Indonesian immigrants from other parts of 
Indonesia) live together in small settlements constructed by clearing the hutan and 
erecting simple wooden houses. Most settlements do not have basic amenities e.g. 
running water, electricity, and telephone lines. There is, however, a reasonable public 
health infrastructure in Arso. Free, primary health care is provided by health workers 
(called mantrees) with basic training, and the larger settlements have government run 
clinics (puskesmas). The majority o f villagers use these government clinics for health
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care. There are no private clinics in rural Arso but some small shops do sell antimalarial 
as well as other drugs.
2.1.2 Population - Irianese, transmigrants, soldiers
The population o f Jayapura and its surrounding rural environs consists of 
indigenous Irianese and transmigrasi. The rural based Irianese and transmigrasi are 
subsistence farmers. The transmigrasi volunteer to immigrate to Irian under a government 
scheme, the Transmigration Programme that resettles people from other parts of 
Indonesia. Most are farmers from rural Java where malaria transmission is low.6 The 
Irianese have had life long exposure to malaria and naturally acquired, malaria immunity. 
By contrast, the transmigrasi have had little or no malaria exposure and correspondingly 
little or no immunity. The transmigrasi who were recruited for the azithromycin 
prophylaxis study had lived in the village o f PIR V for 15 months. As per Indonesian 
Ministry o f Health (MoH) policy, they had received free chloroquine prophylaxis for the 
first three months o f their arrival that was distributed by the mantrees. Bed nets, usually 
not impregnated, were used in PIR V by individual families but there was no government 
run bed net programme.
The Indonesian Army soldiers serve one year o f duty from their home bases in 
other parts o f Indonesia. Soldiers are stationed in small military posts and encampments 
that are situated near villages throughout Arso. Like the transmigrasi, they have had 
limited or no malaria exposure. The recruited soldiers (prophylaxis study) had arrived 6 
months earlier from Lampung, southern Sumatra, an area o f low malaria incidence (F. 
Laihad, personal communication). Upon arrival in Arso, the soldiers were issued with non 
impregnated bed nets and were given several anti malaria prophylactic drugs, 
doxycycline, sulfadoxine/pyrimethamine, or chloroquine. There did not appear to be a 
consistent prophylaxis policy. All were changed to doxycycline by the research team 
whilst preparing for the azithromycin study.
2.1.3 Malaria characteristics in Jayapura and Arso region
2.1.3.1 Epidemiology in Jayapura
Surveys conducted in the 1970s in Jayapura and Abepura showed low malaria 
prevalence rates o f 10% and 20% in 1970 and 6% and 18% in 1979, respectively.57 Two 
thirds o f  cases were due to P. falciparum. There are no recently published malaria 
epidemiological data for Jayapura but the impression from local hospital physicians is
that urban malaria is not a significant problem; the majority o f malaria cases seen are 
from the rural areas.
2.1.3.2 Epidemiology in Arso - data from the Dutch era
There are ample malaria data from the rural environs o f Jayapura, particularly for 
Arso. In the 1950s Dutch malariologists classified the malaria endemicity based on 
parasite rates rather than spleen rates because the latter was deemed a better reflection of 
infection risk (Table 2 .1).367 Interestingly, they noted that adult Irianese had high spleen 
rates (78%) in the Nimboran valley (60 km south west o f Jayapura) an area o f  
holoendemic malaria (parasite rate ~ 95%). This finding contrasted with holoendemic 
Africa. Accordingly, they classified holoendemic malaria as the African type (low spleen 
rates in adults) and the New Guinea type (high adult spleen rates).
Table 2.1 Malaria classification used by Dutch malariologists in Irian Jaya using the 
absolute parasite rate (APR) in children aged 2-10 years.
Transmission intensity APR %
Hypoendemic 0 - 1 0
Mesoendemic 11 - 50
Hyperendemic 51 - 7 5
Holoendemic >75
Malariometric surveys conducted in 1958 in two villages in Arso before the 
pyrimethaminised salt campaign showed an overall malaria prevalence o f 58% of 1,450 
individuals examined. Rates were much higher in children compared to adults and were 
highest in children under five, just over 90%. Rates o f between 35 and 45% were found in 
adults aged 15 and above. Counting mixed infections twice (rates not stated), the species 
breakdown was 31% for P . falciparum, 22%  for P. vivax, and 19% for P. malariae. The 
corresponding figures obtained six months into the salt campaign were 17%, 2%, and 0%. 
Overall malaria prevalence rates decreased to 22% from 58% pre salt campaign.
2.1.3.3 Epidemiology in Arso - recent data
During 1987 and 1993, malariometric surveys were conducted by the US Navy in 
indigenous Irianese and transmigrasi who lived in new as well as well established 
settlements. Malaria prevalence and spleen rates varied between villages but were
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generally high (Table 2.2). P. falciparum  predominated in most villages. P. malariae and 
P. ovale were detected rarely.
Table 2.2 Malaria prevalence rates in transmigrants of all ages from Java who had 
resettled in several villages in the Arso region o f north east Papua. Surveys conducted by 
the US Navy. Data from Cdr. JK. Baird, US Navy.
Location Date N* P. falciparum^ P. vivax t Pf:Pv Total
PIR I Nov 1987 188 37 15 2.5:1 52
PIR II Jan 1989 224 30 37 0.8:1 67
Mar 1990 215 19 17 1.1:1 36
PIR V Jun 1991 689 63 23 2.7:1 86
Mar 1992 553 41 15 2.7:1 56
PIR VI Jun 1991 257 25 26 1:1 51
Mar 1992 477 15 12 1.25:1 27
PIR IV Mar 1993 216 30 14 2.1:1 44
* N=number surveyed 
t  prevalence rate as %
2.1.4 Epidemiological surveys in PIR I
Arso PIR I village was established in 1986. At the time, the population numbered 
960 o f whom 45% were Irianese and 55% were transmigrasi. A malaria prevalence 
survey was conducted in 1987 by screening 473 (49%) villagers; 213 were Irianese, the 
rest (260) were transmigrasi. The overall prevalence o f malaria was ~ 45% (n=213) 
with a falciparum to vivax ratio o f 2:1. Overall, the transmigrasi (~ 51%) had 
significantly higher rate than the Irianese (~ 37%). Older transmigrant children (age >11)  
and adults (age > 15) had higher rates o f P. falciparum  than Irianese. Rates in 
transmigrant (~ 38%) and Irianese (~ 29%) children < 11 years had rates o f P. falciparum  
that were not significantly different. The prevalence rates for P. vivax were similar 
between both groups; only transmigrasi adults (~ 13%) had significantly higher rates than 
the Irianese adults (~ 4%). None o f the villagers carried P. vivax gametocytes but 25/258 
(9.7%) o f transmigrasi carried falciparum gametocytes compared to 5 (2.3%) o f 215 
Irianese (P = 0.001). Gametocytaemia was always associated with asexual parasitaemia 
and was 2% fold (95% Cl 1.1-6.7) more likely in the transmigrasi [25/94 (26.6%)] than 
the Irianese [5/51 (9.8%)]. In this survey, malaria prevalence rates declined with 
increasing age for both groups. Rates were less for the older Irianese, consistent with a
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greater degree o f acquired immunity. Malaria infected Irianese also had lower gametocyte 
carriage rates, suggesting the development o f immunity against sexual stages o f the 
malaria parasite.
In a later study in PIR I, malaria attack rates and incidence rates were measured 
during the high and low transmission seasons.369 Subjects aged > 1 5  received radical cure 
for malaria and were monitored weekly by blood film for 20 weeks during the high 
transmission season (May to October) and for 12 weeks during the low transmission 
season (January to April). The P. falciparum, malaria incidence rates in the low season 
were significantly higher in the transmigrants (3.4/p-y) compared to the Irianese (1.6/p-y) 
but were similar in the high season, 4.6/p-y vs. 4.1/p-y, respectively. Cumulative 
incidence data were consistent. During the low transmission season, 50% of the 
transmigrants developed falciparum parasitaemia by week 10 and 43% of the Irianese 
were positive by week 17, for a relative risk o f 1.65 (95% Cl 1.17-2.34). During the high 
transmission season study, 50% of the transmigrants and 50% o f the Irianese were P. 
falciparum  positive by week 6 and week 9, respectively, for a relative risk 
(transmigrasi:Irianese) o f 1.1 (0.85-1.47). Comparing the risk o f falciparum parasitaemia 
within each group, the transmigrasi had similar attack rates in the high [70% (43/61)] and 
low [64% (42/66)] seasons. The Irianese had a two fold increased risk in the high season 
compared to the low season: 63% (29/46) vs. 32% (16/50), RR=1.97 (1.24-3.12). The 
attack rates for P. vivax were similar between both groups during the high and low 
seasons: 27% (18/66, transmigrasi) vs. 32% (16/50, Irianese), and 11% (7/61, 
transmigrasi) vs. 8.7% (4/46, Irianese), respectively.
Epidemiological data from other villages obtained during clinical trials following 
radical cure have shown variable results compared to those o f PIR I. During one year of 
malaria surveillance in Arso PIR XI, the cumulative incidence o f malaria was -4 8 %  for 
P. vivax and -  36% for P. falciparum; the measured incidence rates were -  0.5/p-y for
• 370each species. In a prophylactic study conducted in non immune Indonesian soldiers, 
stationed throughout Arso, the incidence rates were 3.3/p-y for P. falciparum  and 2.5/p-y 
for P. vivax.136
91
2.1.5 Age, clinical immunity, and malaria
Data to support the hypothesis that protective malaria acquired immunity in 
malaria naive, transmigrasi adults may develop over a short time span o f two years come 
from several epidemiological and serological studies.
One study obtained detailed malaria prevalence data at 15 time points over the 
course o f five years in six villages in Arso: PIR I, II, IV, V, VI, and Nimborokrang 
(Genyem subdistrict).371 Some 4,550 Giemsa-stained thick films were examined and 
sample sizes ranged from 91 to 701 people (mean 304). The Javanese transmigrants in 
these villages had been resident for between three weeks to six years. In the newly 
established villages (Arso PIR I, II, Nimborokrang), malaria prevalence rates decreased 
markedly with increasing age beyond 6-10 or 11-15 years in transmigrants resident for 
more than 16-24 months.
In the second study, conducted in PIR I, five parameters o f malaria infection were 
examined: (i) individual slide positivity rate (proportion of blood films positive for that 
individual during surveillance), (ii) median time to first positive slide, (iii) degree of 
parasitaemia, (iv) proportion o f subjects with symptomatic parasitaemia, and (v) antibody 
levels o f ring-infected erythrocyte surface antigen (RESA). The transmigrasi had been
10Rresident for 1-25 months. Compared to transmigrasi children, the adult transmigrants 
had lower malaria prevalence rates, longer median time to first parasitaemia, lower mean 
parasitaemias, fewer reported symptoms, and higher RESA levels. Similar changes were 
also seen in the Irianese. However, compared to the transmigrasi o f all ages, the Irianese 
had significantly lower malaria prevalence rates, longer median times to first 
parasitaemia, and lower rates o f symptomatic parasitaemia. The overall malaria 
prevalence was significantly lower in the Irianese (23%) compared to the transmigrasi 
(31%), as were the rates o f symptomatic parasitaemia: 16% (n=128) vs. 28% (n=233). 
The ’benefit' o f life long exposure was estimating using the Irianese-transmigrasi 
difference in slide positivity rates. An interesting species dependent difference was 
observed. For P. falciparum  the benefit was approximately 20% across all age groups but 
for P. vivax, the benefit was age dependent, ranging from ~ 5% in the under fives to ~ 
80% in adults. Taken together these malariometric data suggest that the transmigrasi had 
acquired protective immunity against P. falciparum but not little or no immunity against 
P. vivax over approximately two years since their arrival in Irian Jaya.
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Supporting antibody data for an age dependent immune response were found in a 
study o f 30 residents o f PIR I (10 adult Irianese, 10 adult transmigrasi, and 10 
transmigrasi children with 45 months o f malaria exposure).372 Essential findings were 
similar patterns o f the disruption o f red cell rosettes and agglutination for all groups. The 
mean MSP2 and RESA antibody titres were similar between both adult groups but 
significantly lower in the transmigrasi children. In another study, antibody titres to two 
antigens R32LR (a peptide containing sequences from the P. falciparum  
circumsporozoite repeat region) and MSP 19 (a proteolytic fragment o f MSP-1) were 
measured in 66 transmigrasi adults and children after 6 and then 14 months o f malaria
' I H ' l
exposure. Antibody titres rose with time but were independent o f age. The short period 
of exposure may account for these contrasting findings to those o f Reeder et al.
2.1.6 Clinical study of newly arrived transmigrasi
This study was conducted in 1992 when Arso PIR IV, population o f 1,059, was 
newly established.374 Within four months o f their arrival, the prevalence o f P. falciparum  
in the transmigrasi was 72%, and the monthly cumulative incidence o f visits to the 
puskesmas for clinical malaria was 81%. Ninety percent o f the malaria was due to P. 
falciparum. The rates for emergency evacuation to hospital because o f clinically severe 
malaria (usually cerebral signs) was highest in young and middle aged adults (range lb- 
40), accounting for half o f the total. By six months, the risk o f hospital referral was 
significantly higher for adults compared to children: 23.2% (148/639) vs. 8.6% (36/420), 
giving a relative risk o f 2.7 (95% Cl 1.9-3.8). Total deaths numbered 8, six adults and two 
children, for an overall risk o f death o f 0.8%. Of those evacuated, the CFR was 4.4% 
(8/184). As a result o f the deteriorating situation in PIR IV, the public health authorities 
treated all cases o f malaria with chloroquine and primaquine and sprayed the houses with 
insecticide with good effect. The difference in susceptibility to severe disease between the 
adults and children represents a difference in the immune response following primary 
exposure to P. falciparum.
2.1.7 Entomology
Entomological studies from Arso PIR I showed that Anopheles koliensis was the 
predominant vector, accounting for 92% o f the anopheline catch; An. punctulatus and An. 
farauti comprised 5.7% and 3.2%, respectively. Entomological inoculation rates for P.
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falciparum  varied between 0.018 and 0.39 infective bites/person/night (= 6.6 and 142/p-y) 
during the low and high transmission seasons, respectively.
2.2 Clinical trials conducted in Jayapura and Arso
2.2.1 Chloroquine for Plasmodium falciparum
Meuwissen documented the early clinical indication o f reduced chloroquine 
sensitivity in the 1960s by recording prolonged parasite clearance times o f 144 hours (6 
days) in 12 (41%) o f 29 local residents following the administration o f standard dose 
chloroquine.57 By the mid 1970s, chloroquine resistant falciparum malaria was confirmed 
in Jayapura. Seven (26%) o f 27 patients had recurrent parasitaemia (RI resistance) on 
Days 11 (n=l) and 21 (n=6).68 By 1982, high grade clinical chloroquine resistance was 
documented in Jayapura using the 7 day in vivo test. Of 16 patients, seven failed to clear 
their parasites by Day 7: RIII (n=2), RII (n=2), RI (n=3).140 All 16 isolates also showed 
evidence o f in vitro resistance using an extended 48 hour WHO micro test (schizont 
development in CQ concentrations > 5 . 7  pmol/L). High grade CQ resistance (7 day in 
vivo test) was also found in Arso PIR I and II in 1987 and 1992.375 Fifty o f 92 patients 
had RIII (n=21) or RII (n=29) resistance. In vitro data o f eleven isolates showed evidence 
o f resistance to chloroquine (n=9), amodiaquine (n=7), and pyrimethamine (n=6). Data 
from 1995 from the village o f PIR V, cumulative failure rates with CQ were high - 55% 
(Day 7), 83% (Day 14), and 94% (Day 28).™
2.2.2 S/P and mefloquine for Plasmodium falciparum
Pyrimethamine resistance was first reported from Arso several months into the 
medicated salt campaign. Pyrimethamine (= 50 mg for adults on days 0, 4, 9) failed to 
clear P. falciparum  in 23/48 (49%) Arso residents; all failures occurred in children < 1 2  
years. At the start o f the campaign, the same regimen cleared parasites in all patients 
(n=96). Proguanil (= 300 mg/d for adults x 8d) resistance was also found; some patients 
with persistent parasitaemia also failed to respond to an increased dose o f 600 mg/d for a 
further 5 days. S/P resistance was first reported in 1979 in Jayapura. At the time when the 
recommended dose o f S/P was 15 mg/kg, the failure rates were in 37 adults were 17% 
(D7), 37% (D15), and 63% (D 21).43
Two studies conducted in Jayapura in the mid 1980s revealed all grades of 
resistance in a small proportion o f patients who received either S/P alone or as Fansimef, 
a fixed combination o f S/P and mefloquine. Four (5.2%; S/P=2, Fansimef=2) o f 77
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patients failed to clear their parasites by Day 7. The two S/P failures were RII and early 
RI (parasites cleared by Day 2 but returned on Day 3); the Fansimef failures were RII and 
RIII. Serum drug concentrations confirmed drug absorption. In vitro cultures (WHO 
microtest) showed evidence o f resistance to MQ in 7 o f 31 isolates.45 In another study o f  
18 S/P treated patients, two had RI resistance on Days 14 and 2 1.377 The mean (range) 
parasite and fever clearance times in hours were 52.2 (24-144) and 13.8 (0-56), 
respectively. In Arso PIR I and II, 16 (27%) of 59 patients failed S/P treatment by Day 7 
with a striking age related difference. Children aged 18 months accounted for 14 o f the 
failures, for a failure rate o f 58% (14/24).375 In Genyem in 2000, S/P had an overall 
clinical failure rate o f 20% in 46 patients o f all ages 46
2.2.3 Chloroquine resistant Plasmodium vivax
In a prospective treatment and prophylactic study, Murphy et al demonstrated
10unequivocal evidence o f chloroquine resistant P. vivax in children and adults. Of 46 
patients o f all ages with P. vivax malaria who were treated with chloroquine, ten (22%) 
developed recurrent vivax parasitaemia by Day 14; all were children younger than 11 
years, 7 o f whom were younger than 4 years. A second course o f chloroquine was given 
to seven o f these failures, resulting in initial parasite clearance but a recurrence in five 
(71%) within 14 days. The 20 patients who were aparasitaemic by Day 14 were given 
weekly chloroquine prophylaxis for eight weeks. Three were excluded from the analysis 
because o f reduced compliance. Nine (53%) developed breakthrough parasitaemia despite 
adequate chloroquine levels. The median time to parasitaemia was 5.3 weeks.
In a comparative clinical trial, standard dose chloroquine had a failure rate o f 44% 
(n=48) at Day 14 and 78% (n=45) by Day 28. Corresponding rates for chloroquine plus 
primaquine (2.5 mg/kg) were 0% (n=21) and 16% (n=19), and 0% (n=19) and 6% (n=17) 
for halofantrine. Four o f the chloroquine recipients failed to clear parasites by Day 7, 
indicating high grade failure.20 An in vivo test in 1995 also documented high, cumulative 
failure rates o f CQ: 38% (D7), 58% (D14), and 83% (D28).376 Indirect evidence o f  
chloroquine resistance was found in Javanese transmigrasi from several villages in Arso 
(PIR I, VIII, X, & XI). When screened most o f those with either clinical vivax disease 
[35/56 (63%)] or asymptomatic vivax parasitaemia [(106/112 (95%)] had total 
chloroquine concentrations > 100 ng/ml; CQ levels ranged from 0 to 8,342 ng/ml.378
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2.2.4 Prophylaxis trials
Three prophylactic studies against vivax and falciparum malaria have been 
conducted in Arso: (i) daily primaquine vs. placebo vs. chloroquine, (ii) alternative day 
primaquine vs. daily CQ, and (iii) mefloquine vs. doxycycline vs. placebo.
Primaquine (30 mg/d, n=44) had a prophylactic efficacy o f 95% (95% Cl 57-99) 
against P. falciparum  and 90% (58-98) against P. vivax.370 Chloroquine and placebo 
failure rates were high over 52 weeks: 29.7% (n=40) and 35.8% (n=42), respectively, for 
P. falciparum , and 39.6 and 47.7%, respectively, for P. vivax. In the open label study, 
primaquine (30 mg thrice weekly) provided 74% (23-91) and 90% (25-99) protection 
against P. falciparum and P. vivax, respectively, compared to weekly CQ. There were 5 
prophylaxis failures (4 Pf, 1 Pv) in the primaquine recipients over 677 person-weeks 
compared to 30 (18 Pf, 12 Pv) in the CQ arm (796 p-w).379 In both studies, primaquine 
was administered with food and was well tolerated. Mean levels of methaemoglobinaemia 
were significantly higher in the primaquine arm [5.8% (1.4-13%)] compared to the 
placebo [0.7% (0-3%)] and CQ [0.7% (0-3%)] arms. These levels were not associated 
with respiratory symptoms or cyanosis. One week after primaquine was stopped, mean 
methaemoglobin levels fell significantly to 2.4% (0-4.5%).370 The findings in Arso were 
similar to another study o f primaquine in Armopa (200 miles west o f Jayapura). 
Primaquine had a prophylactic efficacy over placebo o f 88 (48-97)% for P. falciparum , 
and > 92 (> 37-99)% for P. vivax3*0
Doxycycline and mefloquine were highly effective against both malaria species 
over 13 weeks. Of 67 doxycycline recipients, there was only one case o f falciparum 
breakthrough, and no cases in the 68 mefloquine recipients. The placebo arm (n=69) had 
30 cases o f falciparum and 23 cases o f vivax parasitaemia. The prophylactic efficacy of 
doxycycline was 98% (88-100) against P. falciparum , and 100% (90-100) against P. 
vivax\ the respective figures for mefloquine were 100% (93-100) and 100% (91-100).136
2.3 Azithromycin prophylaxis study
2.3.1 Study design, site, and participants
This was a randomised, double-blind, placebo-controlled study to estimate the 
prophylactic efficacy o f daily azithromycin against P. falciparum  and P. vivax malaria 
and to assess toxicity. Doxycycline served as a positive control because o f its high 
prophylactic efficacy in the same area.136 The study took place in Arso from July 1996 to
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January 1997. Indonesian soldiers and villagers from PIR V took part in the study. The 
decision to use soldiers and civilians was made in order to reach the sample size and to 
include women subjects. Gender mainstreaming was a consideration. Had the study 
started when it should have done, the PIR V civilians would have only had one year of 
malaria exposure. Based on the incidence rate data from Arso, an expected mean o f four 
infections per person would have occurred during this time. This amount o f malaria 
exposure was thought to induce only a small amount o f malaria immunity.
2.3.2 Ethics
Written, informed consent was obtained from all volunteers. The study was 
conducted according to Indonesian Ministry of Health, Indonesian Army, United States 
Navy and Army regulations governing the protection o f human subjects.
2.3.3 Sample size and randomisation
The statistical framework for determining the sample size was based on the 
objective o f estimating the protective efficacy o f azithromycin in order to rule out a level 
< 70%. To reduce the number assigned to placebo and to increase power, a 2:1 allocation 
(A:P) was used. Assuming an attack rate o f 60% over 20 weeks, and an anticipated 85% 
reduction with azithromycin, a total o f 195 subjects (130 azithromycin, 65 placebo) 
would be required to have 80% power to rule out a protective efficacy o f < 70% (5% 
type I error; one-sided). The number to receive doxycycline was the same as placebo. To 
allow for dropouts the final target number o f volunteers to be randomised was 300. The 
trial was also designed to collect detailed information on drug tolerability but was not 
powered to detect differences in side effects o f low frequency events or small differences 
between events. The randomisation list was computer generated and numbered in 
sequence starting with 001. Blocked randomisation with an average block size o f four 
(computer generated with variable block size) was used to assign the three study drugs, 
azithromycin, placebo, doxycycline to achieve an expected 2:1:1 ratio (2A:1P:1D) after 
every four subjects were randomised. Following radical cure, subjects were sequentially 
assigned a study number that started at 001.
2.3.4 Pre-study assessment and radical curative treatment
The screening o f potential subjects consisted of: (i) medical history, (ii) physical 
examination, (iii) malaria smear, (iv) complete blood count (Coulter, Miami, Florida, 
USA), (v) biochemistry: Na+, K+, creatinine, AST, alkaline phosphatase, and total
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bilirubin (Kodak, Rochester, New York, USA), (vi) qualitative glucose-6-phosphate 
dehydrogenase (G6PD) activity (G6PD spot test, Sigma, USA), (vii) urine dipstick 
(Boehringer, Germany), and (viii) urine pregnancy test (pHCG test pack, Abbott, Illinois, 
USA). Eligible subjects were healthy males or non-pregnant females, aged 18 to 55 who 
completed radical cure. Exclusions were: (i) clinically significant disease, (ii) hepatic 
disease, (iii) splenectomy, (iv) hearing impairment (abnormal Rinne or Weber test), (v) 
glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD spot test, Sigma, USA), 
(vi) known study drug hypersensitivity, and (vii) residence for more than 18 months in 
Arso. Enrolled subjects were given radical cure to eliminate blood and liver forms o f  
malaria using a regimen o f concurrent quinine sulphate [10 mg/kg twice daily (thrice 
daily with positive parasitaemia), 4 days], doxycycline (100 mg twice daily, 10 days) and 
primaquine base (30 mg daily, 14 days). In previous studies in Irian Jaya, this regime has 
been used successfully to clear patent parasitaemia and prevent recurrent parasitaemia for 
at least two weeks post treatment (T. Richie, unpublished observations).
2.3.5 Blinding and drug packaging
No field based investigator knew the randomisation code which was securely 
stored in individually sealed envelopes. Study code was broken only if  a subject had a 
serious adverse event necessitating study withdrawal. Study drugs and identical placebo 
(azithromycin/placebo red tablets, white doxycycline/placebo capsules) were supplied in 
blister packs by Pfizer Central Research, Groton CT, USA. Drug packs were produced 
that contained a one week supply o f both azithromycin/placebo and doxycycline/placebo, 
with two extras o f each drug to use in case o f vomiting within one hour o f study drug 
administration.
2.3.6 Conduct of clinical trial
Radical cure was initiated over seven weeks. The administration o f study drugs 
commenced the day after radical cure (Day 0). All doses were given using the double 
dummy method, the simultaneous administration o f active drug/s and placebo/s or double 
placebos. On Day 0, all subjects received one doxycycline (100 mg)/placebo capsule and 
a loading dose (three tablets) o f azithromycin (750 mg)/placebo. Based on a computer 
simulated model, the loading dose o f azithromycin would attain 90% o f steady state 
serum and tissue levels by Day 1 (C. Ohrt, personal communication). Thereafter, one 
azithromycin (250 mg)/placebo and one doxycycline (100 mg)/placebo were given daily
over a follow up period o f 20 weeks. Drinking water and sweet biscuits were provided 
with each dose. Drug administration and consumption were witnessed and signed for by a 
health worker and the subject. If a soldier was absent, his post commander was given 
study drugs, sweet biscuits, and a record book. The post commander was responsible for 
administering and recording drug administration. Soldiers away on patrol were given a 
two weeks supply o f study drugs. Drug forms were inspected daily, supplemented by 
periodic drug counts and supervisory field visits. Thick and thin malaria smears were 
made every week. Additional slides were made if  subjects became ill in between times. 
Giemsa-stained slides were read by microscopists, unaware o f subject symptom status. 
Two or more asexual malaria parasites defined a positive slide, after reading 200 thick 
smear fields at x 1000 magnification. All positive slides and 10% o f all negative slides 
were confirmed by a second microscopist in a blinded fashion. Discrepant slide results 
were subject to a third blind read. Parasitaemia (number/pL) was quantified using a 
standard approximation method; namely, the number o f asexual forms per 200 wbc x 40. 
All subjects with parasitaemia were interviewed by a study doctor. One or more o f the 
following defined symptomatic parasitaemia: fever, chills, sweating, myalgia, headache, 
anorexia, nausea, vomiting, abdominal pain, and diarrhoea.
2.3.6.1 Health care during the trial & rescue treatment
The Indonesian soldiers were posted in a number o f small encampments and were 
visited daily by team members for drug administration and the collection o f safety data. 
In addition, there was a mobile medical service comprising Indonesian Army and civilian 
doctors who made daily rounds in two vehicles. Not all posts could be visited every day 
but it is a fair assumption that all camps would have been visited two to three times per 
week by the mobile medical teams. These teams were able to issue a limited supplies of 
medicines to treat common illnesses. All soldiers, irrespective o f whether they were in the 
study, were seen and treated. The puskesmas in PIR V was provided with a full time team 
doctor, a microscope and all necessary accessories, and a limited supply o f medicines (as 
above). All medical care was freely provided for all the villagers and not just those in the 
study. Any subject who was found to have malaria was treated with quinine and 
doxycycline.
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2.3.7 End points
The primary efficacy endpoint was the first occurrence o f slide proven 
parasitaemia (prophylaxis failure). Follow-up time for efficacy analysis was defined as 
the time from Day 0 to the date o f prophylaxis failure or the date o f study completion. For 
those not completing scheduled follow-up i.e. withdrawal or protocol violations, follow- 
up time was measured to the date o f the last negative slide. Reasons for non-malaria 
withdrawals were: (i) serious adverse event, (ii) unsupervised drug administration >14 
days, (iii) consumption o f non-study anti-malarial drug, (iv) two doses o f study 
drug/placebo missed within 7 days, and (v) voluntary drop-out.
2.3.8 Assessment of safety and tolerability
Tolerability was assessed by recording symptoms and performing clinical and 
laboratory tests. Symptoms were recorded by questionnaire and in response to the 
question 'Any symptoms ?' The questionnaire consisted o f 26 symptoms: twenty five 
specific symptoms: anorexia, nausea, vomiting, heartburn, mild abdominal pain, severe 
abdominal pain, diarrhoea, severe diarrhoea (> 5 motions/day), mild headache, severe 
headache, 'pusing' (translated as dizziness/muzzy head), hearing loss, tinnitus, 
paraesthesiae, blurred vision, hallucinations, difficulty sleeping, mild itching, severe 
itching, rash, cough, fever, chills, sweats, myalgia, and 'Others.' The questionnaire was 
administered on Days 0 and 1 for loading dose tolerability, and monthly thereafter for 
symptom trends. Symptoms in response to the open question were recorded daily by the 
health workers. At study end, a health questionnaire (general health, certain GI 
symptoms, and hearing) was completed. Hearing was assessed clinically using the Rinne 
and Weber tuning fork tests at enrolment and study end. Other clinical examinations were 
performed as required e.g. to assess an intercurrent illness. A complete blood count and 
routine biochemistry were done at enrolment, one month later, and at study end.
2.3.9 Adverse event classification
An adverse event (AE) was defined as a new symptom, physical sign or illness 
that developed during the study. AE severity was classified as (i) mild: able to conduct 
activities o f daily living, no/little treatment required, (ii) moderate: affecting activities of 
daily living, treatment required, or (iii) severe: affecting activities o f daily living, 
treatment and bed rest or hospital admission required. A serious adverse event was 
defined as lethal, life threatening, and/or requiring hospital admission.381
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2.3.10 Statistical analysis
All randomised volunteers (n=300) were included for analysis o f efficacy and 
drug safety/tolerability. Data were double entered, discrepancies resolved, and end points 
finalised before the data bases were locked and the randomisation code broken. Epi Info 
6.02 (Centers for Disease Control and Prevention, Atlanta, Georgia), Minitab 11 for 
Windows (Minitab Inc., State College, PA), and Statxact 3 for Windows (CYTEL 
Software Corp., Cambridge, MA) were used for data management and analysis.
2.3.10.1 Efficacy
Incidence (density) rates ( I R )  were calculated as the number o f malaria cases 
divided by the total person-years o f follow-up. The protective efficacy (PEf) was defined 
as the percent reduction in the incidence rates o f malaria: 1 - ( I R d r u g / I R p i a c e b o )  • Confidence 
intervals (CIs) for PEf (1-ratio o f two Poisson variables) were calculated using the exact 
conditional distribution. The Kaplan-Meier method was used to estimate the cumulative 
risk and standard error o f developing either falciparum or vivax malaria during follow-up; 
the follow-up time was considered censored if  one malaria species occurred before the 
other. Cumulative risk curves were compared by the log rank test.
2.3.10.2 Tolerability
Reported symptoms in the drug/placebo groups were compared in terms of: (i) the 
proportion of subjects with a new symptom one day after the loading dose, and (ii) the 
proportion o f subjects who reported at least once any symptom at the daily checks, (iii) 
the incidence rate o f daily symptoms reported (total number o f symptoms/total person­
time for safety/tolerance follow-up). Fisher's exact or chi-squared tests were used to 
assess differences (2 arms or 3 arms) o f independent proportions. Koopman’s method was 
used to compute 95% Cl for relative risk measures. Because o f the disproportionately 
high loss to follow-up o f the placebo arm because o f malaria, comparison o f proportions 
(active drug vs placebo) o f subjects reporting daily symptoms was performed only for the 
first four weeks o f follow-up. To account for differences in follow-up, incidence (density) 
rates (IR) o f reported symptoms were computed and compared (as above). Follow-up 
time for assessing daily reported symptoms was calculated taking into account (i) the 
days subjects were absent for questioning (e.g. soldiers on patrol), and (ii) symptoms due 
to malaria (symptoms reported within 7 days o f a positive slide). Where no symptoms 
were reported (daily reported symptoms), an adjustment was made to estimate the rate
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ratios and relative risks. For the rate ratios, this was done by adding a Vi only to the 
numerator counts but and not to the person time data i.e. O+V2, and N+!/2. For the relative 
risks, a V2 was added to both numerator counts and denominator samples sizes i.e. O+V2 / 
sample size A+V2 divided by N+!/2 / sample size B+H.
Analysis o f variance (ANOVA) was used to assess overall differences between 
arms for laboratory data. Student’s t-test (unpaired or paired) was used to assess 
differences between two means (between or within arms). The Mann-Whitney test was 
used to compare median parasite counts or other highly skewed data. Because many 
comparisons were performed, it was decided to flag all comparisons that achieved a 
nominal P  value o f 0.05 (95% Cl for relative risk or rate ratio measures that excluded 1) 
and to report much o f the basic data.
2.4 Chloroquine-doxycycline combination study
2.4.1 Study design, site, and participants
This open clinical trial compared chloroquine combined with doxycycline, to 
chloroquine or doxycycline alone for the treatment of uncomplicated falciparum malaria 
and vivax malaria. The study took place from October 1995 to January 1998 in the 
Rumah Sakit Umum and Indonesian Navy hospitals in Jayapura. Participants were 
civilians and Indonesian Navy personnel who lived in Jayapura or in the surrounding area 
o f Arso.
2.4.2 Ethics
Written, informed consent was obtained from all volunteers. The study was 
conducted according to Indonesian Ministry of Health, Indonesian Army, United States 
Navy and Army regulations governing the protection o f human subjects.
2.4.3 Sample size
The sample size calculations were based on the assumptions that the frequencies 
o f resistance (RI/RII/RIII) were 0.5 for chloroquine alone (CQ) and 0.05 for the 
combination arm (CQD), and 0.4 for doxycycline (D). Using a two-sided alpha o f 0.05, 
sample sizes o f 18 per arm (CQ vs. CQD) would detect these resistance frequencies with 
a probability o f 0.89. Although not the primary aim o f the study, a comparison o f D vs. 
CQD, with the same sample size o f 18 per arm would detect the resistance frequencies 
with a power o f  0.73.
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2.4.4 Patient assessment and selection
Potential subjects were referred to the research team by local physicians and 
medically screened: (i) medical history, (ii) physical examination, (iii) malaria smear, (iv) 
urine pregnancy test (p HCG test pack, Abbott, Illinois, USA), and (v) qualitative 
glucose-6-phosphate dehydrogenase (G6PD) activity (G6PD spot test, Sigma, USA). 
Eligible subjects were healthy males or non-pregnant females aged 15 to 50 years with 
either uncomplicated falciparum malaria or vivax malaria. Specific exclusions included 
mixed infections, symptoms or signs of severe and complicated malaria, malaria 
treatment within 7 days o f presentation, and known study drug hypersensitivity.
2.4.5 Conduct of clinical trial
Enrolled patients were admitted to the hospital and sequentially randomised to 
treatment (CQ, CQD, D, CQ, etc). This was later changed to a system of using labelled 
tickets that were selected randomly by the team physician. Patients with falciparum 
malaria were arbitrarily classified as ’mild': parasitaemia 0.25% (= parasite density 
12,500/pL), or 'moderate': parasitaemia > 0.25-< 3% (= parasite density > 12,500-< 
150,000/pL). This artificial division was designed so that no randomised 'moderate' 
patients would receive doxycycline alone, due to concern over its slow onset o f action.
Patients randomised to chloroquine (Malarex®, Dumex, Indonesia) were treated 
with chloroquine base: 10 mg/kg once on Days 0 and 1, and 5 mg/kg once on Day 2 (CQ 
and CQD arms). The dose o f doxycycline (Pfizer, USA) was 100 mg every 12 hours for 7 
days (D and CQD arms). All drugs doses were administered and documented by ward 
nurses. Patients were hospitalised for 28 days. The wards were screened with mosquito 
mesh on the windows and subjects slept under mosquito nets. Symptoms were recorded 
daily. Oral temperatures were taken every 8 hours during the first week, and daily 
thereafter. Treatment failures were treated with quinine (10 mg/kg thrice daily for 4 days) 
and doxycycline (100 mg twice daily for 10 days). Patients with vivax malaria were given 
primaquine base (30 mg/day for 14 days) at the time o f hospital discharge.
Giemsa-stained malaria smears were read daily until negative; thereafter, three 
times per week until Day 28. A positive smear was defined as one or more asexual form/s 
seen after examining 200 thick smear fields under x 1,000 magnification. The parasite 
count (number/pL) was quantified using the measured total white cell count (WCC). 
Where this was missing, the total WCC was assumed to be 8,000/pL. Filter paper (No. 1
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Whatman, Fairfield, NJ) blots for chloroquine drug levels were made on Days 0, 3, and 
28. One hundred piL o f  whole blood were drawn from a finger stick into a capillary tube 
and spread evenly onto the filter paper. Blots were air dried, stored in individual plastic 
bags at ambient temperatures until analysed. Chloroquine and desethylchloroquine were 
measured in whole blood by HPLC, using a published method.384 The sum of chloroquine 
and desethylchloroquine is reported as the total whole blood chloroquine (TCQ) 
concentration (ng/ml).
2.4.6 End points
The parasitological end points were classified as sensitive (S) or resistant, graded 
as RI, RII, or RIII. For vivax malaria, RI cases were classified as Rl/relapse because both 
are clinically indistinguishable. Genotyping by the polymerase chain reaction (PCR) was 
performed on the recurrent and original (Day 0) parasitaemias for both species by a 
examining MSP1 and MSP2 (falciparum) and MSP1 and circumsporozoite (CS) genes for 
P. vivax.121 385 The secondary clinical end points were: (i) the fever clearance time 
(FCT/hours): the time taken for the patient to become and remain afebrile (oral 
temperature 37°C recorded at least four consecutive times), (ii) the parasite clearance 
time (PCT/days): the number o f days taken for a malaria smear to become negative for at 
least two consecutive days, and (iii) the proportion o f patents remaining symptomatic 
(reporting either fever, chills, headache, myalgia, weakness, anorexia, or nausea) on Days 
3 and 7.
2.4.7 Statistical analysis
Data were double-entered, validated and analysed using Epi Info 6.04b (Centers 
for Disease Control and Prevention, Atlanta, GA, USA) and SPSS for Windows 8.0 
(SPSS, Chicago, IL, USA). Proportional data were analysed using chi squared. 
Laboratory data were analysed using the student's paired/unpaired't' test or ANOVA or 
the corresponding non-parametric tests, as appropriate. All statistical tests were two sided 
and a P  value o f 0.05 was considered statistically significant. The efficacy analysis 
efficacy excluded patients who were lost to follow up or withdrew from the study before 
Day 28.
2.5 Safety monitoring for both clinical trials
At the time when both studies were conducted, there was no ethical requirement to 
establish a Drug Safety and Monitoring Board. Never the less, both studies were
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monitored closely. There were medical monitors assigned to both studies. There was a 
strict reporting system for serious adverse events. These were reported to colleagues and 
collaborators from the US Navy, the US Army, and the Indonesian Ministry o f Health. 
Regular updates and a final report o f all serious AEs were provided. In the azithromycin 
trial, the breaking o f study code was done only after consultation with the above 
mentioned colleagues.
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Chapter 3 - Results
3.1 Azithromycin prophylaxis study
3.1.1 Enrolment and withdrawals
Of the 364 registered volunteers, 48 did not meet entry criteria and 16 failed to 
complete radical cure (Figure 3.1). Three hundred volunteers were randomised to the 
three drug/placebo arms: azithromycin (n=148), doxycycline (n=75), and placebo (n=77). 
Subjects’ enrolment characteristics and baseline laboratory values were similar between 
the three study arms (Table 3.1). All subjects had normal Rinne tests but one (A arm) had 
Weber lateralisation, consistent with a sensineural hearing impairment (a protocol 
violation). The majority o f subjects were male, 286/300 (95.3%), o f mean age 27. Young 
soldiers accounted for 225 o f the 286 (78.7%) male subjects. Many participants [144/300 
(48%)] reported at least one attack o f  malaria since arriving in Irian Jaya. Certain markers 
of recent malaria exposure were significantly higher in the civilians compared to the 
soldiers (see Sub-group analysis).
One hundred and fifty four subjects (51.3%) completed the study as per protocol 
without acquiring parasitaemia. Eighty seven (29%) developed parasitaemia and 59 
(19.6%) withdrew from the study for other reasons (Figure 3.1). The median follow up 
time, in weeks (range), for all subjects in each arm was: doxycycline 16.1 (2.4-20.1), 
azithromycin 15.8 (1.1-20.1) and placebo 7.6 (0-18.6) weeks (P < 0.00001).
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Registered volunteers
n = 364 I ______________
* Excluded n = 48
Weber lateralization = 14 
G6PD deficiency = 9 
Declined venipuncture = 9 
Doxycycline allergy = 4 
Abnormal biochemistry = 4 
Voluntary withdrawal = 4 
Left area = 3 
Cardiac disease = 1
Placebo 
n = 77
Doxycycline 
n = 75
3 Malaria end point 
57 Completed trial
28  Malaria end point 
89 Completed trial
Azithromycin 
n = 148
56 Malaria end point 
8 Completed trial
Randomized 
n = 300
5 withdrawals
adverse events = 1 
moved away = 3 
quit = 1
8 protocol violations 
missed doses = 3 
non-study drug = 2 
unsupervised >14d = 2
10 withdrawals 
adverse events = 1 
moved away = 8 
quit = 1
5 protocol violations
missed doses = 3 
non-study drug = 1 
unsupervised >14d = 1
16 protocol violations 
missed doses = 5 
nonstudy drug = 5 
unsupervised >14d = 6
15 withdrawals 
adverse events = 2 
moved away = 11 
quit = 2
Began radical cure 
n = 316
Failed to complete **-------------
_____
Figure 3.1 Trial profile o f the azithromycin prophylaxis study.
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Table 3.1 Baseline characteristics o f subjects enrolled in the malaria prophylactic study of 
azithromycin, doxycycline, and placebo.
Azithromycin Doxycycline Placebo
Number 148 75 77
Male 142 72 72
Female 6 3 5
Age, median (range) 27(18-52) 27 (21-54) 26 (20-50)
Weight, kg, median (range) 60 (43-75) 58 (39-83) 59 (42-75)
Reported malaria, mean (SD)* 3.8 (3.7) 3.8 (4.4) 3.2 (3.2)
Splenomegaly, % (n) 12.8(19) 8(6) 10.4 (8)
Positive malaria slides, % (n) 25.7 (38) 28 (21) 29.9 (23)
Hb, g/dlt 14.3(1.5) 14.2(1.2) 14.1 (1.7)
Platelet countf 195 (54) 195 (55) 190 (52)
Creatinine, mg/dlf 1.1 (0.2) 1.1 (0.1) 1.1 (0.1)
AST, IU/Lf 29(10) 28 (10) 28 (10)
Total bilirubin, mg/dlf 0.6 (0.2) 0.6 (0.1) 0.7 (0.2)
* Reported malaria illnesses within one year of enrolment, not microscopically 
confirmed.
t  Laboratory values are mean (standard deviation).
3.1.2 Parasitaemia end points
By study end, there were 87 cases o f parasitaemia: 55 P. falciparum, 29 P. vivax, 
and 3 cases o f mixed infection; the latter were counted as P. falciparum, the dominant 
species in each case. The number o f cases o f parasitaemia (% o f randomised) in each arm 
was: placebo 56/77 (72.7%), azithromycin 28/148 (18.9%), and doxycycline 3/75 (4%). 
The cumulative incidence o f parasitaemia as a function o f time is shown in Figure 3.2. 
The curves are significantly different comparing either drug arm with placebo.
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Figure 3.2 Cumulative risks o f malaria acquisition for azithromycin, placebo and 
doxycycline recipients.
The majority o f prophylaxis failures, 75.8% (66/87), had symptomatic 
parasitaemia. By species, these symptomatic infections were 47/58 (81%) for P. 
falciparum , and 19/29 (65.5%) for P. vivax. The distribution by drug arms was not 
significantly different (P=0.14): (i) placebo, 45/56 (80.3%: 27 Pf, 18 Pv), (ii) 
azithromycin, 20/28 (71.4%: 19 Pf, 1 Pv), and (iii) doxycycline, 1/3 (33.3%: 1 Pf). The 
mean number o f symptoms reported by the 66 symptomatic prophylaxis failures was 3.8; 
of whom 55 (83.3%) reported >1 symptom. The three most common symptoms were 
headache 51/66 (77.2%), myalgia 41/66 (62.1%), and fever 33/66 (50%). The median 
falciparum parasitaemia was significantly higher in the placebo arm compared to the 
azithromycin arm: 1,480 (60-32,920) vs. 240 (80-700)/pL (P=0.023).
3.1.3 Prophylactic efficacy
Compared to placebo, the prophylactic efficacy of azithromycin against P. 
falciparum  was 71.6% (50.3-83.8) and 98.8% (93.1-99.9) against P. vivax (Table 3.2). 
Corresponding figures for doxycycline were 96.3% (85.4-99.6) and 98% (88.0-99.9).
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Table 3.2 Incidence rates o f malaria and the prophylactic efficacies o f azithromycin and 
doxycycline relative to placebo against both malaria species.
Azithromycin
(148, 38.88)*
Doxycycline
(75, 22.15)
Placebo
(77, 11.83)
Species Cases IRt PEff Cases IR PEf Cases IR
Both 28 0.72 84.7 (75.6-90.7) 3 0.13 97.1 (91.2-99.4) 56 4.73
Pf 27 0.69 71.6 (50.3-83.8) 2 0.09 96.3 (85.4-99.6) 29 2.45
Pv 1 0.03 98.9 (93.1-99.9) 1 0.05 98.0 (88.0-99.9) 27 2.28
* (number randomised, total follow-up time in person-years), 
t  IR=incidence rate: cases / person year.
X PEf=prophylactic efficacy (95% CIs).
3.1.4 Sub-group analysis of civilians and soldiers
At enrolment, four malariometric indices (reported malaria, splenomegaly, 
prestudy slide positivity, and Hb) showed that prestudy malaria exposure was 
significantly higher in the civilians compared to the soldiers (Table 3.3). However, 
civilians and soldiers who received placebo did not have significantly different outcomes 
with respect to: (i) overall attack rate, (ii) occurrence o f symptomatic parasitaemia, and 
(iii) levels o f parasitaemia (Pf or Pv). The estimated protective efficacies o f azithromycin 
against P. falciparum and P. vivax were higher in the civilians compared to the soldiers 
but neither o f the differences (P=0.08 and 0.68, respectively) were statistically 
significant.
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Table 3.3 Civilian/soldier subgroup analysis: (1) enrolment markers o f prior malaria 
exposure, (2) placebo group outcomes, (3) azithromycin prophylactic efficacy.
Civilians Soldiers P  value
(1) Enrolment characteristics n=75 n=225
Reported malaria*
At least one, % 
Median (range) 
Splenomegaly, % (n)
98.7 (74/75) 
10 (0-20) 
32 (24)
75.5 (170/225) 
2 (0-16) 
4(9 )
<0.001t
<0.001t
Positive malaria slides, % (n) 38.6 (29) 23.5 (53) 0.02f
Hb, g/dl, mean (SD) 13.5(1.7) 14.5(1.3) o . o o i t
(2) Placebo group outcomes n=18 n=59
Attack rate, %§ 83.3 (15/18) 69.5 (41/59) 0.36t
Symptomatic cases, % 86.6(13/15) 78 (32/41) 0.70f
Parasite count/pL || 
Pf 
Pv
940 (80-20,640) 
200 (80-500)
1,600 (60-32,920) 
400(100-1,880)
0.53 H 
0.1011
(3) Prophylactic Efficacy** 
Pf 
Pv
88.4 (56.6-97.4) 
100 (83.9-100)
62.9 (29.5-80.4) 
98.3 (89.4-99.9)
0 .08ft
0 .68tt
* Reported malaria illness, not microscopically confirmed, within one year o f enrolment, 
t  Fisher’s exact test.
I  Unpaired t-test.
§ Crude attack rate: % (number o f cases/number randomised).
Median (range).
1 Mann-Whitney test.
** Prophylactic efficacy (95% CIs), based on incidence rates relative to placebo, 
f t  Exact (conditional) test.
3.1.5 Drug compliance
Of the 26,822 intended doses, 25,181 (93.8%) were administered under direct 
observation by the research team, 860 (3.2%) were witnessed by a post commander, 781 
(2.9%) were taken unwitnessed, and 35 (0.13%) doses were not taken.
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3.1.6 Adverse events, study withdrawal and code breaking
There were eight adverse events (AEs) necessitating study withdrawal. Study code 
was broken in three of these subjects. One azithromycin recipient, a 26 years old soldier, 
developed a widespread, pruritic, erythematous, maculopapular rash with areas of 
crusting after four doses; giving a risk of 0.67% (95% Cl 0.034 -  3.29). This moderately 
severe adverse event was considered azithromycin induced. The seven other AEs were all 
considered unrelated to study drugs: ureteric colic, dengue fever, motor cycle accident 
(azithromycin), acute bronchitis with hyperventilation, sub-arachnoid haemorrhage 
(doxycycline), headache with photophobia, and severe malaria (placebo).
3.1.7 Loading dose tolerance and monthly reported symptoms
Responding to the symptom questionnaire, the proportions o f subjects reporting 
either a new symptom (not present on Day 0) or any symptom on Day 1 were similar 
between all three arms (Figure 3.3). After Day 1, several questionnaire-elicited symptoms 
appear to show a downward trend in the azithromycin and doxycycline arms. Itching 
appears to show an inconsistent trend in all three arms (Figure 3.3). Discerning trends for 
a number o f symptoms in the placebo arm is problematic because o f loss to follow up.
3.1.8 Self reported daily symptoms over 20 weeks
3.1.8.1 Proportional comparisons
By study end, the majority o f all subjects had reported at least one symptom: 
A=96.6% (143/148), D=93.3% (70/75), P=96.1% (74/77). Subjective hearing loss was 
reported by small, roughly equal proportions o f patients from all three arms [5.7% 
(17/300)], %2 (df=2)=2.17; P=0.34]. Of the azithromycin-doxycycline comparisons, more 
doxycycline subjects reported subjectively severe abdominal pain [6.7% (5/75) vs. 1.3% 
(2/148), P=0.031], and more azithromycin subjects reported paraesthesiae [12.2% 
(18/148) vs. 4% (3/75), P=0.048].
3.1.8.2 Rate comparisons
The incidence rates o f any self reported symptom ranged from 0-9.05/p-y, a 
maximum of nine days over one year (Table 3.4). Compared to placebo, azithromycin 
recipients reported more heartburn, mild and severe itching, paraesthesiae, and 'Others'. 
Doxycycline recipients reported more heartburn, severe abdominal pain, 'pusing', 
difficulty sleeping, and 'Others'. Of the azithromycin-doxycycline comparisons, heartburn
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[rate ratio=1.6 (95% Cl 1.04-2.7)], paraesthesiae [8.8 (95% Cl 3.6-27.9)], and severe 
itching [5.3 (95% Cl 1.3-47.5)] were reported more often by the azithromycin recipients, 
and the doxycycline recipients reported severe abdominal pain [8.85 (1.89-83.03)], and 
difficulty sleeping [1.77 (1.17-2.68)] more frequently. Subjective hearing loss in any arm 
was reported with a frequency o f < 0.5/p-yr.
3.1.9 Self reported daily symptoms within the first four weeks
3.1.9.1 Proportional comparisons
The proportions o f subjects reporting any symptom at least once during the first 
four weeks were broadly similar in the three arms (Table 3.5): A=58.8% (87/148), 
P=66.2% (51/77), D=61.3% (46/77), [*2 (df=2) =1.19, P=0.55], Heartburn was the only 
symptom occurring in excess compared to placebo, true for both drug arms. Subjective 
hearing loss was reported by nine (3%) participants distributed equally across the three 
arms [x2(df=2)=l.l;P=0.57],
3.1.9.2 Rate comparisons
The incidence rates o f any self reported symptoms from the three arms during the 
first four weeks ranged from 0-7.8/p-y (Table 3.6). Compared to placebo, heartburn and 
myalgia were reported more frequently by both drug arms, and difficulty sleeping only by 
the doxycycline arm. Of the azithromycin-doxycycline comparisons, difficulty sleeping 
[2.8 (1.64-4.87)] and sweats [3.34 (1.22-10.0)] were reported more frequently in the 
doxycycline arm. Subjective hearing loss in any arm was reported with a frequency o f < 
0.53/p-y.
3.1.10 Health questionnaire and hearing at study end
The health questionnaire was answered by 257/300 (85.6%) subjects. End points 
in these subjects were: (i) study completion [n= 151 (58.7%)], (ii) prophylaxis failure 
[n=76 (29.6%)], (iii) serious AE [n=4 (1.5%)], and (iv) study withdrawal for other 
reasons [n=26 (10.1%)]. The majority o f subjects [94.9% (244/257)] reported feeling 
healthier compared to study start. The proportions of subjects who recollected 
experiencing nausea and/or vomiting, diarrhoea, or hearing impairment at any time during 
the study were 25.3% (65/257), 23.3% (60/257), and 5.1% (13/257), respectively. None 
o f these proportions were significantly different between the three arms (details not 
shown). Weber lateralisation was detected in 7 (2.7%) o f 262 subjects, similarly
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distributed between the three arms: A =8/132 (2.3%), D=2/64 (3.1 %), and P=2/70 (2.8%), 
[%2 (df=2)=0.14; P=0.57]. All had normal Weber tests at enrolment.
3.1.11 Laboratory evaluations
Mean biochemical and haematological values at Day 0, Week 4, and study end 
were not significantly different both between and within each arm (details not shown). 
Mean changes in these laboratory values (study end -  Day 0) were also not significantly 
different between each drug arm and placebo (A vs. D vs. P): (i) Creatinine (mg/dL): - 
0.02 vs. - 0.03 vs. 0, P=0.86, (ii) AST: 3.4 vs. 6.86 vs. 10.8, P=0.15, (iii) total bilirubin 
(mg/dL): 0.079 vs. 0.17 vs. 0.11, P=€.54, (iv) Hb (g/dL): 1.2 vs. 0.76 vs. 1.08, P=0.14, (v) 
total white cell count (/pL): - 0.520 vs. - 0.240 vs. 0.530, P=0.23, and (vi) platelet count 
(x103/uL): 7.3 vs. 7.7 vs. 28.4, P=0.53.
At enrolment, the proportions of anaemic women (Hb <12 g/dL) and men (Hb <
13.5 g/dL) were 5/14 (35.7%), and 64/286 (22.3%), respectively. At Week 4, 4/5 women 
were not anaemic (D=2, P=2). At Week 4 and study end, the proportions of anaemic 
males had declined in all three arms but these were not significantly different comparing 
either active drug with placebo (details not shown). During follow up, the total white 
blood cell count (WBC) of all azithromycin recipients did not fall below 4,500/pL, the 
lower limit of the normal range. Three doxycycline recipients with normal Day 0 WBCs 
[4,600/pL (n=4), 6,400/pL (n=2)] developed WBCs of 4,400/pL at study end.
Subjects from all arms with an elevated AST (> 4 0 IU/L) at enrolment, one month 
later, and study end were 17/300 (5.6%), 23/265 (8.6%) and 14/154 (9.1 %), respectively 
CP =0.28). These proportions were distributed similarly between each arm at each time 
interval (details not shown). Of the 283 subjects with a normal AST (< 40) at enrolment, 
145 (51.2%) had AST levels done at study end. Nine of these 145 subjects (6.2%) had an 
elevated AST; 6 were azithromycin subjects (AST =41-50 IU/L), and three were 
doxycycline recipients (AST =41-63 IU/L).
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3.3 Trends in selected symptoms reported by questionnaire on Days 0 and 1, and at monthly intervals during the study, 
symptom data are different to those presented in Tables 3.4 and 3.6. Note: m=mild, s=severe.
Table 3.4 Incidence rates per person-year by drug arm (azithromycin, doxycycline,
placebo) for all symptoms volunteered daily over 20 weeks of trial. Significant rate ratio
comparisons only are shown.
Symptom Azithromycin 
37.91 p-yr *
RR (95% C l) f  
A vs P
Placebo 
10.88 p-yr
RR (95% C l) 
D vs P
Doxycycline 
21.43 p-yr
A ll svmDtoms 1,525 (40.22) * 416(38.22) 852 (39.75)
GI svrnotoms 323 (8.51) 104 (9.55) 161 (7.51)
Anorexia 104 (2.74) 39 (3.58) 0.56 (0.35-0.89) 43 (2.0)
Nausea 53 (1.39) 19(1.74) 35 (1.63)
Vomiting 11 (0.29) 6 (0.55) 5 (0.23)
Heartbum§ 73(1.92) 10.48 (2.79-8.14) 2(0.18) 6.35(1.58-55.3) 25(1.17)
M ild abdominal pain 43(1.13) 18(1.65) 25(1.17)
Severe abdominal pain 2 (0.05) 0(0) 10.7(1.14-oo)|| 10(0.47)1
Diarrhoea 34 (0.89) 18(1.65) 18(0.84)
Diarrhoea >5/day 3 (0.08) 2(0.18) 0(0)
CNS svmDtoms 492 (12.98) 151 (13.88) 278 (12.97)
Mild headache 227 (5.98) 64 (5.88) 119(5.55)
Severe headache 14 (0.37) 8 (0.73) 7 (0.33)
Tusing'# 100 (2.63) 19(1.75) 2.06(1.23-3.6) 77 (3.59)
Tinnitus 9 (0.24) 0.10(0.04-0.21) 27 (2.48) 0.13(0.05-0.31) 7 (0.33)
Hearing loss 9 (0.24) 5 (0.46) 6 (0.28)
Blurred vision 6(0.16) 4 (0.37) 7 (0.33)
Paraesthesiae§ 78 (2.06) 2.04(1.08-4.24) 11 (1.01) 0.23 (0.06-0.72) 5 (0.23)
Difficulty sleeping 49(1.3) 13 (1.2) 1.91 (1.02-3.84) 49 (2.29)1
Hallucinations 0(0) 0(0) 1 (0.05)
Dermatolosical 160(4.22) 1.84(1.20-2.92) 25 (2.3) 1.65(1.04-2.69) 81(3.78)
M ild itching 135 (3.56) 1.55(1.01-2.48) 25 (2.3) 75 (3.49)
Severe itching§ 19 (0.5) 11.2(1.34-oo)|| 0(0) 2 (0.09)
Rash 6(0.16) 0(0) 4(0.19)
Miscellaneous 207 (5.46) 71 (6.52) 144 (6.72)
Cough 143 (3.77) 43 (3.95) 94 (4.39)
Fever 11 (0.29) 0.21 (0.09-0.49) 15(1.38) 0.37(0.15-0.87) 11 (0.51)
Chills 10 (0.26) 2(0.18) 5 (0.23)
Sweats 10 (0.26) 4 (0.37) 13 (0.60)
Myalgia 33 (0.87) 7 (0.64) 21 (0.98)
’Others’ 343 (9.05) 1.51 (1.16-2.01) 65 (5.97) 1.47(1.1-1.98) 188 (8.77)
* Person-years of follow-up
t  Rate ratio (95% confidence interval)
% Total number of times symptom reported (incidence rate/p-yr)
§ A  vs D: heartburn RR=1.6 (1.04-2.7), paraesthesiae RR=8.8 (3.6-27.9), itching (s) RR=5.3 (1.3-47.5).
|| XA  added to the numerator counts only to estimate the rate ratio. 95% CIs calculated using the observed 
data.
1 D vs A: severe abdominal pain RR=8.85 (1.89 -  83.03), difficulty sleeping RR=1.77 (1.17 -  2.68).
# 'Pusing' - dizziness/muzzy head
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Table 3.5 Number (percent) of persons reporting symptoms at least once (daily reporting) 
within the first four weeks o f trial.*
Azithromycin
n=148
Placebo
n=77
Doxycycline
n=75
All svmDtoms 87 (58.8) t 51 (66.2) 46 (61.3)
GI svmDtoms 49 (33.1) 32 (41.6) 27 (36.0)
Anorexia 23 (15.5) 13 (16.9) 13(17.3)
Nausea 15(10.1) 10(13.0) 11 (14.7)
Vomiting 3 (2.0) 2 (2.6) 2 (2.7)
Heartburn* 14 (9.5)§ 0(0) 7(9.3)||
Mild abdominal pain 14 (9.5) 6(7.8) 5 (6.7)
Severe abdominal pain 1 (0.7) 0(0) 2 (2.7)
Diarrhoea 12(8.1) 8 (10.4) 9 (12.0)
Diarrhoea >5/day 1 (0.7) 1(1.3) 0(0)
CNS svmDtoms 62 (41.9) 29 (37.7) 31 (41.3)
Mild headache 28(18.9) 19 (24.7) 15 (20.0)
Severe headache 3 (2.0) 3 (3.9) 0 (0 )
'Pusing't 29 (19.6) 10(12.9) 14(18.7)
Hearing loss 5 (3.4) 1(1.3) 3 (4.0)
Tinnitus 6(4.1) 4(5.2) 3 (4.0)
Paraesthesiae 13 (8.8) 7(9.1) 3(4)
Blurred vision 5 (3.4) 2 (2.6) 6 (8.0)
Hallucinations 0(0 ) 0(0) 1(1.3)
Difficulty sleeping 15(10.1) 7(9.1) 10(13.3)
Dermatolosical 22(14.9) 6(7.8) 6 (8.0)
Mild itching 19(12.8) 6(7.8) 5 (6.7)
Severe itching 3 (2.0) 0(0) 1 (1.3)
Rash 2(1.4) 0(0) 1 (1.3)
Miscellaneous 51 (34.5) 26 (33.8) 29 (38.7)
Cough 26 (17.6) 11 (14.3) 11 (14.7)
Fever 3 (2.0) 4(5.2) 5 (6.7)
Chills 2(1.4) 1 (1.3) 1(1.3)
Sweats 6(4.1) 3 (3.9) 2 (2.7)
Myalgia 6(4.1) 1 (1.3) 5 (6.7)
’Others’ 28(18.9) 14(18.2) 18(24)
* all A vs P, and D vs P) comparisons (except heartburn) were not significant (P<0.05)
t n  (%)
X V2 added to both numerators and sample sizes to estimate the relative risks. 
§ A vs P RR=15.13 (1.97 -  4), iM ).005 
D vs P RR=15.4 (1.93 -  4), P=0.006.
H 'Pusing' - dizziness/muzzy head.
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Table 3.6 Incidence rates per person-year by drug arm (azithromycin, doxycycline,
placebo) for all symptom categories and selected symptoms volunteered daily within first
four weeks o f trial.
Symptom Azithromycin RR (95% CI)t Placebo RR (95% Cl) Doxycycline
11.2 p-yr * A vs P 5.23 p-yr D vs P 5.75 p-yr
All svmDtoms 401 (35.79)j 196 (37.48) 223 (38.76)
GI svmDtoms 123 (10.97) 63 (12.04) 69(11.99)
Heartburn 27 (2.41) 25.7 (3.19-qo)s 0(0 ) 24.6 (2.77-oo)§ 13 (2.26)
CNS 157(14.01) 85 (16.25) 99(17.21)
Severe headache 5 (0.45) 7(1.34) 0.06 (0-0.63)t 0(0)
Tinnitus 8(0.71) 0.31 (0.11-0.83) 12(2.29) 0.23 (0.04-0.84) 3 (0.52)
Difficulty 25 (2.23) 10(1.91) 3.28(1.59-7.40) 36 (6.26)
sleeping
Dermatolosical 40 (3.57) 9(1.72) 10(1.74)
Miscellaneous 81 (7.23) 39 (7.45) 45 (7.82)
Sweats 7 (0.62) 4 (0.76) 12(2.1)
Myalgia 19(1.70) 8.88(1.41-368.9) 1 (0.19) 8.19(1.14-358.8) 9(1.56)1
’Others’ 74 (6.60) 26 (4.97) 45 (7.82)
* Person-years o f follow-up 
t  Rate ratio (95% confidence interval)
X Total number o f times symptom reported (incidence rate/p-yr)
§ Vi added to the numerator counts to estimate the rate ratio. No adjustment for the 95% 
CIs.
|| D vs A: RR=2.8 (1.64 -  4.87)
K D vs A: RR=3.34 (1.22 -  10.0)
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3.2 Chloroquine-doxycycline therapeutic trial
3.2.1 Enrolment and withdrawals
Of 164 volunteers screened, 12 did not meet the entry criteria for the following 
reasons: negative malaria film (n=6), previous consumption o f antimalarial drugs within 7 
days (n=4), consent to participate not given (n=l), and one female with a positive urine 
pregnancy test (Figure 3.4). Of the 152 patients who entered the trial, 89 had P. 
falciparum , 63 had P. vivax. Twenty five did not complete the study to Day 28 because of 
malaria related, persistent vomiting during the first days o f treatment (n=4), mixed 
infections during follow up (n=6), inadvertent primaquine administration before Day 28 
days (n=7), and (iv) voluntary withdrawal (n=8). There were no withdrawals because of 
drug related toxicity.
Baseline characteristics o f the patients were broadly similar, apart from a lower 
parasite count and residential time in the doxycycline group (Table 3.7). All patients had 
symptoms or signs o f malaria. Of the 152 patients, 142 (93.4%) had measured total white 
cell counts: median 6,300/pL (range 2,100-13,600/pL)]. Using the measured white cell 
counts, and assuming a count o f 8,000/pL for the 10 missing values, the Day 0 parasite 
counts ranged from 20-74,432/pL (median 2,373/pL) for falciparum patients, and 54- 
14,124/pL (median 2,567/pL) for vivax patients. Papuan and transmigrants had similar 
Day 0 median falciparum parasitaemias: 2,359.5/pL vs 2,856/pL, respectively, CP=0.7) 
but transmigrants had higher Day 0 median vivax parasitaemias: 3,168/pL vs 703.5/p.L 
(P=0.05). Residential time in Irian Jaya ranged from one month to 40 years and was 
similar between CQ and CQD groups but significantly less in the doxycycline arm 
compared to the CQD arm for falciparum patients. All drug regimens were well tolerated.
119
12 excluded
164 volunteers considered
152 randomised
P. vivax = 63 
CQ=23, CQD=24, D=16
P. falciparum = 89 
CQ=30, CQD=39, D=20
57 evaluable by Day 28:
27 sensitive: CQ=6 CQD=15 D=6 
30 resistant: CQ=15 CQD=7 D=8
70 evaluable by Day 28:
43 sensitive: CQ=5 CQD=26 D=12 
27 resistant: CQ=18 CQD=3 D=6
19 exclusions from  analysis: 
clinical failure = 4 
given primaquine = 5 
new infections = 4 
subject withdrawal = 6
6 exclusions from  analysis: 
clinical failure = 0 
given primaquine = 2 
new infections = 2 
subject withdrawal = 2
Figure 3.4 Trial profile for the chloroquine-doxycycline study.
Table 3.7 Baseline characteristics at enrolment of patients with malaria randomised to the three drug regimens.
P. falciparum  patients 
CQ CQD D 
n=30 n=39 n=20
CQ
n=23
P. vivax patients 
CQD 
n=24
D
n=46
% Male 93 85 95 96 88 88
Mean (SD) age in y 24.5 (5.0) 23.7 (5.2) 25.0 (5.6) 23.1 (4.9) 23.8 (3.9) 24.9 (5.1)
Median (range) residential time 17 19 3 2 10 3
in Irian Jaya in months or years (lm-40) (4m-30) (3m-26) (5m-24) (2m-30) (2m-29)
Reported malaria* 2 (0 - 10) 3(0-11) 3 (0-9) 5 (0-16) 1 (0-6) 3(0-11)
Mean (SD) weight in kg 55 (6.9) 52 (7.1) 55 (7.9) 54 (7.6) 58 (7.7) 55 (7.7)
n (%) symptomatic 30 (100) 39 (100) 19 (95) 23 (100) 24 (100) 16 (100)
n (%) febrile 25 (83) 35 (90) 18(90) 20 (87) 23 (100) 15 (94)
Mean (SD) temp in °C 38(1) 38(1) 38(1) 38(1) 39(1) 38(1)
Mean (SD) Hb in g/dl 13.2(1.9) 12.3 (2.0) 12.8 (2.3) 13.1 (2.1) 13.4(2.5) 12.3 (2.5)
Median parasite count !\xL 3,108 2,928 1,254 3,120 1,886 3,040
(range) (20-74,432) (20-64,998) (49-25,100) (54-12,648) (70-12,916) (60-14,124)
* median (range) o f reported malaria attacks within the previous two years
3.2.2 Parasitological and clinical responses of P. falciparum patients
3.2.2.1 In vivo test
The cure rates for the three arms were: (i) CQ-5/23 [22% (95% Cl 8-44], (ii) 
CQD-26/29 [90% (73-98)], and (iii) D-12/18 [67% (41-87)] (Table 3.8). These rates were 
significantly higher in: (i) the CQD vs CQ arms: RR=4.12 [(95% Cl 1.88-9.04), P  
<0.001], and (ii) the D vs CQ arms: RR=3.07 [(1.32-7.11, P=0.0037]. The CQD vs D 
rates were not significantly different: RR=1.34 [(0.95-1.91), P=0.067]. All three grades of 
resistance were present in the chloroquine arm, RII/RIII in the doxycycline alone arm, 
and only RIII resistance in the CQD arm. Overall, resistance rates (RI/RII/RIII) were 
18/23 [78% (95% Cl 56-93)] for chloroquine alone, 3/29 [10% (95% Cl 2-27)] for 
chloroquine/doxycycline, and 4/18 [22% (95% Cl 6-48)] for doxycycline. Paired PCR 
genotyping results were available for 4 of the 9 CQ recurrent cases; all genotype pairs had 
matching gel electrophoretic patterns, supporting a diagnosis o f RI resistance. There was 
a trend (P=0.1) towards a higher cure rate in the Irianese [21/29 (72.4%)] compared to the 
other ethnic groups [22/41 (53.6%)].
3.2.2.2 Parasite clearance time
Parasite clearance times (PCTs) were measured in patients with either sensitive or 
RI resistance. In total 52 [CQ=14 (61%), CQD=26 (90%), D=12 (67%)] patients cleared 
their parasitaemias. The mean PCTs were 2.9 days (CQ), 3.3 days (CQD), and 3.9 days 
(D). None o f these differences were significantly different.
3.2.2.3 Fever and symptom clearance
The fever clearance times (FCTs) ranged from 8 to 168 hours. Mean FCTs were 
not significantly different between study arms: 37.lh  (CQ), 46.6h (CQD), and 56h (D). 
The proportions o f symptomatic patients on Day 3 were similar in all arms: (i) CQ 11/18 
(61%), (ii) CQD 15/26 (58%), and (iii) D 8/14 (57%), [-/2 (df=2)=0.07, P= 0.96]. 
However, by Day 7 the proportion of symptomatic doxycycline recipients was 
significantly higher compared to the chloroquine arm: 6/13 (46%) vs 1/17 (6%), 
[RR=7.85 (95% Cl 1.07-57.4), P=0.02], but not compared to the CQD arm [6/26 (23%), 
P=0.16].
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3.2.3 Parasitological and clinical responses of P. vivax
3.2.3.1 In vivo test
The cure rates for the three arms were: (i) CQ-6/21 [28.6% (11.3-52.2)], (ii) CQD- 
15/22 [68.2% (45.1-86.1)], and (iii) D-6/14 [42.8% (17.7-71.1)], (Table 3.8). Only the 
CQD vs CQ cure rates were significantly different: RR=2.39 [(95% Cl 1.15-4.97), 
P=0.01]. All the three grades o f resistance were present in the chloroquine arm, 
Rl/relapse in the CQD arm, and Rl/relapse and RIII in the doxycycline arm. Overall 
resistance/relapse rates were 71% (CQ), 32% (CQD), and 57% (D). PCR results were 
available in 19 (CQ=11, CQD=6, D=2) of the 25 Rl/relapse cases: 17 pairs matched, and 
two CQD patients had mismatching isolates. The cure rates in the Irianese [8/16 (50%)] 
and the other ethnic groups [19/41 (46.3%)] were similar (P=0.8).
3.2.3.2 Parasite clearance time
The PCTs were calculated for the 52 S/RI/relapse patients (CQ=19, CQD=22, 
D = ll) . The mean PCTs were significantly faster in the CQ and CQD arms compared to 
doxycycline alone: 2.4d (CQ) vs 5.4d (PO.OOOl), and 2.9d (CQD) vs 5.4d (P=0.037). 
The CQD vs CQ comparison was unremarkable.
3.2.3.3 Fever and symptom clearance
Fever clearance times ranged from 8 to 144 hours. The mean FCTs were not 
significantly different between the arms: 34. lh (CQ), 47.3h (CQD), and 51.6h (D). 
Similarly, the respective proportions o f symptomatic patients were not significantly 
different between the three arms on: (i) Day 3 [10/19 (53%) vs 11/22 (50%) vs 7/11 
(64%), [x2 (df=2)=0.57, P=0.75], and (ii) Day 7 [4/20 (20%) vs 2/20 (10%) vs 2/10 
(20%), [x2 (df=2)=0.89, P=0.63].
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Table 3.8 The Day 28 parasitological cure rates of P. falciparum and P. vivax to
chloroquine, chloroquine/doxycycline, and doxycycline.
P. falciparum P. vivax
CQ CQD D CQ CQD D
n=23 n=29 n=18 n=21 n=22 n=14
Sensitive 5 (22)* 26 (90)t 12 (67) J 6 (29) 15 (68)§ 6 (43)
RI 9 (39) 0 (0) 0 (0) 13 (62) 7 (32) 5 (36)
RII 5 (22) 0 (0) 2 (11) 1 (5) 0 (0) 0 (0)
RIII 4 (17) 3 (10) 4 (22) 1 (5) 0 (0) 3 (21)
*n(% )
t  CQD vs CQ: PO.OOl 
t  D vs CQ: P=0.004 
§ CQD vs CQ: P=0.01
3.2.4 Chloroquine concentrations and parasitological responses
Whole blood, Day 0 total chloroquine concentrations levels (TCQ) were available 
for a total o f 119/152 (78.3%) patients o f whom 38 (32%) had detectable chloroquine 
(Table 3.9). Only the Day 7-Day 3 TCQ concentrations (n=104) were positively 
correlated: r=0.71, ^=0.5 (95% Cl 0.34-0.64). The median Day 3 TCQs levels were 
similar between (i) falciparum and vivax patients, (ii) sensitive and resistant (RI/RII/RIII) 
patients (either species), and (iii) CQ (700 ng/ml) and CQD (716 ng/ml) arms (P=0.45). 
Insufficient TCQ data for the RIII (Pf=3, Pv=l) and RII (Pf=5, Pv=l) cases precluded 
further analyses based on the degree o f resistance. However, there appears to be a trend of 
decreasing Day 3 TCQ concentrations and increasing resistance for both species. There 
was wide interindividual variation o f absorption with Day 3 TCQ concentrations ranging 
from 315 to 1,504 ng/ml, a 4.7 fold difference.
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Table 3.9 Whole blood, total chloroquine concentrations in patients treated with either
chloroquine or chloroquine/doxycycline for falciparum or vivax malaria.
Day P. falciparum malaria P. vivax malaria
0 0 (0-580)* 0 (0-272)
3 698 (315-1,545) 722 (316-1,405)
7 317 (0-769) 329(162-956)
28 0 (0-460) 0 (0-769)
Day 3
Sensitive 686 (333-1,071) 722 (443-1,405)
Resistant 676.5 (315-1,355) 741 (316-1,311)
Day 3
R1 766 (506-1,355) 774 (316-1,311)
RII 543 (461-1,179) 575t
RIII 407 (315-435) 392f
* median (range) 
t  one sample only
3.2.5 Haematological response
Day 0 haemoglobin data were available in 142 (85 males, 13 females) patients. 
There was no correlation between the Day 0 Hb and the Day 0 parasitaemia for either 
species (details not shown). At enrolment, the proportions o f anaemic males (Hb < 13 .5  
g/d) were: (i) 38/72 (52.8%) for falciparum patients (CQ=11, CQD=18, D=9), and (ii) 
29/57 (50.1%) for vivax patients (CQ=11, CQD=11, D=7). Anaemic females (Hb < 12 
g/dl) numbered 11/13 [83.6% (CQ=3, CQD=5, D=3)]. Day 28 Hb data were available for 
61 cured patients (males=53, females=8). The proportions o f anaemic males for both 
species were 17/53 (32.1%): Pf=15/33 (45.5%), Pv=2/20 (10%). Only the vivax DO vs 
D28 comparison was statistically significant: 50.1% vs 10% [RR=5.1 (1.3-19.5); 
TMl.OOl]. By study end, anaemic females numbered 6/8 (75%): Pf=3, Pv=3. Sample sizes 
for paired D28 DO Hb values are small (Table 3.10). The mean change in haemoglobin 
(Day 28 relative to baseline) was significantly increased only in the CQD treated 
falciparum group.
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Table 3.10 Haemoglobin data for falciparum and vivax patients at Day 0 and Day 28.
P. falciparum P. vivax
CQ________ CQD________ D_________ CQ CQD D
DayO n=27 n=34 n=19 n=23 n=23 n=16
13.1 (1.9)* 12.3 (1.9) 12.8 (2.3) 13.1 (2.1) 13.4 (2.5) 12.3 (2.4)
Day 28 n=4 n=24 n=14 n=6 n=16 n=8
12.3(2.9) 13.5(1.4) 13.8(1.8) 14.8(0.8) 14.3(1.0) 14.4(2.3)
Meanchange -0 .6  (1.7) 1.2 (1.8) t  1.04(2.5) 1.1 ( l . l ) j  0.74(2.9) 0.79(1.2)
* mean (SD) 
t  P=0.003 
t  P=0.056
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Chapter 4 - Discussion and conclusions
4.1 Azithromycin prophylaxis study.
4.1.1 Prophylactic efficacy
This study demonstrated excellent prophylactic efficacy o f  azithromycin against 
chloroquine resistant P. vivax but only modest efficacy against multidrug resistant P. 
falciparum  in north-east Papua. Doxycycline achieved high protective efficacy against 
both species. The tolerability o f both drugs was good.
This double blind, placebo-controlled trial followed a large number o f clinically 
susceptible subjects with limited (6-15 months) malaria exposure who lived under basic 
field conditions, akin to those experienced by refugees, and backpackers. They suffered 
moderately intense malaria transmission, confirmed by the crude attack rate o f just under 
73% (placebo group) over 20 weeks. The high prophylactic efficacy o f the doxycycline 
positive control excludes poor drug compliance and poor study conduct as causes o f the 
low result of azithromycin against P. falciparum.
Recommending a drug for antimalarial prophylaxis depends on its tolerability and 
prophylactic efficacy. The latter should be measured ideally in a non-immune population 
because travellers to and pregnant women living in malaria endemic areas are candidates 
for malaria prophylaxis (since this study was conducted, the WHO has recommended 
intermittent preventive treatment for pregnant African women living in areas o f intense 
transmission). The tolerability and prophylactic efficacy o f a new drug should be 
comparable or better than currently used first line prophylactic drugs. However, there is 
no generally accepted minimum protective efficacy. This trial adopted a priori a 
minimum protective efficacy of 70%, in other words the lower 95% Cl o f the protective 
efficacy had to be greater or equal to 70%. Azithromycin had a lower 95% Cl o f only 
50% against falciparum malaria whilst that of doxycycline was 85%. Direct comparisons 
with other studies gives some perspective but the lower 95% Cl is critically dependent on 
the sample size. The lower 95% CIs recorded in Papua have been 93% for mefloquine 
88% for doxycycline, and 48% and 57% for primaquine. Atovaquone/proguanil
in relatively non immune transmigrasi adults had a protective efficacy o f 96% with a 
lower Cl o f 72%.207 This is lower than those achieved in malaria immune Africans (> 92%) 
but these data are not applicable for non immune populations.204 205 206
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The Indonesian soldiers with only six months o f malaria exposure resembled more 
closely malaria naive individuals compared to civilians who had 15 months o f exposure. 
The prophylactic efficacy in the soldiers against P. falciparum  was lower than in the 
civilians, 63% vs 88%. Although the difference was not statistically significant, this result 
suggests that a comparably low figure would be obtained in non immune travellers to the 
same area. At this level of protective efficacy, 250 mg of daily azithromycin cannot be 
recommended as a first line, prophylactic drug against falciparum malaria for non- 
immune populations.
Another azithromycin prophylaxis study has been conducted in malaria immune 
Kenyan adults. Daily administered azithromycin (250 mg), without a loading dose, had a 
prophylactic efficacy o f 83% (68-91) against falciparum malaria; the efficacy o f 1 gm 
administered weekly was 64% (47-77).199 All of the Kenyan prophylactic failures were 
asymptomatic consistent with a high degree o f malaria acquired immunity. By contrast, 
the majority o f the Indonesian soldiers and civilians were symptomatic, indicating a lesser 
degree o f clinical immunity. The similarity of the efficacy results between the Indonesian 
civilians and the Kenyans suggests that the civilians had acquired sufficient immunity 
after only 15 months of malaria exposure to enhance the antimalarial effect of 
azithromycin. This suggests that the results of malaria prophylactic studies that are 
conducted in populations with even limited immunity to malaria may not be reliably 
applied to non immunes.
The marked difference in the protective efficacy between falciparum and vivax 
malaria was an unexpected result and is probably due to different mechanisms o f action 
o f azithromycin within vivax and falciparum parasites. Our knowledge o f how 
azithromycin acts in malaria parasites is limited to in vitro evidence o f protein synthesis 
inhibition necessary to support DNA production; the site o f action is probably the parasite
- l i e
mitochondrion. There are no comparable in vitro data for P. vivax.
4.1.2 Tolerability
Azithromycin was well tolerated by these Indonesian adults over 20 weeks and 
did not appreciably affect routine haematological or biochemical measurements. 
Tolerability was broadly similar to that o f doxycycline.
Assessing drug related side effects in patients in randomised, placebo-controlled 
trials is different than in clinical practice. Clinicians assess presenting symptoms in the
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context o f the patients’ past medical history, the drug history, the local disease 
epidemiology, physical signs, and pertinent investigations. Clinical trials focus primarily 
on broad assessments involving group comparisons, and benefit from blinding. In this 
phase III trial, a lot of data have been analysed in detail. Some o f the issues inherent in 
such an analysis are raised in this discussion.
The symptom data were reported as proportions and rates. The former is an 
indication o f how many subjects reported a given symptom whilst rates are an indication 
of how often these symptoms were reported. The proportional analysis was done for the 
first four weeks o f follow-up when all subjects were approximately at the same risk. The 
differential attrition o f the placebo group because o f malaria precluded proportional 
comparisons o f risk, relative risk, and symptom trends over the whole period o f follow 
up. Analysis o f symptom rates takes into account the unequal follow-up time and 
calculates the symptom frequency per reported days o f all subjects. This analysis does 
not, however, distinguish recurrent symptoms from those reported on consecutive days, or
TRA '387whether a few symptoms were reported by many subjects and vice versa. Another 
issue involves the interpretation of results obtained from multiple statistical comparisons. 
Determining which symptoms are important or whether differences exist based on simple 
hypothesis testing is challenging. The problems o f multiple comparisons e.g. the over 
reporting (type I error) or failing to detect (type II error due to adjusting P  values) 
significant symptoms is well recognised but there are no completely satisfactory 
solutions.388 Cognisant o f these issues, and with the view that the analysis o f complex 
symptom data is largely exploratory, it was decided to flag comparisons where the P  
value was 0.05.
The most important adverse event was an azithromycin induced maculopapular 
rash in one subject that was classified as a moderately severe drug reaction. The reported
3 3 7  33Q
risk o f developing any rash with azithromycin from large clinical series is 1.1%.
339 Several symptoms in the both drug arms were noteworthy. Heartburn, a well 
recognised effect o f doxycycline, was also reported by our doxycycline recipients but, 
interestingly, at a lower frequency than the azithromycin recipients.263 In published 
reports of azithromycin, heartburn is not often reported separately from abdominal pain, 
making it difficult to put these heartburn data into context. At four weeks, itching, 
paraesthesiae, and severe abdominal pain were unremarkable symptoms reported by the
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srag arms but over 20 weeks, itching and paraesthesiae were reported more frequently by 
the azithromycin arm (vs. placebo), and severe abdominal pain by the doxycycline 
recipients (vs. placebo), suggesting these symptoms emerged gradually over time. By 
contrast, myalgia, reported more frequently by both drug arms at four weeks, might be a 
symptom that develops acutely.
Hearing loss, a significant symptom in some clinical reports, was reported by a 
minority o f all our subjects with a correspondingly low frequency, approximately one 
complaint every two years. At study end, clinical signs consistent with a sensineural 
hearing loss (Weber lateralisation and a normal Rinne test) were detected in a small 
number (2.6%) o f subjects across all three arms. Certainly, tuning fork examination tests 
only hearing at the frequency o f the tuning fork and is subject to inter examiner variation. 
Audiometry would have strengthened considerably this aspect o f safety monitoring but is 
impractical under field conditions and requires expertise in performing and interpreting 
the test. Never the less, we doubt these Rinne and Weber signs represent appreciable 
auditory nerve pathology. Azithromycin-induced, sensineural hearing loss has been 
reported in individuals treated for MAC disease and is usually transient, dose-related, and
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improves with drug discontinuation or dose reduction. Nevertheless, clinicians
should be aware that azithromycin can cause rarely irreversible hearing loss.353 It would 
be prudent to monitor hearing in individuals on long term azithromycin. Hearing 
impairment is also a rare feature of chloroquine and mefloquine use and has recently been 
described with artemether/lumefantrine.224 243 389 This underlies the importance o f  
continual safety monitoring after drug registration.
All azithromycin recipients had total white blood cell counts within the normal 
range when tested at four weeks and study end. This schedule would have missed early, 
transient leukopenia which has been reported, without adverse clinical effect, following 
standard and high dose azithromycin.337 345 A small proportion o f azithromycin recipients 
developed mild elevation o f AST by study end; the peak value was 50 IU/L. This modest 
increase is of doubtful clinical significance but a mild, drug-induced hepatitis cannot be 
excluded. Azithromycin usually causes mild and reversible elevations in liver enzymes in 
a small proportion (< 2%) o f treated patients.337 Clinically significant liver toxicity is rare 
e.g. hepatitis as part o f a systemic hypersensitivity reaction, and cholestatic jaundice.354
355 356 • • •This is similar to erythromycin which may produce an allergic mediated, mixed
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hepatic injury that is predominantly cholestatic; eosinophilia is present in ~ 50% of
390cases.
One azithromycin recipient was withdrawn from the study for drug related 
toxicity, giving a rate o f 0.7% with an upper 95% Cl o f 3.7%. These figures are consistent 
with rates o f withdrawal for azithromycin, for other indications, and the main 
prophylactic drugs (< 1% - < 7%).217337
To conclude, azithromycin had good tolerability in this study when used for up to 
20 weeks. These data support the use o f long term azithromycin for other clinical 
indications.
4.1.3 Limitations of the azithromycin trial
This trial was conducted in a comparatively small number o f predominantly 
healthy and fit young soldiers. Few women were included. Two important vulnerable 
groups for malaria were excluded - pregnant women and young children. The findings of 
both efficacy and tolerability are primarily applicable to men and cannot be extended with 
confidence to children, pregnant women, and patients with AIDS. The small sample size 
precluded the detection o f rare and, possibly, serious drug side effects.
4.1.4 Conclusions of the azithromycin trial and future directions
The prophylactic efficacy o f azithromycin against P. falciparum  malaria was low 
(~ 72%) and appeared to be lower in the lesser immune soldiers (~ 62%). These levels of 
protective efficacy are insufficient to recommend azithromycin as a first choice for non 
immune travellers or pregnant women who are at risk o f contracting P. falciparum  
malaria. Azithromycin might be useful for patients with absolute contraindications or 
unacceptable toxicity to the mefloquine, doxycycline, chloroquine/proguanil, and 
atovaquone/proguanil. Such numbers o f travellers are likely to be very small. Irrespective 
o f the prophylactic regimen employed, clinicians should always remind travellers that 
chemoprophylaxis does not confer absolute protection against malaria and that full 
compliance is essential.
Azithromycin has demonstrated favourable tolerability and reasonable 
antimalarial activity that could be exploited in drug combinations for malaria treatment or 
prophylaxis. If azithromycin were safe in pregnant women, it would be a useful addition 
for this vulnerable group. This role may be o f heightened importance in the HIV era 
where a sizeable minority (~ 25%) o f African women are HIV positive.391 With its broad
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antimicrobial spectrum, azithromycin might be useful against several HIV associated 
pathogens e.g. Pneumocystis jirovecii and Toxoplasma gondii. Azithromycin as malaria 
and streptococcal prophylaxis has not been assessed in children with sickle cell anaemia 
living in malaria endemic countries and is another avenue of research. The mechanisms of 
action and resistance to azithromycin in the two main malaria species also warrant further 
research.
4.2 Chloroquine-doxycycline study
4.2.1 Efficacy
The combination o f chloroquine and doxycycline improved markedly the cure rate 
of uncomplicated, drug resistant falciparum malaria; the increase against P. vivax was 
modest. Doxycycline alone showed some antimalarial activity that was either additive or 
synergistic when combined with chloroquine against both species.
Previous work with tetracycline or doxycycline has been limited to a few small 
studies in patients and volunteers with experimentally induced malaria. Both drugs 
produced slow clinical and parasitological responses. Mean parasite and fever clearance 
times against P. falciparum were 5 and 3-5 days, respectively, and 7 and 6 days, 
respectively, against P. vivax.323 324 325 326 This study has redocumented the slow parasite 
clearance times o f falciparum (mean=4d), and vivax malaria (mean=5d), but the mean 
fever clearance times were faster, just over 2 days for both species.
Chloroquine alone in this study was clearly inadequate against P. falciparum; the 
cure rate was only 22%, and there was a substantial proportion (40%) o f high grade 
RII/RIII infections. The cure rate against P. vivax was marginally better (29%) but the 
proportion o f high grade resistance was lower, 10%. These cure rates probably indicate a 
further decline in CQ efficacy over time. In 1984, 9 (56.2%) o f 16 patients from Jayapura 
with falciparum malaria had S/RI responses to chloroquine. There were 4 cases (25%) of 
high grade (RII/RIII) resistance.140 Other pertinent data from Papua have documented 
high failure rates with chloroquine in Arso e.g. 54% by Day 7, 83% by Day 14, and 
Nabire (89% by Day 28). Chloroquine resistant P. vivax has also emerged in
Papua and is also associated with high rates of treatment failure. These were 22 and 58% 
(Day 14), and 78 and 83% % (Day 28) in Arso, and 64% (Day 28) at Nabire.1920 376
Chloroquine/doxycycline cured the majority (90%) o f patients with P. falciparum 
malaria but this result is tempered by the occurrence o f three patients (10%) with RIII
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resistance, indicating a failure to kill the most resistant parasites. These patients remained 
symptomatic and had rising parasite counts at 48 hours but had no features o f severe 
malaria. This contrasts to a trial o f chloroquine and tetracycline to treat falciparum 
malaria in which two patients with RIII resistance became seriously ill. The investigators 
concluded that chloroquine/tetracycline was a potentially dangerous combination. 
Clinicians should be aware that RIII resistance is the most serious form o f resistance 
because treatment has little or no effect in lowering the parasite count and patients are at 
risk o f developing severe malaria.
RIII chloroquine-resistant P. falciparum is well documented in Papua and was 
12.5% in Jayapura, 16.2% in Nabire, and 22.8% in Arso.19 140 375 Figures from this study 
were consistent - 17%. The 10% rate for CQD suggests the combination might have had a 
small beneficial effect against RIII resistant parasites. However, overcoming RIII 
chloroquine resistance in this area over the long term will require more efficacious 
antimalarial drugs or drug combinations that can also be used in young children and 
pregnant women. It is time to move away from chloroquine.
Chloroquine/doxycycline had a higher cure rate against P. falciparum  compared 
to chloroquine-resistant P. vivax. Intuitively, one would have expected the opposite result. 
This finding underscores the importance of studies aimed at understanding the 
mechanisms o f action and resistance o f chloroquine and doxycycline in P. vivax and P. 
falciparum. Data from this study suggest different mechanisms o f drug resistance may be 
operating between P. falciparum  and P. vivax.
4.2.2 Haemoglobin response
Haematological recovery is a clinically important outcome for patients who are 
treated for malaria but this has received less attention than parasite clearance. The current 
WHO in vivo guidelines now place more emphasis on this issuse.123 In low and moderate 
transmission areas, like some parta o f north-eastern Papua, anaemia is closely related to 
the acute infection and improves with disease resolution.392 In this study, those patients 
who had sustained parasite clearance to Day 28 had higher mean Hb levels compared to 
Day 0 for both malaria species but only the mean change within the CQD group was 
statistically significant. Small sample sizes are the probable cause o f the lack o f statistical 
significance for the two other arms.
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4.2.3 Chloroquine concentration and in vivo parasite response
In the assessment o f drug resistant malaria, excluding inadequate drug absorption
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as the cause o f treatment failure is important. This is complicated by the lack o f a 
therapeutic range for chloroquine and the wide interindividual absorption o f CQ. This 
study found an almost five fold difference in CQ absorption measured on Day 3. The PK 
data from this study do not contribute to defining a therapeutic range for chloroquine. 
Certainly, there was a trend in declining chloroquine concentrations and increasing 
degrees o f resistance for both species, a finding consistent with a PK PD study in 
Tanzania.147 Understanding better the pharmacokinetic - pharmacodynamic relationship 
o f CQ as treatment in both malaria species is one area o f future research.
Chloroquine resistant P. vivax warrants comment. There is now a WHO 
recommended in vivo test for vivax and falciparum malaria that does not mandate the
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measurement o f chloroquine drug levels. Failure to clear vivax parasitaemia despite 
administered CQ is evidence o f resistance despite the absence o f CQ drug levels. 
Recurrent parasitaemia presents a challenge because this may be due to a new or resistant 
infection, or a relapse of the current or antecedent infection. All o f these possibilities are 
considered as treatment failures by the new WHO criteria.
The classification used in this study was an adaptation o f the parasitological 
response (S/RI/RII/RIII) for P. falciparum and classified recurrent parasitaemia as 
Rl/relapse. Another approach, developed by Baird, has been to classify a recurrent 
parasitaemia as resistant if  (i) it occurred on or before Day 14, or (ii) if  the measured 
whole blood CQ concentration was > lOOng/ml at the time o f recurrence.153 This cut off 
value is the MIC for fully sensitive vivax parasites that was derived from dose ranging 
studies that were conducted in 1948.151 Indeed fully sensitive vivax parasites do not 
usually reappear during 28 days o f follow up.124 This system is a good early marker of 
'resistant* parasites but does not in itself predict resistance to either another therapeutic 
course o f chloroquine or to chloroquine prophylaxis. The mean, total whole blood levels 
achieved by CQ prophylaxis (300 mg/week) range from 710-263 ng/ml over 7 days,
'XQ'Xconcentrations appreciably higher than the 100 ng/ml cut off. A greater understanding 
of the PK-PD relationship between chloroquine and the different strains o f P. vivax is 
needed to define a therapeutic range and enable a distinction to be made between 
sensitive and resistant P. vivax.
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4.2.4 The use of PCR to distinguish recurrent parasitaemias
This study used PCR to help differentiate recurrent parasitaemia o f both species. 
Such data are useful to support the clinical diagnosis o f resistance. In the case o f the 
chloroquine treated falciparum patients, only four o f nine had paired samples. The results 
for all four were consistent with RI infections. For the vivax patients with recurrent 
parasitaemia, most o f the paired isolates matched and were consistent with relapse or 
resistance of the primary infection; two mismatched pairs were consistent with relapses of 
antecedent infections or new infections. The effectiveness o f PCR is critically dependent 
on the collection o f good quality specimens, and unfailing laboratory techniques. In this 
study, there was a high proportion (~ 40%) o f recurrent parasitaemia that was unable to 
be classified mainly because samples were not collected. As this technology evolves, it 
would be important to standardise techniques so that results can be compared between 
laboratories.
4.2.5 Limitations of the chloroquine/doxycyciine study
There were several study limitations in this study. This was an open label study 
with small sample sizes in which at the beginning drug allocation was not concealed 
adequately. The study enrolled mostly male patients. Although chloroquine/doxycyciine 
was effective against P. falciparum, doxycycline had to be administered for seven days - 
a distinct drawback for patient compliance outside the research setting. This regimen 
cannot be used in pregnant women and children under eight years because doxycycline is 
contraindicated in these two groups.
4.2.6 Conclusions of the chloroquine-doxycycline trial and future 
directions
This study has demonstrated that drug resistant falciparum malaria in north 
eastern Irian Jaya can be cured with a combination o f chloroquine and doxycycline. These 
two drugs are cheap, currently licensed, and widely available in Indonesia. Whilst this 
combination will not be the definitive answer to the dual problem o f drug resistant vivax 
and falciparum malaria in this area, it is certainly a better option than chloroquine alone, 
the current standard o f care. Seven days o f generic doxycycline would increase the cost of 
chloroquine alone from approximately 7 US cents to 51 cents; this compares to 13 cents 
an adult course o f sulfadoxine/pyrimethamine, and US$2.35 for an adult course (15
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mg/kg) o f generic mefloquine (Mephaquine, Switzerland). The latter is about the same 
price as the recently WHO negotiated price o f artemether/lumefantrine for adults.
More drug trials are needed to assess other drugs and drug combinations in all 
groups susceptible to malaria in NE Papua. The WHO is now advocating the use of 
artemisinin based combinations as a means to reduce the development o f drug resistance, 
improve cure rates, and reduce transmission.394 One small trial o f artesunate and S/P has 
already been conducted in NE Papua with a good result; the treatment failure rate by Day 
28 was 4.4% but these two cases were deteremined to be new infections by PCR 46
4.3 Retrospective critique of both studies
4.3.1 Azithromycin study
4.3.1.1 Study design
This study enrolled civilians and soldiers on the assumption that both groups had 
sufficiently low levels o f immunity so as not to synergise with the drug. Indeed had the 
study started as planned, this assumption was very reasonable. Epidemiological data from 
Arso suggested that about two years o f malaria exposure was necessary for newly arrived 
malaria naive individuals (older children and adults) to establish a reasonable amount of 
malaria immunity against P. falciparum. However, by the time the study started, the 
civilians had 18 months of malaria exposure and epidemiological markers o f higher 
malaria exposure compared to the soldiers. Not surprisingly, they also reported more 
episodes o f self diagnosed clinical malaria. Although the outcomes in the placebo group 
o f the civilians and soldiers were not significantly different in terms o f crude attack rate, 
levels o f parasitaemia, and proportions of symptomatic breakthrough infections, the 
prophylactic efficacy against P. falciparum in the civilians was higher than that in the 
soldiers. Although the confidence intervals overlap and the P  value was 0.08, one can 
conclude that these data are suggestive o f an immune enhancing effect in the civilians. In 
retrospect, recruiting both soldiers and civilians proved to be an error because the two 
groups were not comparable. However, an important conclusion has been brought to light 
that even a small amount o f immunity enhances drug action when used as prophylaxis.
4.3.1.2 Ethical aspects
4.3.1.2.1 Use of a placebo
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This was a placebo controlled trial that was conducted in order to register 
azithromycin as a prophylactic with the US FDA. Because this was a pivotal phase III 
trial, the FDA required a placebo arm.
The views on the use o f placebos have changed in the past 10 years because o f the 
question o f risk to study participants and the view that an experimental arm should be 
compared with the best alternative. However, in 2001, the World Medical Association 
[WMA (http://www.wma.net/e/ accessed December 2005)] issued a clarification note that 
stated that placebo may be used for 'compelling and sound methodological reasons'. It is 
widely accepted that randomised blinded studies generate the best quality data for 
assessing an intervention.171 In this trial, a placebo allowed the prophylactic efficacy to be 
calculated, attack rates to be measured, and the adequate assessment o f the tolerability of 
azithromycin.
An assessment o f the potential impact o f using a placebo is warranted. For the 
transmigrants, the government policy was to take chloroquine for three months, 
thereafter, malaria diagnosis and treatment with chloroquine became the policy. 
Similarly, the soldiers were issued with prophylaxis for the first few months o f their 
deployment (Several colleagues are unable to remember the exact duration). Prophylaxis 
for the whole duration o f their deployment was considered impractical because 
compliance could not be assured. As with the civilians, prophylaxis was replaced by a 
policy o f diagnosis and treatment with chloroquine. SP was used by some soldiers but this 
is a suboptimal choice because of the well recognised risk o f severe cutaneous reactions;
'JQ C
SP prophylaxis is no longer recommended by many authorities. Before the study 
started, the research team provided the soldiers with doxycycline that was taken 
unsupervised and limited in time to when they would have been taken off prophylaxis. 
Once the study started, some o f these soldiers would have been randomised to the placebo 
arm.
In terms o f risk o f acquiring malaria, the civilians and the soldiers were not at an 
increased o f malaria except for a group o f soldiers who would have taken doxycycline up 
until the time it would have stopped, as per Indonesian Army policy. There was a good 
system of follow up in place. Daily visits were made to all subjects by the research team 
health workers who were also trained to take a malaria slide if  a participant reported 
fever. In PIR V, all villagers had access to good quality medical care if  they fell ill, and
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the soldiers were visited several times per week by the mobile medical teams. Therefore, 
there was a robust system to pick up malaria early and provide prompt and effective 
rescue treatment.
A reasonable question to ask is whether a placebo controlled prophylactic study 
could be conducted in US soldiers ? The answer is yes but with two caveats: (i) the 
soldiers are on peace keeping duties (like the Indonesian soldiers in this study), and (ii) 
the system of follow is robust, as was the case in this study. The latter point is crucial.
4.3.1.2.2 Post research responsibility
This issue is first mentioned in the 2000 Declaration o f Helsinki o f the WMA and
encompasses providing the intervention to the wider community for a specified length if  
time. Regarding azithromycin, it is unlikely that the community as a whole from Arso 
would have benefited from azithromycin had it been successful for two reasons. Long 
term antimalarial prophylaxis is not the policy o f the Indonesian MoH and the cost of 
such a policy is likely to be prohibitive. However, short term prophylaxis could have been 
an option in all age groups, and with future research, azithromycin use in pregnancy 
would was an area o f keen interest o f the Indonesian MoH. Azithromycin is due to come 
off patent in 2007 (C. Ohrt, personal communication) so the price may fall to a level that 
the MoH finds attractive. With the increased global interest in malaria and the need to 
have good antimalarial drugs in use by those who need them, a system of dual pricing has 
been introduced for artemether/lumefantrine which is marketed as Riamet in the North 
and CoArtemether in the malaria endemic countries. Such ideas were not circulating in 
the mod to late 90s but there is no reason to suppose that Pfizer, the producer o f 
azithromycin, could not have considered this option. Indeed, Pfizer is involved in a 
humanitarian capacity in the trachoma control.
For the Indonesian Army, azithromycin would have certainly been an option 
because cost is less o f an issue. Also with its close toes to the US military, obtaining drug 
supplies would be easy. In addition, the need for prophylaxis o f soldiers would be short 
either because o f short stays in endemic areas or because the policy is to only provide 
short term prophylaxis.
In view o f the need to consider what to do after the research, then this should be 
discussed at the start o f any proposed research. It is reasonable that sponsors should give 
something back to communities, especially if  the intervention might be difficult to 
implement locally because o f high cost. In the case o f azithromycin, had it been
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successful, then more research could have been done in collaboration with the Indonesian 
MoH to exploit its antimalarial activities, focussing primarily on the local community. 
The sponsor could agree to support local clinics in a sustainable way for a given period of 
time. Again, such ideas should be discussed and negotiated with the MoH.
4.3.2 Chloroquine doxycycline study
4.3.2.1 Choice of drugs to study
This study chose to examine the efficacy o f chloroquine combined with 
doxycycline and have a doxycycline alone arm. The rationale for the latter was to see if  
any improvement in the combination arm could be ascribed to the doxycycline alone.
Ideally, conducting clinical trials for policy should be done in the context o f a 
comprehensive assessment o f current drug policy. This means that a series o f clinical 
trials should be planned to evaluate different options for treatment. In this study, 
chloroquine and doxycycline was evaluated. There is no reason why other inexpensive 
antimalarial drugs could not have been assessed in follow up studies against chloroquine, 
the current standard o f care, or SP, the second line drug. A number o f possibilities spring 
to mind: (i) amodiaquine alone, (ii) chloroquine plus SP, (iii) amodiaquine plus SP, (iv) 
chloroquine plus primaquine, and (v) quinine alone or with doxycycline. In terms o f the 
more expensive options, then mefloquine alone and atovaquone / proguanil. With the 
recent thrust o f the WHO to encourage the use o f artemisinin based combinations, options 
include CoArtemether, artesunate plus amodiaquine, or SP, or mefloquine, and Artekin 
(dihydroartemisinin and piperaquine). Indeed, since the year 2000, a number o f trials 
have been conducted in Papua assessing SP vs. artesunate plus SP, Artekin vs artesunate 
plus amodiaquine, and Artekin vs CoArtemether.
A retrospective critique o f the chloroquine / doxycycline study is certainly a 
useful exercise but at the same time, one should not be naive as to think that that by 
generating a long list o f potential alternative drugs to study that such studies can be done 
easily. The conduct o f large clinical trials is an undertaking that requires considerable 
human and financial resources which are a challenge for the Ministry o f Health. Much of 
the research is done in collaboration with the US Navy, the Menzies School o f Health 
Research, and the Wellcome Trust.
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4.3.2.2 Study design
This was a relatively small study that was conducted in hospital. Many potential 
patients did not like the idea o f remaining an inpatient for one moth. Consequently, the 
recruitment o f patients was slow. Had the study been conducted in the field, patient 
numbers would have been higher and this could have accommodated an additional study 
arm or arms so that several drugs would have been studied I parallel. However, more 
PCR sampling would have been required and more logistical support would have been 
needed.
4.4 Future research in Indonesia and implications for public 
health
Malaria ranks as one of Indonesia’s principal public health challenges. The size of 
the country and the scale of the challenge cannot be underestimated. The malaria 
epidemiology varies widely with the eastern islands experiencing the greatest malaria 
burden. Within Papua the malaria epidemiology also varies, being stable in the lowlands 
and unstable in the highlands. Epidemics in both settings have caused much morbidity 
and mortality. In Java and Bali, malaria control has been highly effective but the potential 
for hypoendemic malaria to cause epidemics has been graphically brought home by the 
epidemic in central Java in 1997.34 Chloroquine resistant P. falciparum  is widespread and 
there are also focal areas of S/P resistance. Chloroquine resistant P. vivax is well 
established and S/P resistance is emerging. P. malariae resistant to chloroquine has also 
been described in a focus in southern Sumatra.56 Clearly, drug resistance is a major 
challenge for Indonesia. Clinical trials of efficacious drugs and drug combinations will be 
needed to determine the optimal treatment for children, adults, and pregnant women.
The results from this thesis have shown that azithromycin would be unsuitable as 
malaria prophylaxis, and that the combination o f chloroquine and doxycycline would at 
best be an interim measure for treating drug resistant P. falciparum  whilst awaiting better 
and affordable alternatives. The response o f chloroquine resistant P. vivax was modest; 
CRPV still awaits suitable treatment.
The goals o f research should be to inform policy makers, deepen our 
understanding o f unresolved scientific issues, and validate research methodologies. There 
are two areas of future research that stem directly from this thesis; namely, clinical trails
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to determine optimal drug treatment and prophylactic regimens, and more scientific work 
on the mechanisms o f drug resistant falciparum and vivax malaria.
The current thrust o f the WHO of combining standard antimalarial drugs with an 
artemisinin derivative (AD) for treating drug resistant falciparum malaria also applies to 
Indonesia.394 Options include artesunate combined with mefloquine, amodiaquine, or S/P, 
and artemether/lumefantrine. Dihydroartemisinin combined with piperaquine is emerging 
as another promising combination but this drug has not yet been registered to 
international standards.396 These drugs are suitable for all age groups. Experience with the 
artemisinins in pregnancy is limited but has shown favourable outcomes for both mother
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and child. The question o f the optimal treatment o f chloroquine resistant P. vivax 
remains unanswered. A major policy decision needs to be taken as to whether CRPV 
should also be treated with an AD. This question has not yet been addressed by the WHO 
(K. Mendis, personal communication). The problem o f the optimal treatment o f vivax 
hypnozoites also poses a challenge because of different sensitivities to primaquine.399 
Radical cure o f vivax malaria is considered a reasonable public health goal in areas of 
low transmission. Clearly, more research on P. vivax is needed.
There are several interesting and important questions that can be addressed in 
therapeutic efficacy trials. The end points of the current WHO in vivo tests for both 
malaria species could be validated and / or refined for an Asian setting. Added to this 
could be the relationship between molecular markers (dhfr, dhps, and pfcrt) and the in 
vivo response. The number o f such studies from Indonesia has been small. More work is 
needed to determine the predictive value of these markers and to assess their role in 
resistance surveillance e.g. molecular data could be used for targeted in vivo tests. The 
long term tracking o f resistance markers in sentinel sites could be a useful public health 
tool. The PK-PD relationship o f antimalarial drugs needs to be better understood for the 
established and newer antimalarial drugs. Ideally, PK data should be collected in all 
efficacy drug trials.
As well as clinical trials, a further step would be to conduct deployment studies of 
efficacious artemisinin based combinations to assess their impact on morbidity, mortality, 
and disease transmission as well as the economic costs associated with deployment. Such 
research could underpin sound drug policies. In the low transmission areas o f western 
Thailand, the systematic deployment o f artesunate/mefloquine improved falciparum cure
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rates and reduced transmission o f P. falciparum .94 Such a favourable outcome is possible 
in many parts of Indonesia.
Prophylaxis studies would also have a role to play in Indonesia because many 
Indonesians travel to other parts of the archipelago and because o f the transmigration 
programme. Transmigrasi are given three months o f chloroquine prophylaxis when they 
first arrive in Papua. A more efficacious alternative is certainly needed. Malaria 
prophylaxis during pregnancy has not been addressed through clinical trials in Indonesia. 
Indeed, there are no published data on the epidemiology o f malaria in pregnancy.
Broader areas o f research not addressed in this thesis were the social, economic, 
and entomological aspects of malaria control. Another critical area is the relationship 
between malaria policy and research and how research findings are channelled to and 
evaluated by policy makers in order for timely decisions to be made.
Much work remains so that sound evidence can be used to roll back malaria.
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Chapter 5 - the research effort
Both research projects were clinical trials that required much planning and work 
by a number o f individuals. Funding for the azithromycin trial came from US Army 
Medical Material Development Activity and the US Naval Medical Research Command. 
The latter also funded the chloroquine doxycycline study.
5.1 Azithromycin study
The following contributed to the research effort in a significant way and are co 
authors on the azithromycin prophylaxis and tolerability papers: Richie TL, Fryauff DJ, 
Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, 
Jones TR, Basri H, Berman J. Their role/s in the study is/are listed below: 
Protocol development: Richie T, Ohrt C, Tang D, Braitman D, Berman J.
Study execution: Richie TL, Fryauff DJ, Picarima H, Murphy GS, Widjaja H, Tjitra E, 
Ganjar A, Jones TR, and Basri H.
Database design & data management’. Richie TL, Fryauff DJ, Picarima H.
Data analysis’. Tang D.
Manuscript writing: Richie TL, Tang D and Berman J.
Critical review o f manuscript: Fryauff DJ, Ohrt C, Braitman D, Murphy GS, Widjaja H, 
Tjitra E, Ganjar A, Jones TR, and Basri H.
Liason with Pfizer: Braitman D, Ohrt C, and Berman J.
Trial monitoring: Braitman D.
In this study, I was the overall manager and had to coordinate all aspects o f the 
study and run the study in the field. The protocol for this study was written by me and 
Drs. Richie, Berman, and Ohrt. Dr. Tang provided the statistical expertise for the sample 
size calculation. An earlier azithromycin prophylactic study had been carried out in 
Kenya and this protocol was used as a guide. The case record forms and SOPs for the 
conduct o f the study in the field were written by me and were reviewed by Drs. Richie, 
Berman, and Ohrt.
In the field, I managed a team o f some 30 people comprising local health workers, 
microscopists, doctors, PhD scientists, and logisticians. The study was conducted to GCP 
and was monitored externally by the US Army: Drs. Braitman and Wesche. There was 
also a rigorous internal system o f checks o f work done by the health workers and team 
physicians done by myself and other senior team members. The study participants were
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seen daily by the health workers. They were supervised and accompanied by team 
physicians (Drs. Murphy, Widjaja, Tjitra, Ganjar A, and Basri). I also participated 
occasionally. These physicians also ran the mobile medical service that visited the 
Indonesian Army posts. My involvement in this activity was small. The laboratory work 
was done by a small laboratory that was set up specifically for this trial. It also operated 
to GCP standards. All malarial slides were read and reread in a blinded fashion by a team 
of experienced microscopists in the field. Slide QC was organised by either me or a 
designee.
The databases (Epi Info) were designed by myself and reviewed by Drs Richie 
and Ohrt. Data were double entered and validated in the field by data entry clerks. Data 
validation against source documents, cleaning and cross checking between different 
databases was supervised by myself and senior team members, notably, Drs. Richie, 
Fryauff, and Murphy. Simple data analyses were done by myself with the help o f Dr. 
Murphy. However, for the publication, the definitive analyses and Survival curves were 
done by Dr. Tang who also provided much critical review o f the tolerability paper.
I wrote both azithromycin publications. For the prophylactic study, I received a lot 
of help from Drs. Berman and Richie in putting together the first draft. This was the first 
major paper I had written. Thereafter, critical input was received from the other co 
authors but in particular form Drs. Ohrt and Fryauff. Dr. Tang helped substantially with 
the discussion o f the tolerability paper.
5.2 Chloroquine doxycycline study
The following authors on the paper: Taylor WR, Widjaja H, Richie TL, Basri H, 
Ohrt C, Tjitra E, Taufik, Jones TR, Kain KC, and Hoffman SL. Their roles are listed 
below.
Protocol development: Ohrt C, Richie T, Tjitra E, and Hoffman S.
Study execution & patient care: Widjaja H, Basri H, Taufik, and Tjitra E.
Data management: Ferry and Nuijaya.
Sample size calculation & data analysis: Jones TR.
Manuscript writing: Richie TL, and Ohrt C.
Critical review o f manuscript: Widjaja H, Basri H, Tjitra E, Kain KC, and Hoffman SL. 
Trial monitoring: Tjitra E.
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The original idea for this comparative clinical trial came from Drs. Hoffman and 
Richie. Together with Dr. C. Ohrt, the process o f protocol development started and a first 
draft was produced. Protocol development was subsequently taken over by myself and 
was completed with the help o f Drs. Ohrt and Richie. Dr. T. Jones did the final sample 
size calculation. Thereafter all other research activities were my responsibility and I 
consulted my supervisor Dr. Richie as required. My work included writing the informed 
consent, designing the case record form and electronic database, overseeing ethical 
review and making amendments, supervision o f team physicians for study execution and 
clinical care o f patients (Dr. Widjaja assumed these responsibilities in my absence), 
overseeing data entry, cleaning, and source documentation checking, data analysis, and 
manuscript writing.
The malaria slides were read by team microscopists and checked by senior slide 
readers. Routine haematology was done by the hospital laboratories. The Parasight F tests 
were done by a team technician. Oversight was by me and Dr. Widjaja. The chloroquine 
concentrations were analysed by HPLC in Jakarta. The filter paper analyses for parasite 
genotyping were done in Canada in Dr. Kain's laboratory. I was not involved in PK or 
PCR analyses.
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Appendices
Appendix 1 The global distribution of malaria transmission, represented by the darker 
shaded areas (Source: WHO 2002).
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Appendix 2 Map of Indonesia.
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Appendix 3 Malaria burden in Indonesia presented as annual prevalence rates per 1,000 population 
(Source: Indonesian MoH, 1997).
. :
Appendix 4 Map of Irian Jaya.
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Appendix 5 Graph illustrating the parasite reduction ratios (PRR) of several antimalarial 
drugs. The artemisinins have the highest and antibiotics the lowest PRRs.
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Appendix 6 Graph showing the sigmoid relationship between drug concentration (A) and 
it's antimalarial effect. As parasite resistance increases, the I C 5 0  increases but the Emax is 
unchanged (B). With further parasite resistance, the I C 5 0  increases and the Emax falls.
Antimalarial effect/parasite killing
Emax
Log drug concentration
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Appendix 7 The 1996 WHO in vivo test for Plasmodium falciparum.
Early Treatment Failure (ETF) for all areas of transmission
Early Clinical Failure: (i) development o f danger signs or severe malaria on Day 1, Day 
2 or Day 3, and parasitaemia, (ii) parasitaemia on Day 3 with fever (axillary 
temperature > 37.5°C).
Early Parasitological Failure:(i) parasitaemia on Day 2 > Day 0 count, (ii) parasitaemia 
on Day 3 > 25 % of count on Day 0.
Late treatment failure for areas of intense transmission
Late Clinical Failure: (i) development o f danger signs or severe malaria after Day 3 in 
the presence of parasitaemia (same species as on Day 0), (ii) presence o f parasitaemia and 
fever on any day from Day 4 to Day 14/28, without previously meeting the criteria of 
ETF, (iii) parasitaemia and significant decrease o f haematocrit or haemoglobin.
Late treatment failure for areas of moderate/low transmission
Late Clinical Failure: (i) development o f danger signs or severe malaria after Day 3 in 
the presence o f parasitaemia (same species as on Day 0), (ii) presence of parasitaemia and 
fever on any day from Day 4 to Day 14/28, and not meeting the criteria o f ETF.
Late Parasitological Failure: presence o f parasitaemia on any day from Day 4 to Day 
14/28 in the absence o f fever (axillary temperature <37.5°C) and without previously the 
criteria o f ETF.
Adequate clinical response (ACR) for areas of intense transmission
ACR and parasitaemia: presence o f parasitaemia without fever without previously 
meeting any criteria o f ETF or LCF.
ACR without parasitaemia: absence o f parasitaemia irrespective o f the axillary 
temperature without previously meeting any criteria o f ETF or LCF.
Adequate clinical response for areas of moderate/low transmission
ACR: absence o f parasitaemia irrespective o f the axillary temperature without previously 
meeting the criteria o f ETF or LCF or LPF.
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Appendix 8 The 2003 WHO in vivo test fox Plasmodium falciparum.
Early Treatment Failure (ETF) for all areas of transmission
(i) development o f danger signs or severe malaria on Day 1, Day 2 or Day 3, in the 
presence o f parasitaemia, (ii) parasitaemia on Day 2 > Day 0 count, (iii) parasitaemia on 
Day 3 > 25 % o f count on Day 0, (iv) parasitaemia on Day 3 with fever (axillary 
temperature > 37.5°C).
Late treatment failure for areas of intense transmission
Late Clinical Failure: (i) development o f danger signs or severe malaria after Day 3 in 
the presence o f parasitaemia, (ii) presence o f parasitaemia and fever on any day from Day 
4 to Day 14, without previously meeting the criteria o f ETF.
Late parasitological failure: (i) presence o f parasitaemia on Day 14 and axillary 
temperature < 37.5°C, without previously meeting the criteria o f ETF or LCF.
Late treatment failure for areas of low to moderate transmission
Late Clinical Failure: (i) development o f danger signs or severe malaria after Day 3 in 
the presence o f parasitaemia, (ii) presence o f parasitaemia and axillary temperature > 
37.5°C (or history o f fever) on any day from Day 4 to Day 28, without previously 
meeting the criteria of ETF.
Late Parasitological Failure: presence o f parasitaemia on any day from Day 7 to Day 28 
and axillary temperature < 37.5°C, without previously the criteria o f ETF or LCF.
Adequate clinical and parasitological response (ACPR)
High transmission areas: absence o f parasitaemia on Day 14 irrespective o f axillary 
temperature without previously meeting any o f the criteria of ETF or LCF or LPF.
Low to moderate transmission areas: absence o f parasitaemia on Day 28 irrespective of 
the axillary temperature without previously meeting the criteria o f ETF or LCF or LPF.
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Appendix 9. Map of the world showing the risk o f acquiring malaria (Source WHO).
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